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Abstract 
Frontotemporal lobar degeneration (FTLD) is the second most common form of pre-
senile dementia. Recent discoveries have identified the proteins present in the 
pathological ubiquitinated inclusions of previously undifferentiated subtypes of FTLD.  
Fused in Sarcoma (FUS) is the primary pathological marker of a subtype now called 
FTLD-FUS. This normally nuclear protein is seen within the cytoplasmic and intranuclear 
aggregates of FTLD-FUS.  FUS, together with Ewing’s Sarcoma (EWS) and TATA box 
binding associated factor 68kDa (TAF15), forms the FET family. These related proteins 
are predominately nuclear owing to the action of the nuclear importin Transportin1 
(TRN1). 
Investigations by other authors have implicated TRN1 in the cytoplasmic aggregation of 
ALS-associated mutant FUS. Since ALS and FTLD represent different ends of a disease 
spectrum, the role of TRN1 in the pathology and biochemistry of FTLD-FUS was 
investigated. Extensive TRN1, TAF15 and EWS cytoplasmic and intranuclear inclusions 
were seen throughout the frontal cortex, hippocampus and entorhinal cortex, medulla, 
XIIth cranial nerve nucleus and spinal cord.  Double-label immunofluorescence revealed 
TRN1 and FUS pathology co-localised. Immunoblotting of solubility fractions 
demonstrated that highly insoluble, likely highly aggregated TRN1 is present in FTLD-
FUS, and not in healthy controls.  
Stress granules are transient cytoplasmic foci consisting of stalled translation initiation 
complexes and associated proteins produced by the cell in response to various stressors. 
Cellular investigations revealed that the same antibodies used to detect TRN1 pathology 
in FTLD-FUS labelled cytoplasmic stress granules induced after oxidative or osmotic 
stress. The re-localisation of wild type endogenous FET proteins was investigated under 
various pharmacological agents as well as TRN1 knockdown and overexpression. 
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Evidence is presented that the pathology of FTLD-FUS is more complex than previously 
thought.  Cellular studies investigate the implication of stress granules in aggregate 
formation and find that there is evidence to support oxidative stress in protein re-
localisation and aggregation.   
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Chapter One: Introduction 
1.1 The clinical presentation of frontotemporal lobar degeneration  
The term frontotemporal dementia (FTD) is used to describe the clinical presentation of 
the underlying frontotemporal lobar degeneration (FTLD) pathology, which defines a 
heterogeneous group of neurodegenerative diseases with varying yet often overlapping 
clinical presentations. Behavioural variant frontotemporal dementia (bvFTD), 
progressive non-fluent aphasia (PNFA) and semantic dementia (SD) are the three best-
characterised clinical syndromes. An overlap with motor neuron disease or amyotrophic 
lateral sclerosis (ALS) is very common, to the extent that they are now considered part of 
a spectrum disorder (Giordana et al., 2011). The behavioural variant is the most 
common, and diagnosis is made upon presentation of emotional blunting, loss of 
empathy, apathy, selfishness or neglect of personal hygiene (Bathgate et al., 2001). Given 
that diagnosis focuses on behavioural changes rather than cognitive decline there is 
some concern that an erroneous diagnosis of late onset depression or schizophrenia may 
be made (Kipps et al., 2009, Kipps et al., 2008). The disease progresses insidiously from 
these initial-onset symptoms, to a more severe and generalised dementia, caused by a 
preferential atrophy of the frontal and anterior temporal lobes. Clinical signs of bvFTD 
are associated with a symmetrical frontal and anterior temporal dysfunction, whilst 
PNFA is typically a left lateralised frontotemporal dysfunction, perhaps relating to the 
left lateralisation of the arcuate fasciculus (Glasser and Rilling, 2008). SD shows greater 
left anterior temporal lobe atrophy and is therefore also asymmetrical.  
1.2 Proteins and pathology associated with frontotemporal lobar 
degeneration 
Ultimate classification of FTLDs relies on the identification of the main protein 
component of the neuronal inclusions observed post-mortem. Although there is some 
17 
 
correlation between the clinical and pathological subtypes, the clinical presentation does 
not always predict the underlying pathology. The proteins responsible for the majority of 
the cases are tau, the TAR DNA-binding protein-43 (TDP43) and the fused in sarcoma 
(FUS) protein (Mackenzie et al., 2010a, Mackenzie et al., 2009).  
 
Figure 1.1 Diagnosis flow diagram for the pathological classification of FTLD variants. 
Variants are in blue; Tau +ve is FTLD-tau, TDP-43 +ve is FTLD-TDP, FUS +ve is FTLD-
FUS, the rarer entities include ubiquitin –ve dementia lacking distinctive histology 
(DLDH), and FUS –ve FTLD- of the ubiquitin proteosome system FTLD-UPS. The 
associated genetic mutations in red italics. 
 
1.2.1 Tau 
Tau is a microtubule associated phosphoprotein that is ubiquitously expressed in the 
central and peripheral nervous systems. Its primary role is to promote microtubule 
assembly and thereby aid the axoplasmic transport of proteins and organelles (Cleveland 
et al., 1977, Weingarten et al., 1975). Aberrant intracellular accumulation of tau is a 
characteristic of several neurodegenerative diseases that are grouped together as 
‘tauopathies’ (Tolnay and Probst, 2003, Lee et al., 2001). Detailed analysis of the 
composition of these aggregates reveals differences in the degree of phosphorylation and 
ratio of tau isoforms between different tauopathies (Delacourte, 2008). The tau gene 
(MAPT) is located on chromosome 17q21 and is predominantly found as two haplotypes: 
18 
 
H1 and H2. The differences between these two haplotypes are a set of single nucleotide 
polymorphisms (SNPs), a 238 base pair deletion in intron 9, and an approximately 900kb 
inversion. Alternative splicing gives rise to 6 possible isoforms expressed in the adult 
human brain. Exons 9, 10, 11 and 12 encode the microtubule binding domains that are 
crucial for its function. The alternative splicing of exon 10 can give rise to a 
predominance of tau containing 3 or 4 microtubule binding domains (3R and 4R-tau). In 
healthy adult brains the ratio is 1:1, but the ratio is often skewed in one direction or 
another in tauopathies (Goedert et al., 1989a, Goedert and Spillantini, 2006, Goedert, 
2004). Inheritance of the H1 haplotype appears to predispose an individual to sporadic 
tauopathies such as progressive supranuclear palsy (PSP)and corticobasal degeneration 
(CBD), both of which present with 4R pathological tau.  
FTLD-tau is a term that encompasses several diseases that could be described as 
individual disease entities. Moreover, these definitions and descriptions have been 
modified and adjusted many times since Arnold Pick first described them over a 100 
years ago (Pick, 1892). The term Pick’s disease is now retained for cases of FTLD with 
intraneuronal agyrophilic inclusions (Pick bodies) that can be identified with 3R tau 
immunohistochemistry. Broadly speaking FTLD-tau includes Pick’s disease, PSP, CBD, 
argyrophilic grain disease, (AGD), tangle predominant dementia, and frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTLDP-17 T). Each of these 
presents with a predominance of 3R or 4R –tau (or both) in the pathological inclusions. 
There are four characteristic histopathological findings of Pick’s disease, which are Pick 
bodies, Pick cells, neuronal loss in particular layers, and gliosis. Pick bodies are rounded 
globose cytoplasmic inclusion bodies approximately 10-15µm in diameter that stain 
strongly with anti-tau AT8 immunohistchemistry. These can also be seen on a standard 
haematoxylin eosin stain and are intensely argyrophilic with silver impregnations such 
as the Bielschowsky method. They can be easily found in the CA1 region of the 
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hippocampus, the subiculum, the dentate fascia neurons and, cerebral cortex, deep grey 
and brainstem nuclei (Munoz-Garcia and Ludwin, 1984). Pick cells are swollen, 
ballooned neurons in which the nucleus is often displaced from the centre of the cell 
body, and the cytoplasm does not retain Nissl substance. These cells are easiest to find in 
areas of the cortex that isn’t drastically affected by neuron loss. The neuronal loss can be 
so extreme that the cortical laminar architecture is severely disrupted due to the loss of 
the neuropil and proliferation of glial cells. Layer III pyramindal neurons are thought to 
be the most vulnerable followed closely by layers II and V (Arnold et al., 1994). The 
resulting spongiosis leaves a network of glial fibres and vessels behind.  
Mutations in MAPT that give rise to tauopathies can be separated into missense 
mutations in exons 9 to 13 that affect the normal function of tau, intronic, and coding 
mutations affecting the splicing of exon 10 at the mRNA level (Goedert et al., 1989b). In 
the later part of the 20th century genetic linkage between a familial form of FTLD with 
parkinsonism and chromosome 17q21-22 was made (FTLDP-17) (Wilhelmsen et al., 
1994). Later, approximately half of the original kindreds were found to have MAPT 
mutations (Hutton et al., 1998, Poorkaj et al., 1998, Spillantini et al., 1998b), and the 
remainder had progranulin (GRN) mutations (Cruts et al., 2006, Baker et al., 2006). 
However, those individuals processing GRN mutations present with TDP43 pathology.  
1.2.2 TDP43 
TDP43 is a ubiquitously expressed, 414 amino acid long protein with a molecular weight 
of 43kDa. TDP43 is encoded by the TADBP gene, which has 6 exons encoding a glycine-
rich region, two RNA recognition motifs and a nuclear export, and import signal (NES 
and NLS respectively), all of which are crucial to its numerous functions (Ou et al., 1995). 
Whilst it was originally studied as one member of a splicing complex affecting the cystic 
fibrosis transmembrane conductance regulator gene (Buratti et al., 2001), more recent 
investigations attribute a multitude of functions to TDP43, including; micro RNA 
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biogenesis, apoptosis, cell division, mRNA stabilisation and neuronal plasticity (Strong et 
al., 2007, Wang et al., 2008). After languishing in relative obscurity for years, TDP43 was 
identified as the primary pathological protein of a proportion of sporadic ALS and FTLD 
cases in 2006 (Neumann et al., 2006, Arai et al., 2006). Thirty-eight TDP43 mutations 
have so far been identified in ALS patients, which explain approximately 4% of the 
familial, and <1% of the sporadic disease burden. Far fewer reports of TDP43 mutations 
in FTLD exist in the literature (Gitcho et al., 2009), and fewer still produce a clinically 
pure FTD (Benajiba et al., 2009).  However, as larger disease cohorts are assembled, 
more probable pathogenic variants are being discovered (Borroni et al., 2010). 
1.2.2.1 GRN, VCP and C9ORF72 
As previously discussed the genetic linkage was identified in patients with FTLD with 
Parkinson’s and many of them had a MAPT mutation and tau pathology. However, there 
remained a subset of cases, which remained negative for tau pathology and MAPT 
mutations. These individuals were found to be harbouring GRN mutations, and 
presenting with TDP43 pathology. The gene GRN is 1.7Mb centromeric to MAPT and 
encodes the progranulin protein. Families bearing GRN mutations exhibit an autosomal 
dominant inheritance of FTLD-TDP with 66 identified mutations causing a 
haploinsufficiency of progranulin through production of premature stop codons, one 
disrupting the splice donor site of intron 0 leading to loss of transcript through nuclear 
degradation, and one lies within the initiation Met leading to a failure to initiate 
translation (Baker et al., 2006, Cruts et al., 2006, Finch et al., 2009). Very little was 
known about this protein at the time of the genetic discovery, but research pointed 
towards a secreted growth factor role (Van Damme et al., 2008). The cell surface 
receptor sortilin has now been identified as a key binding partner of progranulin. Whilst 
an exact theory of pathogenesis is still outstanding, it has been shown that under stress 
activated microglia will release progranulin and sortilin bearing neurones will rapidly 
endocytose it (Hu et al., 2010). Mutations in VCP cause a rare familial syndrome in which 
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a triad of conditions show variable penetrance, namely; inclusion body myopathy, Paget 
disease of the bone, and frontotemporal dementia (FTD) (Watts et al., 2004, Kimonis et 
al., 2008). Twelve different missense VCP mutations in 29 families have been identified 
and correlated with a specific TDP43 pathology that is characterised by numerous 
neuronal intranuclear inclusions, few neuronal cytoplasmic inclusions and abundant 
dystrophic neurites. Several kindreds in the literature presented with a particular TDP43 
pathology genetically linked to chromosome 9p21. This linkage has now been resolved to 
an expansion of a noncoding GGGGCC hexanucleotide repeat in the gene C9ORF72 
(Dejesus-Hernandez et al., 2011, Renton et al., 2011). This discovery is of particular 
significance because the expansion is the most common cause of familial and sporadic 
forms of FTLD and ALS.  
1.2.2.2 TDP43 pathology 
Under normal conditions TDP43 is localised to the nucleus, but as part of its normal 
functioning it is able to shuttle between the cytoplasmic and nuclear compartments. 
Under pathological conditions such as ALS and FTLD abnormal TDP43 redistribution to 
the cytoplasm is considered to be a crucial early step in pathogenesis (Giordana et al., 
2010). Sequestering the protein into cytoplasmic and or intranuclear aggregates is 
thought to further retard TDP43’s normal function and give rise to malignant effects 
(Neumann et al., 2006, Davidson et al., 2007, Igaz et al., 2008, Van Deerlin et al., 2008). 
Sequential solubility extraction and immunoblotting of detergent insoluble protein from 
affected brains reveals a signature pattern of hyperphosphorylated and ubiquitinated 
TDP43 as well as 25kDa fragments from the C-terminal region of TDP43 (Neumann et al., 
2006, Arai et al., 2006). 
TDP43 immunohistochemistry has provided a wealth of knowledge regarding the 
detailed pathology of FTLD-TDP. Previously this FTLD variant was only described in 
terms of routine histological stains and ubiquitin immunohistochemistry. TDP43 
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immunohistochemistry revealed previously unrecognised ubiquitin negative pathology 
such as; glial cytoplasmic inclusions (Neumann et al., 2007), diffuse cytoplasmic pre-
inclusions (Brandmeir et al., 2008, Geser et al., 2009), and CA1 neurites (Hatanpaa et al., 
2008). Further development of antibody technology has produced phosphorylation 
dependant antibodies that label only the aberrantly hyperphosphorylated TDP43 and 
not the normal TDP43 (Hasegawa et al., 2008, Inukai et al., 2008).  The level of detail 
revealed with TDP43 immunohistochemistry has allowed FTLD-TDP to be further 
subdivided into four pathological subtypes. Two authors identified these four subtypes 
independently and concurrently leading to the publication of two labelling systems that 
identified the correct subtypes but labelled them differently, leading to confusion in the 
field (Mackenzie et al., 2006, Sampathu et al., 2006). More recently a harmonized 
classification system was suggested using letters instead of numbers and listing the most 
common first. Type A is characterised by numerous short dystrophic neuritis, and 
crescent shaped or oval neuronal cytoplasmic inclusions occurring mainly in neocortical 
layer 2. Intranuclear lentiform inclusions are common in some but not all cases. Type B 
has more moderate numbers of neuronal cytoplasmic inclusions throughout all cortical 
layers, but few dystrophic neuritis. Type C is characterised by a predominance of 
elongated dystrophic neuritis in upper cortical layers with very few neuronal 
cytoplasmic inclusions. Finally and rarest, Type D includes pathology associated with 
inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 
caused by VCP mutations, namely numerous short dystrophic neurites and frequent 
intranuclear inclusions. Subdividing the pathological characteristics of FTLD-TDP in this 
manner may appear to be a purely academic exercise but support for this practice comes 
from the specific correlations that can be drawn between pathological type and clinical 
phenotype or genetic cause (Mackenzie et al., 2006, Davidson et al., 2007).  
1.2.3 FUS 
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Fused in Sarcoma (FUS), also known as Translocated in liposarcoma (TLS) is one 
member of the FET (Fused in sarcoma, Ewing’s sarcoma, TAF15 RNA polymerase II 
TATA box binding associated factor 68kDa) protein family. All members of this family are 
infamous thanks to their role in particularly malignant tumours often affecting children. 
At the time of writing 20 years have passed since FUS was identified as one half of a 
chimeric protein resulting from a translocation and the driving force of cancerous 
proliferation (Crozat et al., 1993). The chimeric protein harboured by these tumours 
consists of the N-terminus of FUS fused to a transcription factor such as CHOP.   
The full length wild type FUS protein (Figure 1.2) has been shown to preferentially bind 
to GGUG motif mRNA (Lerga et al., 2001), utilizing each of its RNA binding domains thus 
suggesting a complex protein-RNA structure. In the same vein, FUS has also been shown 
to bind telomerase primer RNA signifying a possible role in the maintenance of 
telomeres and senescence (Lerga et al., 2001). FUS and the entire FET family have been 
shown to associate with the RNA polymerase II and TFIID transcription complex 
suggestive of a core role of these proteins in transcription (Schwartz et al., 2012, 
Bertolotti et al., 1996, Bertolotti et al., 1998). However, recent findings have described 
FUS as a repressor of RNA polymerase III dependent transcription of small untranslated 
RNAs, perhaps suggesting a more general role in the orchestration of transcription 
apparatus (Tan and Manley, 2010). What is clear is that the normal role of FUS is 
intimately entwined with RNA.  
 
 
Figure 1.2. Domain structure of the FUS protein. SYGQ-rich: Serine Tyrosine Glycine 
Glutamine-rich domain. RGG: Arginine Glycine Glycine-rich domain. RRM: RNA 
recognition motif. Zn: putative zinc finger. NLS: Nuclear localisation signal. 
Members of the multifunctional FET protein family, including FUS, are all linked to 
malignantly proliferative diseases. Their normal roles support the correct expression of 
protein, but the expression of the FET proteins themselves can be regulated by trans 
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elements surrounding proliferation. Specifically, the proliferating neuroblastoma line 
SH-SY5Y can be differentiated into a more quiescent, neuronal cell type with the addition 
of 1µM all-trans retinoic acid to the culture medium. Over 9days this will reduce cell 
proliferation and induce neurite formation, as well as reducing the detectable protein 
levels of all three FET proteins (Andersson et al., 2008a). 
The significance of FUS in neurodegeneration was recognised with the discovery that 
mutations in the FUS gene are responsible for familial amyotrophic lateral sclerosis 
(ALS) type 6 (ALS-FUS) (Kwiatkowski et al., 2009a, Vance et al., 2009b). At the time of 
writing there are 60 reported mutations in FUS that give rise to familial and sporadic 
disease, 58% of which cluster in the NLS (Appendix 1.1). Subsequently FUS has also 
emerged as a significant disease protein in a subgroup of FTLDs, previously 
characterized by immunoreactivity of the neuronal inclusions for ubiquitin, but not for 
TDP43 or tau with a proportion of the inclusions also containing α-internexin in a further 
subgroup known as neuronal intermediate filament inclusion disease (NIFID). The 
disease entities which are now considered subtypes of FTLD-FUS are atypical 
frontotemporal lobar degeneration with ubiquitinated inclusions (aFTLD-U), NIFID 
(otherwise known as neurofilament inclusion body disease (Josephs et al., 2003b) and 
basophilic inclusion body disease (BIBD), which together with ALS-FUS comprise the 
FUS-opathies (Munoz et al., 2009, Neumann et al., 2009b, Mackenzie et al., 2010b, 
Neumann et al., 2009d).  
The cause and pathomechanism of inclusion formation in the FUS-opathies is only 
partially understood. In keeping with its important functions in transcription regulation, 
FUS protein is present in considerably larger amounts in the nucleus than in the 
cytoplasm of neurons while it is restricted to the nuclei and not found in the cytoplasm of 
glial cells (Andersson et al., 2008b). Under normal physiological conditions the FUS 
protein shuttles between the nucleus and cytoplasm through the nuclear pore (Zinszner 
et al., 1997, Lagier-Tourenne et al., 2010). Transport of FUS from the cytoplasm to the 
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nucleus takes place with the aid of transportin1 (TRN1), also known as M9-interacting 
protein or karyopherin2 (Karb2), which is an 890-amino acid-long protein (OMIM; 
http://omim.org/entry/602901). Karyopherin-s (Karbs), also known as importins and 
exportins are responsible for the majority of the cellular nucleocytoplasmic transport. In 
humans ten Karbs have been shown to carry diverse macromolecular substrates into the 
nucleus and in one of these import pathways Karb2 is responsible for the import of a 
significant group of RNA processing proteins, including FUS (Macara, 2001, Bonifaci et 
al., 1997, Weis, 2003, Xu and Massague, 2004, Lee et al., 2006, Dormann et al., 2010). 
Binding of substrates to import and export Karbs is dependent on the nuclear 
localisation signal and nuclear export signal, which are predicted to be located at the C-
terminal end and the beginning of the RNA recognition motif of FUS, respectively (Lee et 
al., 2006, Lagier-Tourenne et al., 2010). The NLS of FUS can be described as a PY motif 
very similar to previously described M9 signals and a likely target of the TRN1 nuclear 
import system (Dormann et al., 2010, Lee et al., 2006). During nuclear import of proteins, 
the Karb-protein cargo complex translocates into the nucleus through its association 
with the nuclear pore complex. Once inside the nucleus the Karb-protein complex 
dissociates, which is dependent on RanGTP binding to the import Karbs. The free Karbs 
are then recycled into the cytoplasm to be available for a new cycle of cargo import 
(Weis, 2003).  
In 2010, Dormann et al showed that mutations in the nuclear localisation signal of FUS, 
that had been previously linked to ALS, cause a redistribution of FUS to the cytoplasm 
(Dormann et al., 2010).  In a similar manner to TDP43, re-localisation of FUS to the 
cytoplasm is thought to be a crucial early event in pathogenesis. The cell system used to 
model these ALS-FUS mutations also showed that this re-localised FUS began to 
accumulate into punctuate structures that were positive for stress-granule markers. 
Furthermore, this group were able to show that the nuclear importin TRN1 was 
responsible for the primary mode of import.  The most convincing finding was that the 
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degree of FUS re-localisation correlated strongly with the severity of clinical symptoms 
in carriers of that mutation.  
1.2.4 EWS 
Ewing’s Sarcoma protein (EWS) is named after the family of highly malignant cancers 
that includes Askin tumours, and primitive neuroectodermal tumours. These tumours 
occur most frequently in the long bones and sometimes in the soft tissues (Kauer et al., 
2009). Ewing’s sarcoma is associated with specific chromosomal translocations and the 
resulting chimeric transcripts and proteins. Ewing’s sarcoma is the second most common 
bone cancer and is considered highly malignant (Rodriguez-Galindo et al., 2003). They 
harbour translocations of the EWS gene on chromosome 22 and any one of the ETS 
family genes, the most common of which is the FLI1 gene on chromosome 11 (Downing 
et al., 1993).  The resulting chimeric product drives pathological proliferation through 
transcriptional activation of IGF1, NKX2, TOPK, SOX2 and EZH2 all of which are 
proliferative, involved in cell differentiation, or cell survival, but also repression of 
apoptotic and cell cycle arrest genes including IGFBP3, p57kip, p21 and TGFβ2 (Lin et al., 
2011, Cironi et al., 2008, Sollazzo et al., 1999, Herrero-Martin et al., 2009, Smith et al., 
2006, Fukuma et al., 2003, Garcia-Aragoncillo et al., 2008, Zwerner et al., 2008, Richter et 
al., 2009, Siligan et al., 2005, Kikuchi et al., 2007, Hahm et al., 1999, Nakatani et al., 2003, 
Dauphinot et al., 2001, Prieur et al., 2004, Riggi et al., 2010).  
The normal function of EWS appears to be heavy related to its ability to bind RNA and 
DNA (Janknecht, 2005). The protein also interacts with the TFIID pre-initiation complex 
and with subunits of the RNA polymerase II implicating a role in transcriptional 
regulation (Bertolotti et al., 1998). EWS has also been shown to interact with splicing 
apparatus proteins like Y box binding protein 1 (YB-1), and branch point binding protein 
(BBP/SF1) (Dutertre et al., 2010, Zhang et al., 1998).  Perhaps most conclusively, EWS 
was shown to regulate alternative splicing of mouse double minute 2 homolog (MDM2), 
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which is an important repressor of p53 (Dutertre et al., 2010). Depletion of EWS results 
in alterations in alternative splicing of genes involved in DNA repair and geneotoxic 
stress signalling including ABL2, CHERK2 and MAP4k2 (Paronetto et al., 2011). The same 
effect can be seen under ultra violet light (U.V.) irradiation whereupon EWS refocuses 
from a diffuse nuclear distribution to nucleoli presumably away from the splicing 
machinery, with a concomitant reduction in c-ABL protein expression. Given the role of 
c-ABL in cell division and stress response this would appear to be an adaptive response 
to DNA damage elicited by U.V. radiation. Knockout mice survive for only a few days and 
show defects in pre-B cell development, a hypotrophic thymus, defects in spermatocytes, 
premature cellular senescence and hypersensitivity to ionizing radiation (Li et al., 2007). 
Such a wide array of defects suggests EWS has roles in normal immune cell 
differentiation, homologous DNA pairing between XY bivalents (Guipaud et al., 2006), 
and telomere independent senescence. 
Since many of the roles attributed to EWS surround RNA and DNA it is unsurprising that 
its domain structure comprises a transcriptional activation domain, a zinc-finger motif, 
three RGG boxes, one RRM and nuclear localisation signal (NLS) (Zakaryan and Gehring, 
2006) (Figure1.3).  
 
 
Figure 1.3. Domain structure of the EWS protein. SYGQ-rich: Serine Tyrosine Glycine 
Glutamine-rich domain. RGG: Arginine Glycine Glycine-rich domain. RRM: RNA 
recognition motif. Zn: putative zinc finger. NLS: Nuclear localisation signal.  
 
The NLS of EWS consists of 18 amino acid residues (PGKMDKGEHRQERRDRPY) and is 
very well conserved across the FET family. Three arginine residues (R648, R652 and 
R654), a proline (P655) and a tyrosine (Y656) represent a pattern conserved across this 
region in all FET proteins. Replacement of any of these residues with alanine will abolish 
the nuclear localisation of EWS (Zakaryan and Gehring, 2006). Interestingly, replacement 
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of the arginine residues with lysine, another positively charged amino acid, will not 
ablate nuclear import (Zakaryan and Gehring, 2006). This may demonstrate that the 
electrostatic interaction between this region and the importin TRN1 mediates nuclear 
import.  
Relatively little is known about the role EWS might play in neurodegeneration. It was 
first implicated when IHC studies discovered the inclusions of FTLD-FUS, but not those of 
ALS-FUS, were visible with anti-EWS antibodies (Neumann et al., 2011). This was 
accompanied by a relative (but not significant) shift of EWS towards the insoluble 
fraction, which is an important biochemical marker of disease. Genetic screening of the 
EWS gene in these cases revealed no mutations, however the exon screen was not able to 
investigate possible duplications. This lack of apparent genetic cause is repeated in all 
FET proteins and TRN1 despite these proteins apparently aggregating in tandem. Cell 
culture models that block TRN1 driven import by substrate competition have shown that 
EWS will re-localise to the cytoplasm and rapidly amalgamate with stress granules upon 
heat shock (Neumann et al., 2011).  The same is true even if TRN1 import is not 
artificially blocked, oxidative and non-oxidative stress can re-localise EWS to varying 
degrees (Andersson et al., 2008a). Given the extensive similarities between EWS and FUS 
the hypothesises of aberrant cytoplasmic re-localisation being key to pathology could be 
extended to EWS.  
1.2.5 TAF15 
‘TAF15 RNA polymerase II TATA box binding associated factor 68kDa’ (TAF15) is also 
known as TAFII68, TAF2N, RBP56 or Npl3 (OMIM; http://omim.org/entry/601574).  As 
with all the FET proteins, TAF15 is a nuclear protein that shuttles back and forth from 
the cytoplasm (Bertolotti et al., 1996). However, less is known about TAF15 and its role 
within the cell possibly due to the relative rarity of genetic translocations involving this 
gene (Nyquist et al., 2011).  The fusion of TAF15 and the zinc finger containing ZNF384 
29 
 
results in acute lymphoblastic leukemia which is one of the most common malignancies 
in children accounting for 20% of pediatric cancer. What is known regarding TAF15’s 
normal function is that during the initiation of transcription the general RNA polymerase 
II transcription factor IID (TFIID) recognizes the core promoter sequence and initiates 
the assembly of the preinitiation complex. TFIID is an extremely heterogeneous complex 
of various proteins, including TAT-binding protein and a series of associated proteins of 
which TAF15 is one (Bertolotti et al., 1996).  In addition to this transcriptional activation 
domain, TAF15 also possesses RRM and RGG motifs (Figure 1.4) much like FUS (Figure 
1.2) and EWS (Figure 1.3). Cross linking and immunoprecipitation experiments have 
shown that one of the mRNA targets of TAF15 is U1A small nuclear RNA (snRNA) and 
that this U1-TAF15 snRNP associates with chromatin (Jobert et al., 2009b).  Interestingly, 
this association increases 2.5 fold upon transcription arrest stress (Jobert et al., 2009b), 
this sequestration may indicate a role for TAF15 in altering the spliceosomal function of 
U1-SM snRNP or transcriptional activation via U1-TFDIIH (Kwek et al., 2002). High 
throughput analysis of TAF15 targets revealed enrichment for neuronal function, 
including mRNA for NMDA receptor subunits, potassium voltage-gated channels, AMPA 
receptors, neurexin 1 & 3, neuroligin 1 and protocadherin-9. This may be pertinent for 
theories of FTLD-FUS pathogenesis particularly because approximately 89% of TAF15 
targets are also targeted by FUS (Ibrahim et al., 2013). Complete clearance of all the FET 
proteins from the nucleus to aggregate bodies would circumvent this possible functional 
redundancy and likely have a dramatic impact on cell function and viability.  
The NLS of TAF15 is only marginally different to that of FUS and EWS with 6 previously 
conserved residues replaced with similar amino acids. Crucially the PY motif remains 
unchanged and it is therefore a target of TRN1 driven import (Figure 1.5). Contrary to 
results from FUS studies no putative nuclear export signal has been found within TAF15 
(Kino et al., 2011, Marko et al., 2012). Despite being a target of TRN1 its nuclear 
localisation can be partially disrupted by treatment with actinomycin D which inhibits 
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transcription (Marko et al., 2012). Similar results have been shown for FUS suggesting 
both TAF15 and FUS are RNA polymerase II activity sensing (Pinol-Roma and Dreyfuss, 
1993).  
 
Figure 1.4. Domain structure of the TAF15 protein. SYGQ-rich: Serine Tyrosine Glycine 
Glutamine-rich domain. RGG: Arginine Glycine Glycine-rich domain. RRM: RNA 
recognition motif. Zn: putative zinc finger. NLS: Nuclear localisation signal. 
 
Recently identified variants in TAF15 have been suggested to be causative in familial and 
sporadic ALS (Ticozzi et al., 2011, Couthouis et al., 2011). These disease associated 
variants formed cytoplasmic foci when expressed in primary neuron cultures and 
induced neurodegeneration in Drosophia models. These authors also investigated spinal 
cord neurons of sporadic ALS patients and found TAF15 to be accumulating in the 
cytoplasm within small punctate inclusions which contradicts findings of other authors 
who state TAF15 aggregation is unique to FTLD-FUS (Neumann et al., 2011). It remains 
to be seen if the cytoplasmic foci formed in primary neurons and the punctate inclusions 
in ALS co-localise with stress granule markers. Briefly, stress granules are transient foci 
of triaged mRNA and proteins brought about by cellular stress known to harbour mutant 
FUS and wild type TAF15 (Dormann et al., 2010, Blechingberg et al., 2012b)(Discussed 
further in 1.4.2). Notably there have been no reports of mutations in TAF15, putative or 
otherwise, in cases of FTLD-FUS. 
1.2.6 TRN1 
Transportin1 is a key component of the non-classical nuclear import pathway. In 
contrast the classical import pathway TRN1 binds its cargos directly rather than through 
an adaptor protein like karyopherin α (Suzuki et al., 2005).  Binding of TRN1 to target 
cargos depends on the NLS motif present in said cargo. Typically, this motif conforms to 
very well conserved patterns and is referred to as the M9 signal or a PY-motif (Figure 
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1.5). Although only three cargos of TRN1 are discussed in detail here there are many 
more reflecting the importance of TRN1 in nuclear import (Appendix 1.2). 
 
 
Figure 1.5. The M9 signal or PY-motif in each of the FET proteins. Blue cells indicate 
identical residues vital for the PY-motif.  
TRN1 has a super helical structure created by the helical stacking of 20 HEAT 
(Huntington, Elongation factor 3 A subunit of protein phosphatase 2A lipid kinase Tor1) 
repeats (Andrade and Bork, 1995, Lee et al., 2006, Imasaki et al., 2007). Considerable 
flexibility is afforded to this 3D structure which is crucial to its function as a cargo and 
co-factor binding transport protein. Within the eighth HEAT repeat there is an insertion 
termed the ‘acidic-loop’ (residues 311-373) that plays a fundamental role in cargo 
dissociation within the nucleus. In its unbound state the acidic-loop of TRN1 assumes a 
random coil structure which allows a cargo protein to bind. This binding takes place 
within the C-terminal arch of the super helix at 2 distinct sites through a series of H-
bonds (Wang et al., 2011). At this point the TRN1-cargo complex translocates through 
the nuclear pore and into the nucleoplasm. Once in the nucleus the high concentration of 
RanGTP ensures binding of this co-factor to TRN1. This causes the acidic-loop to adopt a 
partially unfolded α-helix conformation, which moves to sterically dislodge the cargo 
(Wang et al., 2011). TRN1 is then recycled back into the cytoplasm where GTP 
hydrolases convert RanGTP to RanGDP. This reduces the affinity of TRN1 for Ran by 4 
orders of magnitude. However, TRN1 remains bound to RanGDP in the cytoplasm 
because of its high concentration until a sufficiently strong interaction between TRN1 
and a possible cargo occurs (Figure 1.6).  
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Figure 1.6. Functional cycle of TRN1. CARGO could be any of the described TRN1 targets 
includes FUS, EWS or TAF15. Changes in the tertiary structure of TRN1 brought about by 
RanGTP binding force the acidic-loop to displace the cargo within the nucleus. 
Exactly how this TRN1-cargo complex is attracted to, and moves through, the nuclear 
pore remains unclear. One model suggests that the movement through the pore occurs 
by facilitated diffusion. In this model, one-way directionality would be conferred by Ran-
dependant steps on either side of the pore. A second model suggests that the direction of 
transport is due to a ratcheted mechanism of gradually increasing affinity between the 
importin and nucleoporins as the TRN1-cargo complex moves through the nuclear pore. 
A more favoured model is based on the observation that the pore is lined with many 
hydrophobic phenylalanine and glycine containing nucleoporins. In this selective phase 
model the hyrophobic attraction of the phenylalanine-glycine rich regions for each other 
creates a hydrophobic phase blocking the passage of most proteins. Essentially this 
model proposes that there is a selective affinity of importins for this environment, which 
would link the ability of the nuclear pore to exclude many proteins from passage and 
facilitate diffusion of TRN1 complexes. Support for the latter model comes from the rapid 
transmission kinetics associated with nuclear import, as well as the observations that 
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importins interact with the phenylalanine-glycine repeats of nucleoporins (Denning et 
al., 2003).  
Before the discovery of TRN1 in the pathology of FTLD-FUS, there was no association of 
TRN1 with any human disease. However, transportin3 (TRN3) was the subject of a spate 
of research papers after genome wide siRNA screens identified it as an important factor 
for efficient HIV infection (Brass et al., 2008, Konig et al., 2008, Zhou et al., 2008, Ocwieja 
et al., 2011). Recent research into nuclear shuttling proteins and FTLD-TDP has 
identified several members of the exportin family as being connected to the disease. 
Expression analysis of 82 nuclear factors in post-mortem brain samples from patients 
with FTLD-TDP revealed a considerable reduction in expression of cellular apoptosis 
susceptibility protein (CAS) (Nishimura et al., 2010).  In nuclear export pathways protein 
cargo and RanGTP bind co-operatively to an exportin such as CAS, and it is the hydrolysis 
of RanGTP to RanGDP in the cytoplasm that releases the protein cargo. 
Further exploration of the importin-exportin proteins may reveal greater insights into 
the pathology of FTLD.  
1.3 Pathology of FTLD-FUS 
FTLD-FUS can be further subdivided into aFTLD-U, NIFID and BIBD. These subtypes 
were originally classified in this manner because a proportion of the intracellular 
inclusions of NIFID were also positive for α-internexin and neurofilaments (Josephs et al., 
2003a, Cairns et al., 2007). Before the discovery of TRN1 and the other FET proteins 
within the inclusions of FTLD-FUS, FUS was the primary pathological marker alongside 
more general markers of pathology such as ubiquitin and p62. Detailed histological 
analysis of pathology revealed superficial spongiosis affecting the frontal and temporal 
cortices (Lashley et al., 2011), which can be seen macroscopically as shrunken lobes, 
widened sulci and reduced gyri. Both subtypes possess the characteristic neuronal 
cytoplasmic inclusions but they are more frequent in the NIFID subtype (Lashley et al., 
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2011). These can be found most readily within the superficial cortical layers and include 
a variety of morphologically distinct types. The NIFID subtype shows crescent-shaped 
cytoplasmic inclusions that rap around the nucleus, large globus Pick body-like 
inclusions that stain evenly throughout the structure, flame or tangle-like inclusions that 
extend into the apical dendrites of pyramidal neurons, as well as rare lentiform or 
vermiform shaped intranuclear inclusions. The aFTLD-U subtype presents with the same 
cresent-shaped cytoplasmic inclusions, but also smaller bean-like rather than Pick body-
like inclusions, intranuclear inclusions are absent from the cortex of aFTLD-U cases but 
not the hippocampal formation. Cases of aFTLD-U typically show some degree of 
hippocampal sclerosis which can extend into the subiculum (Lashley et al., 2011). 
However, the degree of inclusion pathology can vary significantly between cases. Some 
cases show frequent intranuclear inclusions throughout the granule cell layer, 
sometimes accompanied by bean-shaped cytoplasmic inclusions, others contain only 
occasional inclusions. The same variability can be seen in NIFID cases where instances of 
intranuclear inclusions occurring alongside cytoplasmic inclusions in the same cell 
pepper the granule cell layer in some cases but not others. In contrast, BIBD pathology 
demonstrates a predilection for pyramidal and extrapyramidal motor regions with 
relative sparing of the cerebral cortex. Neuronal cytoplasmic inclusions affect the dorsal 
midbrain, locus ceruleus, substantia nigra, globus pallidus, and spinal cord. These vary in 
morphology ranging from compact and rounded, tangle-like, and crescent shaped. 
Neuronal intranuclear inclusions are also present as well as dystrophic neurites and 
swollen axons.  
In light of the spectrum disorder hypothesis that argues FTLD-FUS and ALS-FUS 
represent cortical and motor ends of a disease spectrum, it is not unsurprising that 
motor neurons are affected in FTLD-FUS. The XIIth cranial nerve nucleus appears to 
maintain its neuronal population but also harbours either compact or filamentous skein-
like cytoplasmic inclusions in both subtypes (Lashley et al., 2011). The spinal cord of 
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FTLD-FUS patients is also notably affected, filamentous skein-like inclusions, punctate 
dot-like inclusions, or more compact cytoplasmic inclusions are common in the cervical 
segments. Beyond typical FTLD-FUS pathology markers such as FUS, the spinal cord has 
also been reported to show increased microglia and macrophages by CD68 
immunohistochemistry indicating degeneration of these tracts (Lashley et al., 2011). 
Biochemical markers of pathology in FTLD-FUS focus of the detection of highly insoluble 
proteins also seen in characteristic immunohistopathology. Despite a predicted 
molecular weight of 53kDa FUS has been shown to run at 2 distinct bands, one at 53kDa 
and another at approximately 75kDa (Lashley et al., 2011). Neuron cell lysate runs at 
75kDa whilst brain homogenate produces two bands which has led to debate about 
which band or bands represent FUS. Sequential solubility extractions reveal the FUS 
biochemical signature of this disease is quite complicated. Sequential solubility 
fractionation separates proteins via ultracentrifugation and buffers of increasing 
detergent strength. Those proteins found in the final urea buffer fraction are considered 
to be highly insoluble and likely highly aggregated. Detecting proteins present in the 
inclusions of FTLD-FUS in the urea fraction is an important confirmatory step before 
including them in the pathology of disease. However, depending on the exact technique 
used to separate the fractions, FUS is either present or completely absent from the urea 
fraction of healthy controls (Page et al., 2011, Lashley et al., 2011). Generally speaking a 
shift towards the insoluble fraction is seen with FUS immunoblots and this is considered 
pathologically relevant in terms of protein aggregation.   
A similar shift in protein insolubility can be seen with TAF15 immunoblotting in both 
aFTLD-U and NIFID (Neumann et al., 2011). Notably, this shift can be far more 
pronounced than that seen for FUS, which when coupled with the fact that TAF15 
antibodies give a simpler banding pattern suggests TAF15 is a more clear-cut 
biochemical marker. Whilst EWS displays a similar tendency for higher insoluble levels, 
this does not reach significance (Neumann et al., 2011).  
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It is important to note that neither FUS, TAF15 nor EWS display abnormal molecular 
weight species associated with ubiquitination which presents a quandary given that 
ubiquitin is abundant within FUS TAF15 EWS inclusions.  
1.4 Putative mechanisms of pathogenesis  
1.4.1Protein mis-folding and prionoid proteins  
The conversion from soluble predominantly -helix secondary structure to insoluble -
sheet-rich aggregates is a common phenomenon in neurodegenerative disease. 
Alzheimer’s disease is the best known example of a mis-folded protein aggregating and 
causing disease. The usually soluble products of amyloid precursor protein (APP) have 
their metabolism altered in some manner, which results in greater production of the 
Amyloid- 1-42 fragment (A). This peptide is intrinsically aggregate prone and will self-
aggregate in aqueous solution under conditions of high peptide concentration by taking 
on a -sheet form (Barrow et al., 1992). The residues 17-21 and 32-42 have a higher 
hydrophobicity and are therefore more likely to assume a β-sheet conformation. 
Additionally, the residues 9-21 can transition between α-helix and β-sheet forms and 
replacement of any residue between amino acids 17-23 with proline will increase 
solubility, reduce -sheet formation and also prevent fibrilisation (De Strooper et al., 
1995). This fribrilisation is seen in disease, ultrastructural analysis of A aggregates 
reveals anti-parallel -sheet structure organized into unbranching fibrils (Fraser et al., 
1991, Serpell et al., 1995). Thus fibrillogenesis is linked to the conversion from α-helix to 
β-sheet structure.  
Parkinson’s disease is the classic example of Lewy body disease, but many 
neurodegenerative diseases have also been found to harbour some degree of Lewy body 
burden (Jensen et al., 1995, Spillantini et al., 1998a). Lewy bodies are intracellular 
aggregates composed of aggregated -synuclein, a very small (14kDa) presynaptic 
molecule found throughout various regions of the brain (Jakes et al., 1994). Circular 
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dichromism predicts a largely unstructured random coil protein but residues 1-60 have 
at least the ability to form -helices, 61-95 are predicted to be highly amyloidogenic, and 
the remainder is an acidic proline rich region (Kim, 1997, Davidson et al., 1998, George et 
al., 1995, Manning-Bog et al., 2002). Similarly to A this protein’s -helical content will 
increase if it is in a lipid environment (Shen and Murphy, 1995, Davidson et al., 1998). 
This maintenance of -helical structure in these conditions is logical given its likely 
synaptic role, from which it takes its name. Highly malignant mutations in SNCA that give 
rise to familial Parkinson’s disease (PARK1/4) have been shown to increase the rate of -
sheet adoption and fibrilisation (Serpell et al., 2000), and that these fribils are formed 
through a nucleation step (Conway et al., 2000, Wood et al., 1999). Injection of mice with 
mis-folded insoluble α-synuclein produces a prionoid spreading of α-synuclein pathology 
as soluble protein is templated into insoluble β-sheet conformations (Masuda-Suzukake 
et al., 2013, Li et al., 2008). Therefore, Parkinson’s disease is another protein folding 
prionoid neurodegenerative disease.  
FTLD-TDP and cases of sporadic ALS demonstrate thioflavin-S staining within the 
intranuclear and cytoplasmic aggregates suggesting a strong -sheet content (Bigio et al., 
2013). The density of FTLD-TDP thioflavin-S positive inclusions is similar to that seen 
under ubiquitin immunohistochemistry but fewer compared with TDP43 
immunohistochemistry, suggesting that there may be 2 stages of inclusion formation and 
aggregation. First TDP43 re-localises and coalesces in the cytoplasm (TDP43 positive 
inclusion), then over time it becomes mis-folded, thiofavin-S positive, and ubiquitinated 
(TDP43 positive aggregate). FTLD-FUS inclusions were typically negative for thioflavin-S, 
however there were some positive granular cytoplasmic inclusions in the hippocampal 
dentate gyrus neurons (Bigio et al., 2013). Bacterial expression systems of both TDP43 
and FUS have shown these proteins do spontaneously form fibrils visible under electron 
microscopy, but the lack of thioflavin-S staining in FTLD-FUS may suggest a divergent 
pathogenesis between these two highly related proteins and diseases.  
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This theory of mis-folded protein being a convergent moment in the pathogeneisis of 
multiple diseases comes hand in hand with the theory of prionoid spread and the 
phenomenon of permissive-templating (Hardy, 2005). Well described permissive-
templating diseases include transmissible spongiform encephalopathies like Creutzfeldt–
Jakob disease, and inheritable prion diseases caused by mutations in the PRNP gene. In 
these cases normally folded PrPC changes to a β-sheet-rich conformation (PrPSc) that is 
protease resistant and insoluble. The key property of PrPSc that makes this disease so 
devastating is its ability to template this change onto the reservoir of normally folded 
PrP, not just within the cell but adjoining brain regions.  Interestingly, this self-
templating prion behavior is rooted in survival not disease. Yeast cells use prion proteins 
as genetic elements which confer survival benefits under certain conditions. For 
example, yeast Sup35 protein is normally required for stop-codon recognition and 
translational termination; however, under certain stressful conditions it can form a self-
propagating fibrillar β-sheet conformation that is inheritable to daughter cells (Liebman 
and Sherman, 1979, Patino et al., 1996). This self-templating β-sheet conformation seems 
to be dependent on the N-terminal region, which is rich in Q/N residues. Because this 
glutamine/asparagine rich region is characteristic to prion-like propagation, it is 
referred to as the 'prion domain' (Masison and Wickner, 1995). Conversion of the yeast 
Sup35 protein to the prion state leads to loss of function and as a consequence 
widespread read through of stop codons. This radical change in gene expression allows 
the rapid emergence of novel survival phenotypes. This represents a molecular adaptive 
strategy for yeast survival under stressful conditions based on the phenomena of 
conformational change. 
The mammalian proteome, and particularly those proteins capable of binding RNA, 
contain several glutamine/asparagine rich prionoid domains that may use self-
aggregation to modulate their activity. A well-known example is the RNA binding protein 
T-Cell-Restricted Intracellular Antigen-1 (TIA-1), which is a vital component of stress 
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granules (Gilks et al., 2004). Briefly, these cytoplasmic RNA-protein complexes form 
under conditions of cellular stress, and mediate adaptive mRNA translational 
suppression.  The prion-related glutamine/asparagine domain of TIA1 is essential for 
self-aggregation and stress granule formation. Thus, one consistent theme for proteins 
containing prion-related glutamine/asparagine rich domains from yeast to mammals is 
stress-induced conformational change leading to self-aggregation, which then alters 
protein function to orchestrate an adaptive response in gene expression or translation. 
Several predictive algorithms have been used to identify proteins containing prion-like 
domains in both yeast and human proteomes, many of which bind to DNA/RNA based on 
their amino acid sequence (King et al., 2012). Where particular proteins rank in terms of 
prionogenicity depends on the design and sensitivity of the algorithm as well as how it 
was trained. However, in all published analyses FUS, EWS, and TAF15 rank exceptionally 
high in terms of prionoid properties, often higher than TIA1 (Alberti et al., 2009, Toombs 
et al., 2010, Couthouis et al., 2011). 
1.4.2 Stress Granules and P-bodies 
The aggregation of proteins in neurodegenerative disease contrasts with the functional 
aggregation of Sup35 in yeast, but also TIA1 in mammalian stress granules. These 
cytoplasmic foci are heavily involved in the processing and turn-over of mRNA. RNA 
binding proteins such as those we see aggregating in FTLD-FUS have both nuclear and 
cytoplasmic functions related to mRNA. Nuclear functions encompass regulating mRNA 
maturation including; RNA helicase activity, RNA polymerase elongation, splicing, and 
nuclear export (Heyd and Lynch, 2011). In the cytoplasm these proteins can regulate 
RNA transport, translation or silencing, as well as degradation (Liu-Yesucevitz et al., 
2011). Much of this cytoplasmic regulative activity occurs at distinct macromolecular 
sites assembled by protein-protein interactions through glycine rich domains and Q/N 
rich regions, and protein-mRNA interactions through RNA recognition motifs (RRM) 
(Krichevsky and Kosik, 2001).  Importantly, different macromolecular granules are 
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assembled to undertake different functions. Visualizing proteins associated with these 
different functions allows microscopic delineation of these separate granules.  
Stress granules can be visualized with antibodies directed to TIA-1, whose RRM will 
recognize uracil rich 30-37 nucleotide bipartite motifs (Lopez de Silanes et al., 2005), or 
TIA1 cytotoxic granule-associated RNA binding protein-like 1 (TIAR) that will recognize 
mRNA with 28-32 long stem loops (Kim et al., 2007). The HuR proteins will bind mRNA 
uracil rich 17-20 nucleotide long sequences (Lopez de Silanes et al., 2004), and Ras-GAP 
associated endoribonucelase (G3BP), which is important in the formation of stress 
granules, cleaves mRNA between CA dinucleotides (Tourriere et al., 2001). The reaction 
cascade that leads to stress granule formation is complex but can be best interpreted 
through the phosphorylation of eukaryotic translation initiation factor 2α (eIF2α).  
Cellular stress prompts the phosphorylation of eIF2α at serine 51 by stress kinases (PKR, 
HRI, PERK or GCN2), which inhibits the translation complex containing 
tRNAimet.(Kedersha et al., 1999). Capped mRNA remains bound to the pre-initiation 
complex and forms a nucleus for aggregation through TIA-1 and other protein-protein 
interactions. Stress granules are initially small and punctate but will increase in size as 
the RNA binding proteins listed above begin to coalesce and aggregate through their 
glycine-rich domains and Q/N rich regions. The vital nature of stress granules in the 
survival response is highlighted by increase apoptosis upon stress after knockdown of 
TIA-1 or inhibition of eIF2α phosphorylation (Phillips et al., 2004, Jiang et al., 2003). 
However, this response has evolved to cope with acute transient stress, and the 
consequence of long term persistence of stress granules has not been explored. Stress 
granules dissociate relatively rapidly (1-3 hours) once the stress has been removed 
(Kedersha et al., 1999), once again through the phosphorylation status of eIF2α (Moreno 
et al., 2012). Pharmacological agents allow the manipulation of stress granules by 
altering the processes outlined here. Cycloheximide and emetine inhibit their formation 
by interrupting protein elongation whilst maintaining polysomes, thus preventing free 
41 
 
mRNA accumulating in the cytoplasm and therefore stress granule nucleation (Kedersha 
and Anderson, 2007). Conversely, puromycin causes premature chain termination within 
the ribosome, and therefore disassembly of the polysome.  
Whilst sequestration of basal mRNA is the remit of stress granules, their subsequent 
degradation is mediated by a separate but related granule called P-bodies. These can be 
visualized by a separate group of markers including; mRNA-decapping enzyme 1a 
(DCP1a), the Sm and SM-like (LSm 1-7) proteins (Ingelfinger et al., 2002). Given their 
highly related function it is not unexpected that some components of one can be found 
within the other and moreover they are often found adjacent to one another (Parker and 
Sheth, 2007). The vast majority of P-body constituents are geared towards mRNA 
repression, interference and non-sense mediated decay. Examples include, mRNA 
decapping machinery, activators of decapping and the 5’ to 3’ exonuclease Xrn1p (Cougot 
et al., 2004, Ingelfinger et al., 2002).  
Both stress granules and P-bodies are not free floating entities but rather they are closely 
associated to the cytoskeleton and require microtubule alteration to function properly 
(Kwon et al., 2007). Histone deacetylase 6 (HDAC6) deacetylates tubulin to reduce 
cellular motility and is vital to the formation of stress granules. This enzyme also 
provides an interesting link with tau, because low activity is associated with tau 
accumulation, a hallmark of neurodegeneration (Cook et al., 2012). Furthermore, the 
dynein motor has been shown to tether stress granules to the cytoskeleton and aid the 
coalescence of small granules (Tsai et al., 2009). 
The discovery that the cytoplasmic inclusions of FTLD-FUS contain stress granule 
markers (Dormann et al., 2010) has led to a flurry of research around this theme (Bosco 
et al., 2010, Gal et al., 2011).  Some authors hypothesized that stress granule formation 
may be a precursor to the more sinister cytoplasmic aggregates (Dormann et al., 2010).  
Yet these proteins are known to easily disperse and return to solution (Kedersha et al., 
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2000).  Despite this, stress granule markers such as TIA-1 co-localize with the 
characteristic neuronal aggregates of Alzheimers disease, ALS, FTLDP-17, FTLD-TDP, and 
FTLD-FUS (Liu-Yesucevitz et al., 2010) suggesting there may be a link between the two 
phenomena. However, when considering human pathological tissue it is worth 
remembering that any observation is of the absolute final time point of death. It is 
possible that as the aggregate grew it absorbed other non-membranous structures like 
stress granules as it dominated the cytoplasm. Evidence to the contrary comes from 
animal models which aim to emulate decades of disease in a matter of weeks. These 
animals also show stress granule markers within their induced pathology (Vanderweyde 
et al., 2012). 
All of the widely accepted pathological markers of FTLD-FUS have been found to re-
localise to stress granules or P-bodies when subjected to cellular stress (Liu-Yesucevitz 
et al., 2010, Blechingberg et al., 2012b, Chang and Tarn, 2009). However, re-localisation 
to the cytoplasm and arrangement into foci does not cause these proteins to become 
highly insoluble. This is crucial since highly insoluble protein is a core feature of 
aggregated disease protein. 
1.4.3 Oxidative and non-oxidative stress 
The term ‘reactive oxygen species’ (ROS) is widely used in conjunction with 
neurodegeneration, particularly in the field of Alzheimer’s disease (Hardy and Allsop, 
1991, Selkoe, 1996). It refers to the generation of the superoxide anion [O2]- , this species 
is highly reactive and widely described as damaging to DNA and proteins alike.  ROS are 
included in the pathogenesis hypothesis of Alzheimers’ disease because of several 
observations. Firstly, the alteration of mitochondrial function in this disease is likely to 
lead to electron leakage in the respiratory chain and the consequent formation of 
superoxide radicals. The unbalanced high activity of superoxide dismutase and 
monoamine oxidase B causes the production of more H2O2. The increase of lipid 
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peroxidation and other cell membrane changes indicative of ROS attack. However, many 
of these changes can be found in otherwise healthy aged brains. The milieu of an aging 
brain is therefore considered a more oxidizing environment than its younger 
counterpart. 
Early evidence implicating oxidative stress in ALS was gleaned from identifying clues 
such as lipid peroxidation in the spinal cord and cortex of patients (Shibata et al., 2001, 
Ferrante et al., 1997). As the disease progresses products of peroxidation like 
malondialdehyde and 8-hydroxy-2’-deoxyguanosine from DNA damage can be detected 
in the cerebrospinal fluid and even the blood sera (Oteiza et al., 1997). Strong evidence 
for the deleterious role of oxidative stress comes from patients harbouring SOD1 
mutations. These mutations are causative in ALS can affect the function of superoxide 
dismutase 1, an enzyme responsible for eliminating superoxide free radicals. Since ALS 
and FTLD are now thought to be two ends of a disease spectrum it is not unexpected that 
they share signs of oxidative stress. Increases in 4-hydroxynonenal adducts are found in 
all subtypes of FTLD (tau/TDP43/FUS) as a product of lipid peroxidation (Martinez et al., 
2008). These unstable nucleophiles react with nucleophilic side chains of cysteine, 
histidine, and lysine residues generating covalent bonds between aldehyde carobonyl 
groups and peptide chains, often resulting in a loss of protein function and eventual 
apoptosis (Kruman et al., 1997, Uchida, 2003, Zarkovic, 2003). Lipid peroxidation 
damage is associated with changes in membrane unsaturation and fatty acid profile, 
which in a highly membrane dependent cell type such as neurons could have profound 
implications for proper function. Similarly to ALS the clearest evidence of oxidative 
stress in the pathogenesis of FTLD comes from patients with progranulin null or 
missense mutations. It has been shown that progranulin protein stimulates 
phosphorylation activation of the neuronal extracellular regulated kinase ERK/p90 
ribosomal S6 kinase and phosphatidylinositol-3 kinase cell survival pathways (He et al., 
2002, Lu and Serrero, 2001, Monami et al., 2006, Zanocco-Marani et al., 1999). These are 
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capable of neuroprotection from apoptosis induced by glutamate hyperexcitotoxicity and 
oxidative stress. The progranulin haploinsufficiency associated with FTLD-TDP has yet to 
be fully explored but in the context of what is known about progranulin function it would 
seem that oxidative stress is paramount to pathogenesis. The use of oxidizing agents on 
cell models attempts to mimic the environment of the aged brain and has produced some 
interesting results.  
Sodium arsenite (NaAsO2) is a well-characterized oxidative stressor widely used in cell 
culture experiments to model oxidative stress and stress granules (Vahter et al., 1995, 
Wang et al., 1997, Lynn et al., 1998). It is known to inhibit pyruvate dehydrogenase and 
thereby reduce the adenosine-5'-triphosphate (ATP) energy production of the cell, but 
also produce ROS as is interferes with basal metabolic oxidation-reduction reactions. It is 
this property that drives lipid peroxidation (Schlenk et al., 1997), protein/enzyme 
oxidation and glutathione depletion, poly ADP-ribosylation,  and apoptosis (Abernathy et 
al., 1999). Tert-butyl hydroperoxide (tBH) a relatively stable alkyl hydroperoxide that is 
metabolized by cytochrome P450, haemoproteins, and other systems to produce free 
radical intermediates that initiate lipid peroxidation and glutathione depletion, resulting 
in cellular damage (Barr and Mason, 1995, Schnellmann, 1988, Van Duuren et al., 1966, 
Younes and Wess, 1990). Sorbitol is a relatively less well-characterized stressor that is 
generally not grouped together with the oxidative stressors since its metabolism 
produces only low levels of ROS through the polyol pathway and the sorbitol 
dehydrogenase reaction. It is more commonly dissolved in the liquid media at high 
enough concentrations to produce an osmotic imbalance between the cell and its 
environment. In this regard it is referred to as an osmotic stressor (Dewey et al., 2011). 
1.4.4 Cell and animal models of FTLD-FUS 
The ability to effectively model neurodegenerative diseases in cellular systems has been 
a long sort-after boon to research. However, developing accurate and malleable models 
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takes time and requires a detailed understanding of the pathway being modified.  For 
instance, one issue that has confounded attempts to effectively model neurodegenerative 
disease is the uncertain nature of the cytoplasmic and intranuclear inclusions that are 
almost ubiquitous to all forms of neurodegeneration.  Theories range from; they are 
themselves composed of a toxic species that are harmful to the cell, or that they are 
epiphenomena brought about by a toxic event and are not responsible for disease, or that 
they are in fact the result of protective efforts by the cell and should be encouraged. 
Attempts to model the various forms of FTLD have produced varying levels of success.  
Pure TDP43 synthesized from bacteria is highly prone to aggregation, thanks to the 
intrinsic properties of its C-terminal region (Johnson et al., 2009). Furthermore, these 
aggregates formed amorphous non-amyloid structures strikingly similar in properties to 
those found in TDP43 positive ALS and FTLD.  Yeast models have compounded this 
finding by demonstrating TDP43 aggregation when over expressed (Johnson et al., 2009, 
Johnson et al., 2008). These studies were also able to show that over expression of 
TDP43 was toxic to the cell.  However, attempts to recapitulate these finding in 
mammalian cells have struggled. Over expression of full length TDP43 in mammalian 
cells produced predominantly soluble and nuclear TDP43 (Wang et al., 2004, Ayala et al., 
2008, Winton et al., 2008). Instead it was the expression of the C-terminal fragment 
implicated earlier that produced cytoplasmic insoluble TDP43. FUS research has 
produced similar findings, namely that bacterially expressed FUS spontaneously 
aggregates into filamentous structures (Sun et al., 2011).  However, over expression of 
FUS in mammalian cells produced a soluble and normally localised phenotype. To 
reproduce the pathological findings of insoluble FUS aggregating in cytoplasmic and 
intranuclear inclusions in a cellular system will require more than just over expression. 
Given that one of the prominent hypotheses of FTLD-FUS and ALS-FUS hinges on the loss 
of FUS function, discussing the phenotypes of knockout mice is worthwhile. 
Heterozygous knockouts are slightly smaller at birth, a characteristic that is exacerbated 
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during weaning resulting in an animal 30% smaller than wild type (Kuroda et al., 2000). 
Interestingly, other than their reduced size they appear developmentally normal, and 
outbred strains survive for just as long. However, animals on an inbred background do 
not survive beyond weaning (Kuroda et al., 2000). No clear reason for this difference is 
forthcoming. Homozygotes are severely infertile with males showing complete sterility 
and females reduced fertility. This male sterility was not androgen related because 
animals showed normal mounting behaviour and internal sexual organs (Kuroda et al., 
2000). However, these mice did show deficits in homologous pairing of chromosomes 
leading to defects in spermatogenesis. Unfortunately, these authors were not specifically 
interesting in possible neurological deficits associated with ALS and FTLD and therefore 
did not perform in-depth immunohistochemical examination of the CNS. However, since 
normal mounting behaviour was noted it could be surmised that normal motor function 
remains. Knockin mice overexpressing tagged human FUS (hFUS) show highest 
expression in the brain, spinal cord and testis (Mitchell et al., 2013).  It is tempting to 
take this finding as indicative of anatomical areas reliant on FUS for proper function, but 
this pattern is typical of human PrP promoter driven expression (Borchelt et al., 1996). 
Overexpression was accompanied by a concomitant down regulation of murine FUS, 
suggesting an expression feedback loop. At 4 weeks these mice develop tremor and a 
stilted gait, then rapidly progressing motor neuron deficits exemplified by poor rotor-
rod and open field performance (Mitchell et al., 2013).  At 7-8 weeks the hind limbs are 
paralyzed, which contrasts with heterozygotes that show normal growth and motor 
performance. Immunohistochemical examination of the CNS reveals cytoplasmic 
accumulation of hFUS but this is not accompanied by the ubiquitination so characteristic 
of FTLD-FUS (Mitchell et al., 2013). In rat models overexpressing mutant (R521C) but 
not wild type hFUS causes progressive paralysis in transgenic rats. This motor neuron 
degeneration is similar to that seen in mice, but it was also accompanied by significant 
neuron loss in the frontal cortex and dentate gyrus, two areas predominantly affected in 
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FTLD-FUS. Interestingly, unlike paralysis this was evident under both mutant and wild 
type hFUS (Huang et al., 2011). Ubiquitinated inclusions were evident in mutant 
expressing animals at the same time point of paralysis, and present in wild type 
expressing animals at advanced stages of cortical degeneration (Huang et al., 2011).  
These inclusions were not FUS positive regardless of genotype and furthermore FUS 
remained mainly nuclear despite the R521C mutation producing strong cytoplasmic 
staining in cell culture (Dormann et al., 2010).  How this relates to the pathogenesis of 
human disease is unclear. Clearly aberrantly high levels of FUS are neurotoxic but the 
protein is not as aggregation prone as previously thought, at least in rats.  
Due to the relatively new discoveries of EWS, TAF15 and not least TRN1 in the pathology 
of FTLD-FUS, no animal models have been created to investigate these proteins. It will be 
interesting to see if simultaneous overexpression of the FET proteins or TRN1 will 
produce the most accurate pathology and behavioural measures. 
 
1.5 Aims of this study 
Due to the similarities in pathology between ALS-FUS and FTLD-FUS, TRN1 and nuclear 
import in the context of oxidative stress could have an important role to play in FTLD-
FUS.  
This study aimed to investigate the role of TRN1 in FTLD-FUS in terms of: 
 Pathology and biochemistry of TRN1 in FTLD-FUS 
 Characterizing the response of TRN1 and the FET proteins in SH-SY5Y cells 
subjected to various stressors. 
 Characterizing the response of TRN1 and the FET proteins in rat primary 
hippocampal neurons subjected to oxidative stress 
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Chapter Two: Materials and 
Methods 
2.1 Tissue procurement  
Human tissue for these studies was partly obtained from the archive at the Queen Square 
Brain Bank for Neurological Disorders, UCL Institute of Neurology where tissue is 
collected with the ethical approval of the London Multicentre Research Ethics Committee 
and with the informed consent of next-of-kin. Tissue were also obtained from the MRC 
London Brain Bank for Neurodegenerative Diseases, Institute of Psychiatry, King’s 
College, London, UK ;  Neuropathology Department, Århus Kommunehospital, Århus, 
Denmark and NeuroResource, UCL Institute of Neurology, University College London. All 
patients had details of a standard clinical history and had undergone both neurological 
examination and cognitive assessment. Details of FTLD-FUS cases including age of onset 
and post-mortem delay are available in the next chapter.   
2.2 Tissue Processing: Paraffin embedded tissue  
Representative areas of formalin fixed brain and spinal cord tissue were processed as 
shown in table 1. 
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Step 
Reagent Time (hrs) 
1 70% alcohol 6:00 
2 90% alcohol 6:00 
3 90% alcohol 6:00 
4 Absolute alcohol 6:00 
5 Absolute alcohol 6:00 
6 Absolute alcohol 6:00 
7 Absolute alcohol 6:00 
8 Chloroform 6:00 
9 Chloroform 6:00 
10 Wax 6:00 
11 Wax 6:00 
12 Wax 6:00 
 
                 
Table 2.1 Processing of paraffin tissue. Reagents and times used 
 
After processing tissue was embedded in paraffin wax and stored until required. Paraffin 
sections were cut using a Shandon Finesse (Thermo) rotary microtombe at 8μm and 
floated out onto warm water. The sections were picked up on HistoBond (Marienfield ) 
slides, and left to dry at 37oC for several hours followed by an overnight incubation at 
60oC. 
2.3 Immunohistochemistry on paraffin embedded sections 
Sections were de-waxed in three changes of xylene for 5 minutes, followed by 
rehydration using graded alcohols (100%, 90% and 70%). For all immunohistochemical 
staining the endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol 
for 10 minutes followed by washes in tap water for at least 5 minutes. Sections were pre-
treated for antigen retrieval in pH 6 citrate buffer and pressure cooked at over 120°C and 
100 kPa. Non-specific protein binding was blocked using 10% non-fat milk in PBS (0.05M 
pH 7.2) by incubating the sections for 30 minutes at room temperature. The milk was 
then replaced with the required primary antibody and incubated for 1 hour at room 
temperature or overnight at 40C (Table 2.2) depending on the primary antibody used 
(e.g. mouse monoclonal 1hr at room temperature, rabbit polyclonal over night at 4˚C), 
followed by two washes in PBS. Incubation with the relevant secondary antibody (Table 
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2.3) was carried out for 30 minutes at room temperature, followed by washing in PBS. 
Sections were incubated in avidin-biotin complex (ABC, Dako) for 30 minutes at room 
temperature, followed by washes in PBS. The antigen-antibody reaction was visualized 
using di-aminobenzidine (DAB, Sigma) as the chromogen by using 500μg/100ml DAB in 
PBS solution that was activated with 32l H202 (30% solution, VWR chemicals) for 2 
minutes before the colour intensity checked. Sections were replaced into the DAB 
solution if darker colour intensity was required. Sections were counterstained with 
Mayers haematoxylin (VWR chemicals) for 15 seconds, washed in warm tap water and 
finally dehydrated through 70%, 90% and absolute alcohol before being cleared in three 
changes of xylene and permanently mounted with DPX (VWR chemicals).  
2.4 Immunohistochemistry on frozen sections  
Frozen sections were cut at 10m from either flash frozen or slow frozen material, using 
a cryostat (Bright), and mounted onto either superfrost slides (VWR) or vectabond 
coated slides (Vector), depending on the size of the sections collected. Sections were air 
dried for 30 minutes, frozen at –80oC and stored until needed. Sections were removed 
from the freezer and placed on foil and air dried for 10 minutes, post-fixed in 4% 
paraformaldehyde, for 30 minutes at room temperature. This was followed by washes in 
distilled water and two washes in PBS.  The endogenous peroxidase activity was blocked 
using 0.3% H2O2 in methanol for 10 minutes followed by washes in distilled water and 
two changes of PBS. The non-specific protein was blocked using 10% non-fat milk for 30 
minutes at room temperature. The sections were incubated with the primary antibody 
for 1 hour at room temperature and the remaining protocol was followed as previously 
described. 
2.5 Double immunofluorescence on paraffin embedded sections  
Sections were de-waxed in three changes of xylene for 5 minutes, followed by 
rehydration using graded alcohols (100%, 90% and 70%). For all immunohistochemical 
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staining the endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol 
for 10 minutes followed by washes in tap water for at least 5 minutes. Sections were pre-
treated for antigen retrieval in pH 6 citrate buffer pressure cooked at over 120°C and 
100 kPa. Non-specific protein binding was blocked using 10% non-fat milk in PBS (0.05M 
pH 7.2) by incubating the sections for 30 minutes at room temperature. The milk was 
then replaced with the required primary antibody and incubated for 1 hour at room 
temperature or overnight at 40C depending on the primary antibody used, followed by 
two washes in PBS. Anti-mouse fluorescent secondary antibody was incubated with the 
tissue for 1 hour followed by two washes in PBS. Anti-rabbit biotinylated secondary 
antibody was then incubated with the tissue for 30 minutes followed by washing in PBS. 
Incubation with avidin-biotin complex for 30 minutes and washing was followed by 
visualization with tyramide signal amplification (PerkinElmer). Sections were washed in 
PBS and mounted with vectashield DAPI containing media (Vector) and sealed with nail 
varnish for long term storage.  
To establish the proportion of FUS-positive inclusions also labelled with the anti-TRN1 
antibody double-labelled sections of the hippocampus were chosen from 3 NIFID and 3 
FTLD-U cases, the granule cell layer was identified using the Leica DM5500B 
fluorescence microscope and ten sequential visual fields of this structure using an X63 
objective were captured. Subsequently z-stack of images through the full depth of the 
tissue section were taken and a non-blind deconvolution algorithm was applied. A 
maximum projection of the z-stack provided the final image for analysis. TRN1 or FUS-
positive NCIs and NIIs were visually identified on the appropriate channels and the co-
localisation was confirmed on the combined images.  
2.6 Bacterial cell culture protocols  
The lysogeny broth (LB) media used in the bacterial procedures was 10% w/v Bacto 
Tryptone (Beckon Dickinson), 5% Bacto Yeast Extract (Beckon Dickinson) and 10% NaCl 
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dissolved in distilled de-ionised water which was subsequently autoclaved. Agar 
(Invitrogen) was added at 15% w/v before sterilization to make agar plates. Kanamycin 
(sigma Aldrich) was added to a final concentration of 50µg/ml when making colony 
selection plates.  
Plasmid DNA was obtained from OriGene (RC218884). The vector was pCMV6-Entry and 
drove expression of human TNPO1 transcript variant 1. Bacterial antibiotic resistance 
was against kanamycin.  
Lab stocks of previously made competent XL1-Blue E.coli from the CaCl method were 
thawed on ice and 1µg of plasmid DNA was added and gently mixed, the tubes were 
incubated on ice for 30 minutes. The tubes were then pulse heated in a 42°C heating 
block for 45 seconds and subsequently quenched on ice for 2 minutes. Pre-warmed LB 
was added (1ml) and the tubes were incubated at 37°C for 1 hour while shaking. The 
cells were then pelleted by pulse-centrifugation and 800µl of the supernatant was 
discarded. The pellet was re-suspended in the remaining 200µl and streaked on 
ampicillin-containing agar plates then incubated at 37°C over night. 
A single colony was picked with the aid of a sterile plastic loop and used to inoculate 5ml 
of ampicillin containing LB media. This was then incubated at 37°C for 6 hours whilst 
shaking at 250 rpm.  This starter culture was then used to inoculate a total of 500ml of 
ampicillin containing LB that was incubated at 37°C over night with 250 rpm shaking.  
Stocks of transformed bacteria were made by transferring 700µl of an over night culture 
to a 1.5ml eppendorf tube and adding 300µl of 50% sterile glycerol solution to obtain a 
final 15% v/v glycerol content. This was gently mixed and frozen to -80°C for long term 
storage.  
Plasmid purification was achieved using the mega prep kit from Qiagen and following the 
manufacturer’s instructions. Briefly, the over night bacterial culture was pelleted by 
centrifugation and resuspended in a tris-based buffer. Subsequent alkaline lysis of the 
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cells followed neutralization of the lysate by the addition of a low salt and low pH buffer. 
An anion-exchange resin was used to bind the DNA while RNA, proteins and low 
molecular weight impurities were removed by washing with a medium salt buffer. The 
plasmid DNA was purified in a high salt buffer and subsequently concentrated and 
desalted by isopropanol precipitation. The purified DNA was finally resuspended in 
500µl of 10mM tris-HCl pH 8.  
A single microliter of purified plasmid was assessed by spectrophotometry to determine 
its DNA concentration and purity. The absorbance was measured with the aid of a nano-
drop spectrophotometer at wavelengths of 260nm and 280nm, against a blank sample of 
tris buffer. DNA absorbs ultraviolet light with an absorption peak of 260nm, and protein 
shows an absorption peak at 280nm. A ratio of the absorptions at two wavelengths gives 
an indication of purity with respect to protein contamination, a result of 1.8 is 
considered ‘pure’. The concentration of DNA is assessed using the following equation; 
Concentration (mg/ml)=[(total volume/DNA volume) x A260 x 50] / 1000 
To increase the purity of DNA the method of Phenol-Chloroform extraction was used. An 
equal volume of phenol/chloroform/isoamyl alcohol (at a ratio of 25:24:1) was added to 
the DNA sample and mixed by brief vortexing. The mixture was then centrifuged in a 
microcentrifuge at 14,000 rpm for 5 minutes. The upper aqueous phase was carefully 
transferred to a fresh tube, avoiding the white interphase region containing the protein 
impurities. The phenol extraction process was repeated and the final aqueous phase was 
transferred to a fresh tube. Sample was extracted two times with equal volumes of 
chloroform:isoamyl alcohol to remove traces of phenol. Two volumes of pure ethanol 
were added to the sample and sodium acetate pH 5.2 was added to a final concentration 
of 0.3M. The solution was mixed and incubated on dry-ice for 10 minutes. The tube was 
centrifuged at 14,000 rpm for 10 minutes. The supernatant was carefully discarded and 
the DNA pellet was washed with 200µl of 70% ethanol. The tube was centrifuged again 
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for 2 minutes at 14,000 rpm and the supernatant was again discarded. The pellet was 
dried in a vacuum centrifuge for 5 minutes and the DNA was finally resuspended in 
10mM tris pH 8.  
2.7 Mammalian cell culture protocols 
The immortalised neuroblastoma cell line SH-SY5Y is derived from a neuronal 
population, and was chosen because such a line would allow investigation of events that 
could prime neurons for pathogenesis. 
Cells were initially recovered from frozen stocks stored in liquid nitrogen. Cells were 
thawed in 37°C and re-suspended in pre-warmed media before being centrifuged at 150g 
for 5 minutes. The medium was decanted and the cell pellet re-suspended in fresh media 
then plated onto cell culture dishes. Frozen stock was replenished once new cells had 
reached adequate confluence levels by removing cells from plate via trypsinisation 
(0.5mg/ml in PBS) and centrifugation at 150g for 5 minutes. The supernatant was 
decanted and the cell pellet was re-suspended in 1.5ml of freezing stock solution (10% 
DMSO in complete media) and placed into a Cryovial. Cells were frozen gradually to -
80°C over night in an isopropanol-insulated container, before being moved to liquid 
nitrogen for long term storage.  
Mammalian cells were grown and maintained in 6cm Petri dishes with Dulbecco's 
Modified Eagle Medium (DMEM)(Life Technologies) with 10% foetal bovine serum (Life 
Technologies) and 1% antibiotics (Life Technologies) in incubators maintained at 37°C 
and 5% CO2.  
Glass coverslips (24 x 24mm2 thickness 1) were treated with 40% HCL for 10 minutes 
with shaking, and then washed thoroughly with water. Coverslips were dried on blotting 
paper and baked overnight at 80°C wrapped in foil. In plating primary neurons the 
coverslips were treated with 30µg/ml ply-D-lysine for 30 minutes before being washed 
with distilled water and dried. 
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Transfection for siRNA mediated knockdown was achieved by plating cells at 
approximately 70% confluency on coverslips or 6-well plates in antibiotic free DMEM. 
The transfection mix was 90µl room temperature DMEM, 4µl lipofectamine RNAimax 
and an appropriate volume of siRNA solution depending on the desired concentration. 
This was left to complex at room temperature for 20 minutes. The mix was added 
dropwise to the cells and media for a total volume of 1ml per well. This was repeated 
three days later and left for another three days before lysis or fixation. Effect of this 
siRNA transfection on detectable protein levels is shown in Figure 2.1. 
 
Figure 2.1. Reduction of TRN1 and TRN2 protein levels by siRNA knockdown.  
Densitiometric quantification is expressed at percent of protein detected compared to 
untreated cells (0nM). Scramble siRNA has no effect on either TRN1 or TRN2 protein 
levels at any concentration. Pool of anti TNPO1 and TNPO2 siRNA reduced TRN1 protein 
levels by 71.7% and TRN2 by 73.4% at 100nM each. Error bars SEM, n=3. 
Transient transfection for over expression was achieved by plating cells at 
approximately 70% confluency on coverslips or Petri dishes. Cells were serum starved in 
DMEM for 1hr 45 minutes before the transfection mix was added. The transfection mix 
was 190µl room temperature DMEM, 4µl lipofectamine2000 (Invitrogen) and 5µg DNA. 
This was added to cells dropwise and left for 4 hours and 30 minutes, then replaced with 
complete media.  Harvesting or fixation occurred 24 hours later to allow sufficient 
expression of the plasmid.  
Compounds (drugs or toxins) were added to pre-warmed complete media from stock 
solutions. The following were kept in either de-ionized distilled autoclaved water or 
DMSO; arsenite (Sigma Aldrich) at 0.5M in distilled water, tBOOH (Sigma Aldrich) at 
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7.3M in distilled water, puromycin dihydrochloride (Sigma Aldrich) at 18.4mM in 
distilled water, emetine dihydrochloride (Sigma Aldrich) at 180mM in DMSO. Sorbitol 
was kept in dry stock until needed whereupon it was dissolved in warm media.  
2.8 Preparation of dissociated e18 rat hippocampal neurons  
Embryonic day 18 rats were obtained from the Biological Services Unit at University 
College London. Individual embryos were separated from the amniotic sack and the 
heads removed and placed in dissection solution (Hank’s Balanced Salt Solution (HBSS) 
containing sodium pyruvate at 10mM and HEPES pH7.4 at 100mM (Sigma-aldrich). Two 
pairs of forceps were used to steady the head and peel away the skull and meninges. The 
brain was then scooped out of the skull and any remaining membrane or blood vessels 
were removed.  The brain naturally opens along the hemispheres exposing the deep 
structures, the hippocampus is the most obvious structure and can be removed with a 
snipping action from the forceps. The excised hippocampi were held in a separate dish 
containing chilled dissection solution. Once all the hippocampi had been harvested they 
were placed into pre-warmed papain solution (neurobasal media (Invitrogen) and 
15U/ml papain (Sigma-aldrich) for 25 minutes at 37°C. The papain solution is then 
replaced with papain inhibitor solution (neurobasal media and DNase 1 0.2mg/ml 
(ROCHE) and the tissue physically dissociated using flame narrowed Pasteur pipettes. 
The cells are then spun down at 75g for 5 minutes and the supernatant aspirated. The 
pellet is then resuspended in plating media (neurobasal media containing glutamine 
(Sigma-aldrich) and B27 (Gibco) supplements and penicillin/streptomycin) and counted 
on a haemocytometer using 1% trypan blue. Cells were plated at 200,000 cells per 
coverslip , and allowed to settle in plating media. The coverslips had been treated with 
poly-D-lysine at 0.1mg/ml for 30 minutes with shaking to ensure cell adherence. Three 
days later the media was replenished by removing 1/3 of the volume and replacing it with 
1/2 the volume of replenishing media (neurobasal media containing glutamine and B27). 
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Differentiation was followed morphologically over 5 days using phase contrast 
microscopy.  
  
Figure 2.2. Stages of differentiation in rat hippocampal neurons. By day 5 neurons are 
fully differentiated. 
2.9 Cell immunocytochemistry  
Cells on coverslips were fixed in 4% paraformaldehyde (in PBS) for 15 minutes on ice 
and subsequently washed three times in PBS for 10 minutes each. Cells were 
permeabilised in 0.2% triton (in PBS) for 7 minutes and blocked in 3% bovine serum 
albumen (BSA) at room temperature. Primary antibodies were added at the appropriate 
dilution in 1% BSA in PBS and incubated at 37°C for 2 hours. The cells were then washed 
three times in PBS for 10 minutes. Secondary antibodies were added at a 1:200 dilution 
and the cells were left at room temperature in the dark for 1 hour. After three washes in 
PBS for 10 minutes each the coverslips were mounted using vectashield DAPI containing 
media (Vector) and sealed with nail varnish for long term storage. Fluorescence 
microscopy was conducted with a Leica DM5500B widefield in most cases, or LSM 710 
confocal in the case of Figure 5.3. 
2.10 Quantification of stress granule counts  
Microscope slides were blinded for treatment (e.g. arsenite, tBH, or sorbitol) and stain 
(e.g. TRN1+G3BP or TRN1+FUS), coverslips were then divided into a grid of 30 19.2mm2 
squares. A random number generator produced values between 1 and 30 and the cells 
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visible in one visual field from that grid-square were analysed under the 63X objective. 
The number of cells was counted via nuclear DAPI staining; the number of cytoplasmic 
TRN1 foci were counted and compared to either G3BP, FET protein or ubiquitin staining 
for co-localisation. This was repeated for 10 non-duplicated grid squares. Graphing of co-
localisation with TRN1 foci was done as percentage of total TRN1 foci for ease of 
interpretation. An analysis of variance adjusted for multiple testing with Bonferroni was 
performed on the raw data to determine the proportion of co-localisation between TRN1 
and the counter stain (e.g. G3BP), and compare this under different conditions.  
Statistical analysis was done with the aid of Stata™ and graphing with the aid of 
GraphPadPrism™.  
2.11 Thioflavin S staining in cells  
Cells grown on coverslips were fixed with 4% paraformaldehyde (in PBS) for 15 minutes 
on ice and washed three times in PBS for 10 minutes each. Cells were then permeabilized 
with 0.2% triton (in PBS) for 7 minutes and washed three times in PBS for 10 minutes, 
before being stained with 0.01% thioflavin S (in distilled water) for 5 minutes. Cells were 
then washed in 70% ethanol (in distilled water) twice for 7 minutes each, then twice in 
distilled water for 5 minutes. After a final wash in PBS the cells were blocked in 3% BSA 
for 30 minutes ready for incubation with primary and secondary antibodies as described 
previously.  
2.12 BCA protein assay 
The concentration from cell lysates or brain fractions was determined with a 
bicinchoninic acid assay (Pierce).  The protocol was followed according to the 
manufacturer’s guide lines. The assay follows the principle that peptide bonds from the 
sample to be assessed reduce Cu2+ ions in cupric sulphate to Cu+. The amount of Cu+ 
produced is proportional to the amount of protein present in the solution and the 
temperature the reaction occurs at (37°C). Two molecules of bicinchoninic acid chelate 
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with each Cu+ ion forming a purple product that absorbs light at 562nm. The 
concentration of protein in sampled solutions can be quantified by measuring the 
absorption spectra and comparing it to that of known concentrations.  
2.13 Sequential solubility extractions and western blotting: Tissue  
Tissue samples from frontal cortex (grey matter) from 4 controls, 3 NIFID and 4 aFTLD-U 
cases were homogenised at a ratio of 1:2 (wt/vol) in high-salt (HS) buffer (50mM Tris-
HCl, 750mM NaCl, 10mM NaF, 5mM EDTA) containing 1% Triton-X and protease and 
phosphatase inhibitors (Roche). Tissue homogenate was spun at 1000g to remove 
nuclear and membrane debris. The resulting supernatant was subjected to 
ultracentrifugation at 120,000g for 30 min at 40C, following which the supernatant was 
retained (HS fraction).  Using this HS fraction we performed immunoblotting with both 
the monoclonal (Abcam ab10303, 1:500) and the polyclonal antibodies (Abcam ab67352, 
1:500) to test antibody specificity. Antibody specificity was confirmed by omission of the 
primary antibody. The results of these preliminary experiments indicated that the 
monoclonal antibody identified a strong band at ~100 kDa representing the expected 
molecular weight of TRN1. In addition to this band the polyclonal antibody also labeled 
additional low molecular weight bands. Therefore the monoclonal antibody was 
regarded as more specific and was chosen for the full biochemical analysis. 
The pellet, retained after harvesting the HS fraction, was subjected to further extractions 
with RIPA buffer (50mM Tris-HCl, 150mM NaCl, 1% NP-40, 0.5% deoxycholate) 
containing 2% SDS and protease and phosphatase inhibitors as before, which was 
subjected to ultracentrifugation at 120,000g for 30 min at 15°C to avoid SDS 
precipitation, with the resulting supernatant being termed RIPA-SDS fraction. The final 
pellet was resuspended in 8M urea containing 8% SDS (urea-soluble) fraction.  Protein 
concentration was determined by the BCA protein assay (Pierce) and 20µg of protein 
from the HS and RIPA-SDS fraction, and 5 µg of protein from the urea fraction, of each 
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case was loaded onto 10% Bis-Tris polyacrylamide gels (Invitrogen) and run at 200V 
with MES buffer (Invitrogen) under reducing conditions. Following electrophoresis, the 
proteins were transferred onto Hybond P membrane (GE Healthcare), blocked with 5% 
non-fat dried milk in PBS containing 0.1% Tween (PBS-T) and probed overnight with the 
monoclonal anti-TRN1 (Abcam ab10303, 1:500) antibody at 4˚C. Following washes in 
PBS-T, the blot was treated with HRP-conjugated secondary antibody (Santa Cruz). Blots 
were visualised by enhanced chemiluminesence (Pierce) and the image captured onto 
Kodak, X-Omat (Sigma) films.  
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2.14 Sequential solubility extractions and western blotting: Cells 
Stressor containing media was aspirated from the cells, which were then washed three 
times in ice cold phosphate buffered saline (PBS).  Ice-cold RIPA buffer containing 
phosphotase and protease inhibitor was then used to lyses the cells. Cell lysates were 
then agitated for 30 minutes at 4°C. Lysates were then subjected to ultracentrifugation at 
120,000g for 30 min at 4°C with the resulting supernatant being termed RIPA fraction. 
The pellet was resuspended in 7M urea containing 4% 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 30mM TRIS-HCl pH8 
and termed the urea-soluble fraction.  Protein concentration was determined by the BCA 
protein assay and 5µg of protein from the RIPA fraction and the urea-soluble fraction, of 
each time point was loaded onto 12% Bis-Tris polyacrylamide gels and run at 200V with 
MES buffer under reducing conditions. Following electrophoresis, the proteins were 
transferred onto Hybond P membrane (GE Healthcare Life Sciences), blocked with 5% 
non-fat dried milk in PBS-T and probed overnight with the monoclonal anti-TRN1 
(1:500) antibody at 4˚C. Following washes in PBS-T, the blots were treated with HRP-
conjugated secondary antibody. Blots were visualised by enhanced chemiluminesence 
and the image captured onto Kodak, X-Omat films (Sigma Aldrich).  
2.15 Densitometric quantification of Western blotting 
Computer scanning of X-Omat films with CanoScanLiDE700F digitised them to an 8-bit 
TIFF image. Briefly, to quantify the bands obtained via Western blot analysis, we applied 
ImageJ software based analysis (http://rsb.info.nih.gov/ij/). The area under curve (AUC) 
of the specific signal was corrected for the AUC of the loading control (β-actin). If β-actin 
normalisation was not possible because of the erratic distribution of actin in RIPA and 
urea fractions as in the case of insolubility extractions this is noted in the legend. The 
fraction of protein in question over actin load was plotted (arbitrary values)  and 
analysed with either one-way ANOVA followed by a Dunett’s post-test or Mann-Whitney 
U statistical test depending on the experimental design, to determine any statistical 
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difference between conditions.  Statistically significant differences are noted with 
asterisks symbols as follows: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.   
2.16 Co-immunoprecipiation  
Cells were lysed in co-immunoprecipiation (Co-IP) buffer (1% NP-40, 25mM tris pH8, 
150mM NaCl, 100mM EDTA, 5% glycerol), clarified at 30,000g for 30 minutes at 4°C, the 
supernatant was added to 50µl of IgG conjugated beads (TrueBlot) and pre-cleared for 1 
hour by rotation at 40rpm. The mixture was spun down at 1000g for 10 minutes and the 
supernatant recovered for protein assay. A sample of 10µg was removed and held as 
input. The remaining sample was rotated with the appropriate antibody at 1:500 (or not 
if sample was IP negative control) overnight at 4°C. Another 50µl of species specific 
beads (same as pre-clear) was added and rotated with sample for 2 hours at 4°C. The 
mixture was spun down at 1000g for 5 minutes and the supernatant discarded. The 
pellet was washed six times with 1ml of Co-IP buffer and centrifugation. The pellet was 
finally resuspended in Co-IP buffer and laemmli buffer with reducing agent ready for 
western blotting. To avoid detection of non-specific immunoglobulin heavy and light 
chains specialist TrueBlot® HRP-conjugates secondary antibodies (eBioscienec) were 
used (Table 1.3). 
2.17 FTLD-FUS and other cases of neurodegenerative disease  
Brains were donated to the Queen Square Brain Bank for Neurological Disorders, UCL 
Institute of Neurology, University College London; the MRC London Brain Bank for 
Neurodegenerative Diseases, Institute of Psychiatry, King’s College, London, UK ; 
Neuropathology Department, Århus Kommunehospital, Århus, Denmark and 
NeuroResource, UCL Institute of Neurology, University College London. All FTLD-FUS 
cases had previously been diagnosed as NIFID (7 cases) or aFTLD-U (7 cases) (Table 3.1). 
Two aFTLD-U (case 13 was the mother of case 9) cases are from the same family, 
although no mutations in the FUS gene have been found (Lashley et al., 2011).  In 
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addition, 3 normal control cases and 3 cases each with multiple system atrophy, 
corticobasal degeneration, motor neuron disease, Alzheimer’s disease, Parkinson’s 
disease, progressive supranuclear palsy, Pick’s disease and FTLD-TDP types 1 and 3 
were selected from the archives of the Queen Square Brain Bank.  Three cases with 
FTLD-TDP type 2 pathology, which included one of the motor neuron disease cases with 
extensive cortical TDP43 pathology and also used as motor neuron disease control, were 
also used for the TRN1 in FTLD-FUS study. In addition to frontal and hippocampal 
regions, the cervical or thoracic spinal cord from each motor neurone disease cases was 
also stained for TRN1. No BIBD cases were available for this study in our archives. The 
investigation into TRN1 and FUS in polyglutamine diseases used 6 cases of 
spinocerebellar ataxia (two of type 3, and one of types 1, 2, 6 & 7), 2 cases of 
Huntington’s disease, and one case of neuronal intranuclear inclusion body disease. 
Regions investigated included; frontal cortex, hippocampus, medulla, pons, basal ganglia, 
cerebellum, and spinal cord.  
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2.18 Primary antibodies used for this thesis 
 
 Antibody Table 
Antibody Species Dilution 
for IHC 
Dilution for 
Western blot 
Company 
DCP1a rabbit 1:200 NA sigma aldrich 
DDX3 rabbit 1:100 NA abcam 
eIF2α goat 1:2000 1:500 Santa Cruz 
eIF2α(phospho) goat 1:2000 1:500 Stanta Cruz 
eIF4G rabbit 1:200 NA Cell Signalling  
EWS (G-5) mouse 1:50 NA Santa Cruz 
FUS mouse 1:200 1:1000 sigma aldrich 
FUS  rabbit 1:200 NA sigma aldrich 
FUS (565) rabbit 1:200 1:10,000 Novus Biologicals 
G3BP rabbit 1:100 1:1000 abcam 
G3BP mouse 1:200 1:1000 abcam 
hnRNP A1 mouse 1:200 NA abcam 
Importin β1 rabbit 1:50 NA abcam 
karyopherin β3 mouse 1:200 NA abcam 
myc-tag mouse 1:200 NA abcam 
myc-tag rabbit 1:200 1:500 abcam 
NUP98 rat 1:200 NA abcam 
NXF1 mouse 1:50 NA abcam 
PABP1  mouse 1:100 NA sigma aldrich 
TAF15 rabbit 1:200 NA Novus Biologicals 
TAF15 mouse 1:200 1:1000 sigma aldrich 
TIA-1 mouse 1:200 1:500 sigma aldrich 
TRN1  rabbit 1:200 1:500 abcam 
TRN1 (D45) mouse 1:200 1:500 abcam 
TRN2 rabbit 1:200 1:500 abcam 
Ubiquitin rabbit 1:200 1:500 Dako 
Ubiquitin mouse 1:200 1:500 sigma aldrich 
YB1 rabbit 1:100 NA abcam 
 
Table 2.2. The primary antibodies used, their species and dilution for experiments 
in this thesis. 
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2.19 Secondary antibodies used for this thesis  
 
Secondary Antibody Table 
Antibody Species Target 
species 
Dilution Company 
AlexaFluor 
488 
goat  mouse 1:200 Life 
Techologies 
AlexaFluor 
488 
donkey rabbit 1:200 Life 
Techologies 
AlexaFluor 
568 
goat  mouse 1:200 Life 
Techologies 
AlexaFluor 
568 
donkey rabbit 1:200 Life 
Techologies 
AlexaFluor 
657 
goat  mouse 1:200 Life 
Techologies 
Biotinylated goat  rabbit 1:200 Dako 
Biotinylated rabbit mouse 1:200 Dako 
HRP-
conjugate 
goat  rabbit 1:2000 abcam 
HRP-
conjugate 
goat  mouse 1:2000 abcam 
Trueblot - rabbit 1:2000 eBioscience 
Trueblot - mouse 1:2000 eBioscience 
 
Table 2.3. The secondary antibodies used, their species and dilution for 
experiments in this thesis. 
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Chapter Three: New proteins in 
the pathology of FTLD-FUS and 
other neurodegenerative diseases 
(Results I) 
3.1 Introduction 
The neuropathological hallmark of FTLD-FUS and familial ALS-FUS is extensive FUS 
pathology. The discovery of FUS inclusions in both ALS and FTLD has further confirmed 
the spectrum disorder hypothesis that argues these disease entities represent cortical 
and motor ends of a disease continuum (Neumann et al., 2009a). This is further 
supported by reports of up to 50% of ALS patients show some degree of cognitive 
impairment and a substantial number of FTLD patients develop motor neuron disease 
(Talbot and Ansorge, 2006). The FUS protein is a DNA and RNA binding protein that 
continuously shuttles back and forth between the cytoplasm and the nucleus where it is 
at a much higher concentration in healthy cells (Zinszner et al., 1997). However, in FTLD 
and ALS FUS inclusions form predominately in the cytoplasm implying that defects in 
nuclear shuttling may lead to cytoplasmic miss-localisation and subsequent aggregation. 
This may sequester the protein away from its normal nuclear localisation and therefore 
represent a loss of nuclear function, or cause a toxic gain of function due to excessively 
high concentrations in the cytosol. The mutations that cause familial ALS-FUS cluster in 
the C-terminus of the protein, within the NLS (Belzil et al., 2009, Chio et al., 2009, 
Kwiatkowski et al., 2009b, Ticozzi et al., 2009, Vance et al., 2009a, Corrado et al., 2010). It 
has been shown that the NLS of FUS is necessary and sufficient to import FUS into the 
nucleus, and that ALS associated mutations in the NLS disrupt this import (Dormann et 
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al., 2010).  Crucially, it has also been shown that it is the interaction with TRN1 that is 
retarded when the NLS of FUS is mutated. Given what is known about the close 
relationship between ALS-FUS and FTLD-FUS and the emerging importance of TRN1 in 
the miss-localisation of FUS in familial ALS-FUS, it is possible TRN1 may have a role to 
play in FTLD-FUS. 
3.2 Hypothesis 
TRN1 plays an important role in the pathogenesis of FTLD-FUS and aggregates alongside 
FUS in the inclusions of this, but not other, neurodegenerative diseases. 
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3.3 Cases 
Brains were donated to the Queen Square Brain Bank for Neurological Disorders, UCL 
Institute of Neurology, University College London; the MRC London Brain Bank for 
Neurodegenerative Diseases, Institute of Psychiatry, King’s College, London, UK ;  
Neuropathology Department, Århus Kommunehospital, Århus, Denmark and 
NeuroResource, UCL Institute of Neurology, University College London. All patients had 
details of a standard clinical history and had undergone both neurological examination 
and cognitive assessment. All cases had previously been diagnosed as NIFID (6 cases) or 
aFTLD-U (7 cases).  
3.4 Clinical summary 
Our NIFID group consisted of six women and one man whilst the aFTLD-U group 
consisted of three women and four men. The mean age of onset was similar in both 
groups; mean 45.6 (standard deviation 15.3) years old in the NIFID group and 47.0 
(standard deviation 5.1) years old in the aFTLD-U group. However, the variability of age 
of onset was greater in the NIFID group with a range of 28 to 69 years, with a much 
smaller range of 40 to 55 years in the aFTLD-U group. There was a notable difference 
between the disease duration from symptom onset to death between the groups with a 
shorter relatively rapid disease course in the NIFID group; mean 3.0 (standard deviation 
1.1) years compared to a longer disease duration in aFTLD of 7.3 (standard deviation 
2.9) years. The most common clinical diagnosis was the behavioural variant of 
frontotemporal dementia and all of the aFTLD-U patients had initial behavioural features 
with a combination of dis-inhibition, apathy, obsessive/compulsive behaviour and 
change in appetite, which usually took the form of sugar craving. Patients later developed 
cognitive impairment, most prominently executive dysfunction, but often episodic 
memory impairment as well. Post mortem (PM) delay is recorded in table 3.1 because it 
is a significant factor in the preservation of antigens and therefore histological 
characteristics. Those cases with longer PM delay have weaker normal nuclear 
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TRN1/FUS/EWS/TAF15 immuno-reactivity, but retained pathological staining 
(inclusions). The short disease duration and younger onset reported here is typical of the 
FTLD-FUS subtype.  
Case 
No. 
Clinical 
Diagnosis 
Previous 
pathological 
diagnosis 
Sex Age of 
onset 
(years) 
Age at 
Death 
(years) 
PM 
delay 
(hrs) 
Disease 
duration 
(years) 
1 bvFTD NIFID F 27 n/a n/a n/a 
2 CBS NIFID F 41 43 55 2 
3 bvFTD 
with CBS 
like 
syndrome 
NIFID F 43 46 30 3 
4 MND with 
PSP like 
syndrome 
NIFID M 44 46 96 2 
5 MND NIFID F 63 68 2 5 
6 MND NIFID F 69 72 90 3 
7 CBS NIFID M 32 35 n/a 3 
8 bvFTD aFTLD-U M 40 51 12 11 
9 bvFTD aFTLD-U F 43 53 96 10 
10* bvFTD aFTLD-U M 44 51 24 7 
11 bvFTD aFTLD-U M 47 52 72 5 
12 PSP aFTLD-U F 49 55 3.5 6 
13 bvFTD aFTLD-U M 51 60 48 9 
14* bvFTD aFTLD-U F 55 58 n/a 3 
 
Table 3.1. Clinical and case summaries of FTLD-FUS cases available for this study. 
Where information is not available this is indicated with n/a. Cases 10 and 14 are 
marked with a * to indicate 14 is the mother of 10. 
3.5 The immunohistochemical profile of TRN1 in healthy controls  and 
other neurodegenerative diseases 
The cellular localization of TRN1, examined in normal control cases using formalin fixed 
tissue and TRN1 immunohistochemistry showed that immunoreactivity was localized to 
the nuclei of both neurons and glial cells (Figure 3.1 M). A similar staining pattern was 
seen in unaffected neurons in the FTLD-FUS cases and cases with other 
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neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, FTLD-TDP 
types A B and C, Pick’s disease (FTLD-tau), multiple system atrophy (MSA), corticobasal 
degeneration (CBD), motor neuron disease (NMD), progressive supranuclear palsy 
(PSP), Huntington’s disease (HD), and spinocerebellar ataxia (SCA). 
3.6 Cerebral cortex pathology and TRN1 immunohistochemistry in FLTD-
FUS 
In contrast to healthy controls and the other neurodegenerative diseases listed above, 
FTLD-FUS cases presented with abundant TRN1 inclusion pathology, which also 
demonstrated subtle differences between the NIFID and aFTLD-U subgroups. All the 
cases listed in table 3.1 showed some degree of superficial spongiosis affecting the 
frontal and temporal cortices, with subpial and white matter gliosis also evident. The 
characteristic crescent shaped neuronal cytoplasmic inclusions were TRN1 positive in all 
cases, but were notably more numerous in the NIFID subtype than in the aFTLD-U group 
(Figure 3.1). However, this difference may be the result of severe cell loss found in the 
cortex in the aFTLD-U subgroup.  The superficial cortical layers were more severely 
affected by inclusion load than the deeper cortical layers in both NIFID and aFTLD-U.  
The NIFID subgroup presented with a variety of TRN1 positive neuronal cytoplasmic 
inclusion morphologies including; Pick body-like homogenously stained inclusions and 
flame shaped tangle-like inclusions, which could be seen extending into the apical 
dendrites of pyramidal neurons (Figure 3.1 A, B and D). Additionally, smaller bean-like, 
crescent and annular-shaped TRN1 positive cytoplasmic inclusions were present in the 
aFTLD-U subgroup. Rarer vermiform neuronal intranuclear inclusions were found in the 
cortex of NIFID cases (Figure 3.1 C and E), but not in aFTLD-U cases. TRN1 positive 
neurites were found in the white matter of the aFTLD-U subgroup, but not the NIFID 
subgroup (Figure 3.1 L).  
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3.7 Hippocampal pathology and TRN1 immunohistochemistry in FTLD-FUS 
The severity of pathology and strength of staining varied notably between subtypes and 
even between cases of the same subtype. Whilst both intranuclear and cytoplasmic 
inclusions were evident in all cases within this structure, neuronal loss affecting the CA1 
subregion and subiculum was obvious in NIFID cases 2 and 3, but unremarkable in the 
remaining NIFID cases. Perhaps related to this, TRN1-positive bean-shaped or Pick body-
like neuronal cytoplasmic inclusions and neuronal intranuclear inclusions were present 
in the granule cell layer of the dentate fascia and neurons of the subiculum in both NIFID 
cases 2 and 3. TRN1 immunoreactive intranuclear inclusions were also frequent in the 
granule cell layer of these cases, and remarkably some neurons contained both a 
neuronal cytoplasmic inclusion and a neuronal intranuclear inclusion (Figure 3.3 D). 
Compounding the unique nature of these two cases, TRN1-positive oligodendroglial 
coiled bodies were also seen in the white matter of cases 2 and 3.  
The rest of the NIFID cases possessed an occasional crescent shaped TRN1 positive 
neuronal cytoplasmic inclusion in the granule cell layer of the dentate fascia. In contrast 
to NIFID cases 2 and 3, no neuronal intranuclear inclusions were observed in the granule 
cell layer in these cases.  
All aFTLD-U cases showed some degree of hippocampal sclerosis (Figure 3.2). Intense 
cell loss was seen in the CA1 hippocampal subregion extending into the subiculim in 
aFTLD-U cases 10, 13 and 14. TRN1 immunoreactive neuronal intranuclear inclusions 
were numerous in the granule cell layer of the dentate fascia. Unusually, these 
intranuclear inclusions outnumbered the bean-shaped neuronal cytoplasmic inclusions 
found in the same anatomical region in cases; 9 10 and 11. However this was not the 
trend overall, the remaining cases only contained an occasional neuronal cytoplasmic 
inclusion in this structure.  
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The CA1 subregion was affected by neuronal loss to different degrees in all cases. A 
proportion of the remaining neurons contained a cytoplasmic inclusion, an intranuclear 
inclusion or both.  
Abnormal neurites were also present in the entorhinal cortex and fusiform gyrus of all 
aFTLD-U cases. 
3.8 Pathology of TRN1 in the motor cells of FTLD-FUS 
Motor cells of the XIIth nerve nucleus and spinal cord contained either granular, globular 
or filamentous Skein-like inclusions as previously seen with FUS immunohistochemistry. 
No difference was observed the in the inclusion types between the NIFID and aFTLD-U 
subgroups (Figure 3.4). 
3.9 Co-localisation of TRN1 and FUS pathology through double-label 
immunofluorescence  
All cases of FTLD-FUS the cortex, medulla and hippocampal formation were double 
stained for TRN1 and FUS. Qualitative assessment clearly showed overall very good co-
localisation of TRN1 and FUS within the neuronal cytoplasmic and neuronal intranuclear 
inclusions in both NIFID and aFTLD-U (Figure 3.5).  Furthermore, quantitative analysis of 
three NIFID and aFTLD-U cases also demonstrated that the vast majority of FUS positive 
inclusions in the granule cell layer of the dentate fascia were also positive for TRN1 
(99.4% NIFID 100% aFTLD-U). Interestingly, it was noted that TRN1 labelling of some 
neuronal intranuclear inclusions was weaker than that seen with FUS antibodies. 
Additionally, while some nuclear FUS remained in cells baring cytoplasmic inclusions, 
TRN1 staining was often absent entirely.  
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Figure 3.1. TRN1 
inclusion morphology 
in NIFID and FTLD-U. 
Representative neurons 
containing classical 
crescent shaped 
neuronal cytoplasmic 
inclusions a NIFID and 
aFTLD-U (A and D). 
Pick body-like 
inclusions were found 
in the NIFID cases (B) 
whereas smaller 
rounded ‘bean’ shaped 
inclusions were found 
in aFTLD-U (C). 
Neuronal intranuclear 
veriform inclusions (C 
and E) were also seen 
in both NIFID and 
aFTLD-U respectively. 
Granular cytoplasmic 
inclusions were 
prominent in NIFID 
case2 (F and G), 
extending into the 
dendrites (arrows). 
Swollen axons were 
visible with positivity 
extending into the axon 
(H arrow). In NIFID 
case6 Betz cells showed 
globular and skein-like 
inclusions (I and J). 
Argyrophilic grain-like 
structures were 
observed in the 
entorhinal cortex in 
NIFID case2 (K). 
Neuritic threads were 
seen in aFTLD-U case 8 
(L). Normal neuronal 
nuclear (double arrow) 
and glial nuclear 
staining (arrow) in 
frontal cortex of normal 
controls.  Scale bar on A 
represents 5µm on A-E 
and L; 10 µm on F-J and 
40 µm on K and M.  
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Figure 3.2. Hippocampal sclerosis in FTLD-FUS. Healthy control hippocampal formation 
shows clearly defined structures and regions CA4, CA3, and CA1 (A). Typical FTLD-FUS 
hippocampal formation showing cell loss, particularly pronounced in the CA1 region (B). 
Scale bar in A represents 0.5mm.
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Figure 3.3. TRN1 pathology in the hippocampal granule cell layer. NIFID (A and B) and 
aFTLD-U (C and D). TRN1 staining in the hippocampal granule cell layer shows 
both neuronal cytoplasmic inclusions (arrow) and neuronal intranuclear 
inclusions (double arrow).  Scale bar in A represents 50 µm.  
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Figure 3.4. TRN1 pathology in the spinal cord and XIIth cranial nerve nucleus in NIFID 
(A-D) and aFTLD-U (E-H). TRN1 pathology in motor neurons of the XIIth   cranial nerve 
nucleus (A,B,E and F) and spinal cord (C,D,G and H) demonstrated a number of 
cytoplasmic inclusion types including large globular (A, D and G, F), diffuse granular (B), 
compacted granular (C and F), filamentous (E). TRN1 clearance from the nucleus is 
evident in most cases in both NIFID (D) and aFTLD-U (H). Bar in A represents 5µm.  
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Figure 3.5. Both neuronal cytoplasmic and neuronal intranuclear inclusions are positive 
for FUS and TRN1. Granule cell layer neurons from representative healthy control (A-C) 
aFTLD(D-F) and NIFID -U (G-I). Both NIFID and aFTLD-U harbour neuronal cytoplasmic 
(arrow) and intranuclear (double arrow) inclusions positive for TRN1 and FUS, the 
intranuclear inclusions of aFTLD-U stain weaker with TRN1 than FUS. Overlay panels 
include blue nuclear DAPI staining Scale bar on A 5µm.  
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3.10 Sequential solubility extraction and immunoblot of TRN1 in FTLD -FUS 
and healthy controls 
To investigate the solubility of TRN1 in FTLD-FUS compared to healthy control brain 
tissue, a sequential solubility extraction was undertaken. Three NIFID and four aFTLD-U 
cases were processed alongside three healthy controls. Frontal cortex grey matter from 
flash frozen brains was homogenized and clarified in a high salt buffer. The whole 
homogenate was first clarified by centrifugation (at 1000g) to pellet out myelin and 
membranous debris. Ultracentrifugation resolved the clarified supernatant into a 
solubility fraction of proteins soluble in high salt buffer and a pellet of insoluble species. 
This pellet was then resuspended in a stronger RIPA based buffer containing 2% SDS and 
the supernatant retained as the soluble high salt fraction. This was repeated and another 
pellet of insoluble protein species was resolved. The supernatant was retained as the 
RIPA soluble fraction and the pellet was dissolved in a urea based buffer containing 8% 
SDS. This final fraction was termed the urea fraction and contained only the highly 
insoluble protein species. Size separation of proteins by SDS-polyacrylamide gel 
electrophoresis and immunoblotting on polyvinylidene fluoride membrane revealed 
firstly that the antibody used to detect TRN1 pathology immunohistochemically 
recognised a band at the predicted molecular weight of TRN1. Secondly, TRN1 was 
present in only the high salt and RIPA fractions in healthy controls, but in NIFID and 
aFTLD-U TRN1 is present in the urea fraction as well (Figure 3.6). This indicates TRN1 
has become highly insoluble in both subtypes of FTLD-FUS, and therefore likely highly 
aggregated. Interestingly, no abnormally high molecular weight species were observed 
suggesting TRN1 is not poly-ubiquitinated.  
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Figure 3.6. Sequential solubility extraction and immunoblotting of three representative 
cases. Highly insoluble TRN1 is present in the urea fraction of both FTLD-FUS subtypes 
but absent from healthy controls. Molecular weight of TRN1 102kDa. 
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3.11 Other importins in FTLD and neurodegenerative diseases  
To investigate the possibility that other importins or nuclear import factors may be 
aggregating in FTLD-FUS frontal cortex tissue was immunohistochemically screened 
against several proteins related to TRN1. Karyopherin β2b (also known as Transportin2 
(TRN2)), karopherin β3 (also known as importin β3), importin β1, and nucleophorin 
98kDa (NUP98) were chosen to be screen against FTLD-FUS and healthy control tissue. 
Immunohistochemical analysis demonstrates that TRN2, karyopherin β3 and NUP98 are 
present in the nucleus of neurons, whilst importin β1 stains only the nuclear membrane 
(Figure 3.7 A C E and G). This pattern is repeated in FTLD-FUS with the one exception of 
NUP98 (Figure 3.7 H), which appears to label occasional cytoplasmic inclusions. NUP98 
pathology was visible in NIFID cases but even then labelling appeared to be confined to 
cytoplasmic inclusions because no additional pathology such as threads, intranuclear 
inclusions or dot/grain pathology was visible.  
3.12 Co-localisation of FUS and NUP98 pathology through 
immunofluorescence  
To confirm that the apparent staining of a cytoplasmic inclusion by NUP98 the frontal 
cortex of three representative NIFID and three aFTLD-U cases were double stained for 
FUS and NUP98. Examples of co-localisation were seen in cytoplasmic inclusions 
between FUS and NUP98 in NIFID cases but not in the aFTLD-U investigated (Figure 3.8). 
Unfortunately hippocampal tissue was unavailable for this investigation and it was 
therefore not possible to investigate intranuclear inclusions since these are most 
abundant in the granule cell layer. 
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Figure 3.7. Immunohistochemical screen of importins and nuclear pore factors reveals 
NUP98 as staining cytoplasmic inclusions. Healthy control frontal cortex (A, C, E and G) 
and FTLD-FUS frontal cortex (B, D, F and H) stained for TRN2 (A and B), karyopherin β3 
(C and D), Importin β1 (E and F), and NUP98 (G and H).  Normal staining is seen in all 
except H where the NUP98 antibody stained occasional cytoplasmic inclusions (arrow). 
Scale bar on A represents 25µm. 
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Figure 3.8. Cortical cytoplasmic inclusions of NIFID but not aFTLD-U are positive for both 
FUS and NUP98.  Healthy control neurons from the frontal cortex (A-C). A typical 
crescent shaped inclusion from a NIFID case (D-F arrow), and a typical bean-like 
inclusion from an aFTLD-U case (G-I arrow). Overlay panels include blue nuclear DAPI 
staining Scale bar on A represents 5µm.  
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3.13 TRN1 immunohistochemistry in other neurodegenerative diseases  
Given that the expanded polyglutamine inclusions of Huntington’s disease, and 
spinocerebellar ataxia demonstrate FUS immunoreactivity (Doi et al., 2010)(Figure 3.9 B, 
D and F), and the FUS-opathy FTLD-FUS demonstrates TRN1 pathology, this might 
implicate TRN1 in the polyglutamine expansion disorders. Therefore the 
immunoreactivity of TRN1 was investigated in the polyglutamine expansion disorders to 
determine if TRN1 inclusion body pathology was unique to FTLD-FUS. The pons, basal 
ganglia, cerebellum, medulla, and hippocampus were investigated in two Huntington’s 
disease, six spinocerebellar ataxias (two of type 3, and one of types 1, 2, 6 & 7) with 
immunohistochemistry which revealed no TRN1 reactivity in the characteristic 
intranuclear inclusions (Figure 3.9 C and E). However, the extremely rare entity neuronal 
intranuclear inclusion body disease (NIIBD) (one case available) has characteristic 
hyaline intranuclear inclusions which are visible in both TRN1 and FUS 
immunohistochemistry (Figure 3.9 A double arrow).  Whilst this disease does not 
possess an expanded polyglutamine tract, the characteristic hyaline intranuclear 
inclusions are sometimes visible with antibodies raised against polyglutamine (Liu et al., 
2008).  
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Figure 3.9. The intranuclear inclusions of Huntington’s disease, spinocerebellar ataxia, 
and neuronal intranuclear inclusion body disease are immunoreactive for FUS but only 
neuronal intranuclear inclusion body disease is positive for TRN1 pathology. The hyaline 
inclusions of neuronal intranuclear inclusion body disease are visible with FUS (B arrow) 
and TRN1 (A double arrow) immunohistochemistry. Huntinton’s disease (C and D) and 
spinocerebellar ataxia (E and F) are only positive for FUS (arrows). Sections taken from 
Pons. Scale bar on A represents 25µm. 
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3.14 Other TRN1 cargos aggregating alongside the FET proteins  
The aggregation of TRN1 in cytoplasmic and intranuclear inclusions and a partial or 
complete loss of normal nuclear TRN1 staining (Figure 3.5) may lead to sequestration of 
TRN1 targets beyond the FET proteins. Additionally, the TRN1 cargos EWS and TAF15 
have been shown to be aggregating alongside TRN1 and FUS in collections of FTLD-FUS 
from other brain banks (Neumann et al., 2011).  Therefore a similar investigation was 
mounted on the QSBB collection. 
Firstly, the presence of EWS and TAF15 within the inclusions of the QSBB collection of 
FTLD-FUS was confirmed with immunohistochemistry (Figure 3.10). All cases were 
stained using previously published and characterized antibodies and compared to 
healthy controls. A variety of morphologically different inclusions could be seen and 
these mirrored those observed under FUS and TRN1 immunohistochemistry (Figure 3.1 
and Figure3.10). It is of note that the EWS antibody was not as robust as those raised 
against FUS, TAF15 or TRN1 but a significant amount of pathology was still visible 
(Figure 3.10 H-M). Both EWS and TAF15 were found in the nucleus of neurons and some 
glial cells in healthy control tissue (Figure 3.10 O and P).  The anatomical locations of 
EWS and TAF15 pathology mirrored those previously described for FUS and TRN1 and 
included; frontal cortex, hippocampal formation, and the motor cells of the medulla and 
spinal cord. Co-localisation of TRN1 and FET protein pathology has been confirmed via 
double immunofluorescence by other authors (Neumann et al., 2012).  
Given the pronounced loss of TRN1 from the nucleus of cells displaying cytoplasmic or 
intranuclear inclusions (Figure 3.5) the apparent loss of nuclear function this would 
presumably imbue should disrupt the transport of dozens of cargo proteins. To 
investigate whether the pathology of FTLD-FUS extends beyond TRN1 and the FET 
proteins, several targets of TRN1 were screened against FTLD-FUS frontal cortex tissue. 
A full list of TRN1 cargos investigated by this thesis and other authors is attached in 
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appendix 1.2. Four targets of TRN1 driven import were investigated in this thesis; 
heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), dead box 3 (DDX3), nuclear 
RNA export factor 1 (NXF1), and Y box-binding protein 1 (YB1). Characterization in 
healthy control tissue revealed hnRNP A1 (Figure 3.11 G), DDX3 (Figure 3.11 A) and 
NXF1 (Figure 3.11 C) to be predominantly nuclear in the neurons of frontal cortex tissue. 
Only YB1 showed marked presence in the cytoplasm as well as the nucleus (Figure 3.11 
E). Only hnRNP A1 appeared to label some of the morphologically characteristic 
inclusions of FTLD-FUS. Crescent shaped neuronal cytoplasmic inclusions were visible in 
NIFID case 6 and case 3 scattered throughout the superficial layer of the frontal cortex. 
Larger Pick-body like inclusions were also relatively common in NIFID cases. The aFTLD-
U subtype had considerably less hnRNP A1 pathology but those inclusions that were 
visible were typically bean shaped (Figure 3.11 K). It is of note that no intranuclear 
inclusions were visible under hnRNP A1 immunohistochemistry even in those areas 
previously shown to harbour considerable intranuclear pathology such as the granule 
cell layer of the hippocampus.  Double label immunofluorescence showed strong co-
localisation between cortical FUS and hnRNP A1 pathology in both NIFID and aFTLD-U 
(Figure 3.12). This would seem to suggest that hnRNP A1 is incorporated into a subset of 
inclusions in FTLD-FUS much like NUP98. 
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Figure 3.10. TAF15 and EWS immunohistochemistry shows a variety of inclusion 
morphology in FTLD-FUS. TAF15 labelled cytoplasmic crescent (A), Pick body-like (B), 
granular (C), Skein-like (E), neuritic threads (F), intranuclear lentiform (D), and 
dot/grain pathology in the neuropil (G) in NIFID and aFTLD-U. EWS labeled the same 
pathology but often less strongly, such as bean-like (H), granular (I), Skein-like (K), 
threads (L), and intranuclear inclusions (J). Normal nuclear TAF15 (O) and EWS (P) in 
healthy controls. Scale bar on A represents 25µm. 
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Figure 3.11. Only hnRNP A1 immunohistochemistry shows labelling of some inclusion 
types. The TRN1 cargos DDX3 and NXF1 are localised to the nucleus in healthy control (A 
and C) and FTLD-FUS (B and D) frontal cortical neurons. YB1 is predominately nuclear 
with some cytoplasmic staining in healthy control (E) and FTLD-FUS (F). Similarly 
hnRNP A1 is strongly nuclear in healthy control neurons (G), but a proportion of FTLD-
FUS inclusions are also labelled. Compact crescent shaped (H), large Pick body-like (I), 
small bean shaped (J and K), and possible flame shaped neuronal cytoplasmic inclusions 
(L arrow) are visible with hnRNP A1 immunohistochemistry. Nuclear clearing of hnRNP 
A1 is visible in NIFID (I and J) and aFTLD-U (K), but not in all cases (H). Scale bar in A 
represents 25µm. 
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Figure 3.12. hnRNP A1 co-localises with FUS in the inclusions of FTLD-FUS. Frontal 
cortical neurons from healthy control (A-C) NIFID (D-F) and aFTLD-U (G-I). Both NIFID 
and aFTLD-U neurons bare cytoplasmic (arrow) inclusions immunoreactive for hnRNP 
A1 and FUS. Overlay panels include blue nuclear DAPI staining. Scale bar on A represents 
5µm. 
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3.15 Stress granule markers in FTLD-FUS pathology 
It has been previously shown by other authors that the inclusions of FTLD-FUS but not 
FTLD-TDP contain stress granule markers. The QSBB collection of FTLD-FUS was 
investigated immunohistochemically with antibodies raised against poly-(A) binding 
protein (PABP1) and GAP SH3 domain-binding protein (G3BP), two widely used markers 
of stress granules. As has been shown by other authors, antibodies raised against stress 
granule components label the cytoplasmic inclusions of FTLD-FUS (Figure 3.13). 
Interestingly, these antibodies did not stain intranuclear inclusions in either NIFID or 
aFTLD-U cases. This may yield clues to inclusion formation on either side of the nuclear 
membrane due to the cytoplasmic nature of stress granules.  
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Figure 3.13. The stress granule markers PABP1 and G3BP label the cytoplasmic 
inclusions of FTLD-FUS.  Normal cytoplasmic granular staining of PABP1 (A) and G3BP 
(B) in healthy control frontal cortex contrasts with the inclusion pathology seen in FTLD-
FUS. PAPB1 labels a variety of cytoplasmic inclusions including; crescent shaped (C), 
bean-like (D), loose filamentous (E), Pick body-like (F) and granular (G). G3BP also labels 
a variety of inclusions including; granular (H), crescent shaped (I), Pick body-like (J and 
L) and more filamentous (K). Affected elements include frontal cortex (C D E I J K), 
granule cell layer of the hippocampus (F and L), and the motor cells of the medulla (G 
and H). Scale bar in A represents 25µm. 
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3.16 Total and phosphorylated eIF2α may be increasing in FTLD -FUS 
Under normal conditions eukaryotic initiation factor 2α (eIF2α) initiates protein 
translation in a GTP dependant manner with tRNAmet. However, phosphorylation of eIF2α 
prevents GDP-GTP exchange by eIF2B, which lowers the effective concentration of eIF2-
GTP-tRNAMet. Under these conditions, the stress granule marker TIA-1 is incorporated 
into a now translationally silent pre-initiation complex. TIA-1 self-aggregation then 
promotes the accumulation of these complexes into stress granules. In this way the 
phosphorylation of eIF2α acts as a molecular trigger for stress granule assembly. Given 
the implication of stress granules in inclusion formation the eIF2α status of FTLD-FUS 
tissue was investigated. Frontal cortex homogenates from three healthy controls, three 
aFTLD-U and three NIFID subtypes were cleared and immunoblotted for total and 
phosphorylated forms of eIF2α (Figure 3.14 A). Densitometric quantification reveals a 
trend of increased total eIF2α in aFTLD-U and NIFID compared with controls (Figure 
3.14 B), and an apparently significant increase in phosphorylated-eIF2α in NIFID cases 
(Figure 3.14 C). However the significance is lost when readings are expressed as a 
proportion of total eIF2α (Figure 3.14 D). This trend may become significant if more 
cases were available for investigation because there was considerable variation in the 
samples. 
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Figure 3.14. Increasing total and phosphorylated eIF2α in FTLD-FUS compared with 
healthy controls.  Representative immunoblots of three healthy control, three aFTLD-U 
and three NIFID frontal cortex homogenates probed for either total eIF2α or phospho-
eIF2α (A). Blots were stripped and re-probed for phospho-eIF2 or beta actin. 
Densitometric quantification and analysis with ANOVA followed by Dunnett’s correction 
shows there is an upward trend of total eIF2α in aFTLD-U and NIFID (B), and a 
significant increase in phosphor-eIF2α detected (*p<0.05) (C), but this significance is lost 
when expressed as a proportion of total eIF2α (D). Error bars SEM. Molecular weight of 
eIF2α 36kD.  
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3.17 Discussion 
These data strongly suggest a role for TRN1 in the pathogenesis of FTLD-FUS. The results 
have shown that TRN1 is deposited within the FUS positive inclusions of FTLD-FUS, and 
becomes insoluble and therefore likely highly aggregated in this disease. Several other 
targets of TRN1 import have also been discovered within the inclusions of this disease 
including all members of the FET family and the hnRNP A1 protein. Additionally, the 
TRN1 nuclear pore interacting protein NUP98 is present in a proportion of neuronal 
cytoplasmic inclusions. TRN1 does not co-localise with FUS in Huntington’s disease and 
spinocerebellar ataxia, despite these diseases possessing FUS as a secondary pathological 
marker.  This may suggest that TRN1 is a more specific disease marker for FTLD-FUS 
than the current primary pathological marker FUS. However, it remains to be seen if the 
other members of the FET family (TAF15 and EWS) are present in the polyglutamine 
inclusions of Huntington’s disease and spinocerebellar ataxia. No other importins or 
karyopherins are mis-localised or sequestered into the inclusions of FTLD-FUS 
suggesting there is something unique about the TRN1-cargo functionality in FTLD-FUS 
compared with healthy controls and other neurodegenerative diseases. The stress 
granule markers PABP1 and G3BP stained the neuronal cytoplasmic inclusions of FTLD-
FUS suggesting a relationship between these cytoplasmic proteins and the formation of 
inclusion bodies.  
Immunohistochemical investigation of 14 cases of FTLD-FUS (7 NIFID, 7aFTLD-U) 
revealed TRN1 is deposited in the inclusions of FTLD-FUS and recapitulates other 
pathological findings such as fine neuropil threads, coarse neurites, swollen axons, dots, 
and ‘grains’ that were previously described with FUS antibodies (Lashley et al., 2011). 
The dots and ‘grains’ are likely to originate from dentritic processes cut in cross-section 
because they were clearly seen in the dendritic processes of larger neurons that had 
been sectioned in such a way so that the cell body and dentritic tree were in one plane. 
These neurons were typically of the cellular islands of the pre- layer of the entorhinal 
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cortex. This may be functionally relevant in view of the fact that FUS has a role in mRNA 
export and transport to dendritic spines (Fujii et al., 2005, Fujii and Takumi, 2005). The 
qualitative assessment of the anatomical distribution of TRN1 pathology mirrors that 
shown by FUS immunohistochemistry. This is exemplified by the double 
immunofluorescence of TRN1 and FUS within the intranuclear and cytoplasmic neuronal 
inclusions of the hippocampal granule cell layer. Whilst some variation was observed 
between the intensity of TRN1 and FUS staining supplementary morphometry indicated 
a good degree of co-localisation. Differences in the immunolabeling between cases and 
even between different regions of the same case are not unexpected, and could be due to 
the length of formalin fixation (Holund et al., 1981, Puchtler and Meloan, 1985). Since the 
publication of these immunohistochemical findings several independent authors have 
verified the TRN1 profile in FTLD-FUS (Neumann et al., 2012, Davidson et al., 2012). The 
discovery of TRN1 in FTLD-FUS moved the focus of pathogenic theories away from the 
singular protein FUS and put them in context of a functional nuclear import cycle. 
Consequently, shortly after the publication of the TRN1 investigations, other TRN1 
cargos (TAF15 and EWS) were found to recapitulate the pathology of FTLD-FUS 
(Neumann et al., 2011, Neumann et al., 2012).  Whilst these authors attempted to 
investigate other TRN1 cargos beyond the FET proteins in a similar manner to the data 
presented here, their antibody selection may have prevented them from detecting 
hnRNP A1 (Neumann et al., 2012). However such differences are not uncommon 
between different laboratories and brain banks. For example, the QSBB collection of 
healthy control and FTLD-FUS tissue demonstrates a clear cut biochemical TRN1 
signature of highly insoluble TRN1 in only FTLD-FUS tissue. Meanwhile other authors 
have failed to reproduce this pattern (Neumann et al., 2012), although this could be due 
to differences in the extraction protocol.  
FUS immunoreactive inclusions are not unique to FTLD-FUS and ALS-FUS. The 
polyglutamine expansion disorders, including Huntington’s disease and some 
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spinocerebellar ataxias, display FUS immunoreactivity in the intranuclear inclusions 
(Nukina, 2010a).  It has become clear that truncated N-terminal huntingtin aggregates 
can bind FUS and sequester the protein away from its normal diffuse nuclear pattern 
(Nukina, 2010b). In the QSBB and UCL Institute of Neurology sample of Huntington’s and 
spinocerebellar ataxia cases TRN1 does not appear to mimic these findings and remains 
nuclear. However, neuronal intranuclear inclusion body disease has shown positivity for 
both FUS and TRN1. Neuronal intranuclear inclusion disease is an extremely rare entity 
with fewer than 40 cases described in the literature (Josephs, 2011).  Normally 
diagnosed post-mortem, the characteristic hyaline inclusions are eosinophilic and 
positive for ubiqutin, small ubiquitin-related modifier 1 (SUMO1), and occasionally 1C2 
(anti-polyglutamine expansion).  It is possible that FUS is recruited to the inclusions in a 
similar manner to Huntington’s disease, but small differences in the incorporation of FUS 
allow TRN1 to bind FUS as well. At this point it is purely conjecture and will likely remain 
so because the instances of neuronal inclusion body disease are so rare and its 
pathogenesis so poorly understood. 
The lack of other importin or karyopherin proteins aggregating in tandem with TRN1 
and a selection of its cargos implies there is something unique about TRN1 and its 
interaction with these proteins that leads to aggregation in the diseased brain. Highly 
malignant ALS associated FUS mutations like P525L produce an abnormal cytoplasmic 
phenotype which is thought to be crucial for cytoplasmic aggregation and disease 
pathogenesis. In this vein, investigations into ALS associated mutations in the M9 NLS of 
FUS have revealed that the aberrant re-localisation of FUS seen in cell models can be 
rescued by treatment with methylation inhibitors (Dormann et al., 2012). Periodate 
oxidised adenosine (AdOx) is an inhibitor of all S-adenosyl-L-methionine (SAM) 
dependant methylation by protein N-arginine methyltransferase (PRMT).  By either 
inhibiting this enzyme or silencing it through siRNA knockdown the normal methylation 
of FUS can be reduced, specifically within the RGG domain closest to the NLS. It is this 
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hypomethlation that rescues the interaction with TRN1 and returns the mutant FUS to its 
normal nuclear localisation. The authors of this work extend their hypothesis further to 
explain the TRN1-cargo protein inclusions of FTLD-FUS by arguing that a specific subset 
of proteins have their methylation status altered, which creates an overly strong 
interaction with TRN1 resulting in a failure to release its cargo. Support for this comes 
from immunohistochemistry using methylated-FUS specific antibodies which shows ALS 
but not FTLD-FUS inclusions are hypermethylated. However, the theory does not 
satisfactorily explain why inclusions form on both sides of the nuclear membrane. For 
instance, if the binding of TRN1 and cargo was overly strong this should not retard the 
movement through the nuclear pore meaning that inclusions should form only within the 
nucleus.  
Since 2009 our knowledge of FTLD-FUS inclusions as increased dramatically. Yet new 
theories of pathogenesis continue to use FUS as the main protagonist in inclusion 
formation. Any new theory of inclusion formation centred around the properties of FUS 
must be satisfactorily extended to include not only the published EWS and TAF15 
aggregation but also hnRNP A1 and NUP98.    
Aggregation in the cytoplasmic compartment might be explained with the phenomenon 
of stress granules. These temporary aggregates of mRNA and associated proteins are 
produced by a cell in response to various stressors to suspend and sequester away non-
essential transcripts. It has been shown by other authors that the inclusions 
characteristic of ALS-FUS and FTLD-FUS are positive for stress granule markers (Fujita et 
al., 2008, Dormann et al., 2010), and now the QSBB collection of FTLD-FUS can be 
included in this. Additionally, there appears to be an upward trend in the total and 
phosphorylated form of eIF2α found in the cases available for biochemistry. Since 
phosphorylated eIF2α is the molecular trigger for stress granule formation in response 
to numerous stressors, this could be highly relevant. However, these results are only 
preliminary and require comparison with other neurodegenerative diseases. For 
98 
 
instance eIF2α phosphorylation has been linked to the neurodegeneration seen in prion 
disease (Moreno et al., 2012). Combined with the observation that cytoplasmically mis-
localised FUS will quickly amalgamate into the stress granules in cell models, stress 
granules have been proposed as precursors to the ubiquitinated inclusions seen post-
mortem. To test this hypothesis, further investigations into the nature of stress granules 
in the context of FTLD-FUS are carried out in the next chapter.    
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Chapter Four: Endogenous TRN1 
and the FET proteins are 
recruited to stress granules under 
conditions of oxidative and 
osmotic stress (Results II) 
4.1 Introduction 
As previously mentioned the FET proteins (FUS, EWS and TAF15) are all RNA binding 
proteins with a plethora of functions not least of which is the binding of pre-mRNA in the 
splicosomal complex (Orozco et al., 2012), leading many to believe that loss of nuclear 
function associated with aberrant cytoplasmic localisation is  a key feature of 
pathogenesis (Orozco and Edbauer, 2013).  
Stress granules are cytoplasmic foci formed rapidly when the cell is subjected to stress. 
This stress can be from a variety of stressors affecting a variety of organelles. These foci 
are temporary aggregates designed to store mRNA encoding basal translation proteins 
sequestering them away from the translation apparatus. This allows the cell to refocus 
translation towards survival factors like heat shock proteins. Aside from mRNA stress 
granules also contain proteins both directly associated with said mRNA, and proteins not 
directly involved in RNA binding. Some of these include G3BP, TIA-1, PABP1, and TIAR 
which can be used as reliable markers of stress granules due to the rapid and clear 
change in staining pattern when stress granules are induced. This induction can take the 
form of heat-shock, hypoxia, polysome destabilization, oxidative and osmotic stress 
(Matsuki et al., 2013, Zurla et al., 2011, Shih et al., 2012) to name a few.   
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From the data presented in the last chapter coupled with previously published 
description of stress granule markers in the cytoplasmic inclusions of FTLD-FUS 
(Dormann et al., 2010), a theory of stress granule nucleated inclusion formation has 
emerged (Bosco et al., 2010, Gal et al., 2011).  Some authors hypothesized that stress 
granule formation may be a precursor to the more sinister cytoplasmic aggregates in 
both ALS-FUS and FTLD-FUS (Dormann et al., 2010).  One major hurdle to this 
hypothesis is that these stress granule proteins are known to easily disperse and return 
to solution once the stress has been removed (Kedersha et al., 2000).  Despite this, stress 
granule markers such as TIA-1 co-localize with the characteristic neuronal aggregates of 
numerous neurodegenerative diseases including FTLD-FUS (Liu-Yesucevitz et al., 2010) 
suggesting there may be a link between the two phenomena. Stress granules are easily 
inducible in cell models which allows characterisation after just 15 minutes, but 
relatively little is known about these foci under prolonged stressful conditions. 
Furthermore, whilst the list of stress granule components continues to grow with new 
proteins published regularly little is known about the possible inclusion of the newly 
discovered FTLD-FUS proteins TRN1, TAF15, and EWS.  
4.2 Hypothesis 
In SH-SY5Y cells oxidative stress can induce translocation of TRN1 and FET proteins to 
cytoplasmic stress granules that can prime aggregate formation seen in FTLD-FUS. This 
re-localisation is due to TRN1 and its ability to bind the FET proteins through their M9 
motif.  Overexpression of TRN1 will exaggerate the phenotype seen in endogenous cells. 
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4.3 TRN1 is a good surrogate marker of G3BP positive  stress granules, and 
also labels post-stress G3BP negative foci  
The widely accepted best markers of pathology in FTLD-FUS are all functionally related 
to TRN1, and its role as a nuclear importer might be important to the malignant 
cytoplasmic aggregation. To investigate the response of TRN1 in the context of FET 
proteins and aggregation to conditions thought to mimic the aged demented brain, the 
neuroblastoma cell line SH-SY5Y was subjected to oxidative or osmotic stress over acute 
(2 hours) or prolonged (24 hours) incubation periods.  
In unstressed SH-SY5Y cells TRN1 appeared mainly nuclear, whilst G3BP staining was 
weak and diffuse throughout the cell. Upon acute treatment with oxidative stress (0.5mM 
arsenite or 50mM tBH for 2hrs) a radical re-localisation of TRN1 to cytoplasmic foci was 
evident. These foci very strongly co-localised with G3BP and were therefore stress 
granules (Figure 4.1 and 4.2). Prolonged exposure to oxidative stress (10µM arsenite or 
190µM tBH over 24hrs) produces foci, consisting of TRN1 and G3BP that appeared larger 
but were far less common. However, when the cells were allowed to recover in fresh 
media for 6hrs, the staining pattern changed to reflect stress granule dissolution. The 
majority of what remained were TRN1-positive, G3BP-negative cytoplasmic foci (Figure 
4.1 and 4.2).  
To compare TRN1 response between oxidative and non-oxidative stressors the osmotic 
stressor sorbitol was also employed. Osmotic stress was chosen over other possibilities 
like heat-shock because temperature changes are less physiologically relevant to a 
central organ like the brain. Under acute stress (600mM for 2hrs) nuclear TRN1 re-
localised to numerous, punctate cytoplasmic foci that were strongly positive for G3BP 
(Figure 4.3). These foci were notably smaller (~1-2µm in diameter) than those produced 
by 2hrs 0.5mM arsenite stress. Prolonged exposure to sorbitol (400mM for 24hrs) 
produced fewer TRN1 foci per cell but these remained strongly positive for G3BP. 
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Recovery in fresh media recapitulated the TRN1 positive, G3BP negative foci seen after 
oxidative stress (Figure 4.3). 
TRN1 was chosen as the primary marker of foci to investigate co-localisation with FET 
proteins in the following experiments because these experiments aimed to investigate 
re-localisation of FET proteins to stress granules through a possible TRN1 interaction, 
furthermore TRN1 consistently labeled stress granules but also labeled post-stress 
granule foci (Figure 4.1 4.2 and 4.3).  
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Figure 4.1. Arsenite stress induces translocation of nuclear TRN1 to the cytoplasmic 
compartment partially co-localising with stress granules. Recovery in fresh media leaves 
TRN1 positive, G3BP negative foci. TRN1 positive foci (A arrows). Co-localisation 
quantification of foci counts shows 96.11% co-localisation in TRN1 foci at 2hrs and 
104 
 
100% at 24hrs, but a 20.33% co-localisation after 6hrs recovery (B). Counts graphed as 
percentage of TRN1 foci also positive for G3BP for ease of interpretation. Error bars SEM. 
Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm 
within insets. N=3. 
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Figure 4.2. tBH stress induces translocation of nuclear TRN1 to the cytoplasmic 
compartment partially co-localising with stress granules. Recovery in fresh media leaves 
TRN1 positive, G3BP negative foci. TRN1 positive foci (A arrows). Co-localisation 
quantification of foci counts shows 98.48% co-localisation in TRN1 foci at 2hrs and 
100% at 24hrs, but a 0.03% co-localisation after 6hrs recovery (B). Counts graphed as 
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percentage of TRN1 foci also positive for G3BP for ease of interpretation. Error bars SEM. 
Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm 
within insets. N=3 
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Figure 4.3. Sorbitol stress induces translocation of nuclear TRN1 to the cytoplasmic 
compartment partially co-localising with stress granules. Recovery in fresh media leaves 
TRN1 positive, G3BP negative foci. TRN1 positive foci (A arrows). Co-localisation 
quantification of foci counts shows 99.07% co-localisation in TRN1 foci at 2hrs and 99% 
at 24hrs, but a 4.86% co-localisation after 6hrs recovery (B). Counts graphed as 
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percentage of TRN1 foci also positive for G3BP for ease of interpretation. Error bars SEM. 
Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm 
within insets. N=3 
 
4.4 TRN1 and the FET proteins co-localise in stress granules and post-
stress foci to varying degrees  
Given the potential role of TRN1 in the pathology of FTLD-FUS, it was used as the 
primary marker of cytoplasmic foci when investigating the FET proteins and ubiquitin. In 
unstressed control cells, TRN1 staining always appeared in the nucleus together with the 
FET proteins (Figure 4.4 Figure 4.7 Figure 4.10).  Here the extent of co-localisation 
between TRN1 positive cytoplasmic stress granules, with the three FET proteins and 
ubiquitin is described. 
4.5 Co-localisation with FUS 
Acute treatment with arsenite stress produced occasional FUS immunoreactivity in the 
TRN1 positive stress granule (7.07%) foci whilst the majority remained negative for FUS 
(Figure 4.4 A and B).  Similarly, under prolonged arsenite stress the vast majority of 
TRN1 foci observed were not FUS positive (96.52% negative 3.48% positive). The same 
was true of the post-stress TRN1 foci observed after recovery in fresh media (4.70% 
positive). 
Acute tBH stress produced the expected numerous punctate TRN1 stress granules 
(Figure 4.5 A). Despite a notable increase in the positivity for FUS (29.19% up by 
22.12%), the majority were negative (Figure 4.5 B). This pattern continued in the 
prolonged tBH stress condition (only 15.27% positive), however these foci were less 
numerous. Recovery in fresh media appeared to show a slight increase in the number of 
FUS positive TRN1 foci (38.26%) but again a substantial number remained negative 
(Figure 4.5 B).  
Acute osmotic stress produced the most FUS immunoreactive TRN1 stress granules 
(65.64%), however co-localisation could not be considered complete because there was 
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still a considerable number of TRN1 positive, FUS negative foci (Figure 4.6 A and B). 
After prolonged sorbitol stress there were fewer TRN1 foci in a similar fashion to 
oxidative stress, and under the reduced concentration and 24 hour incubation only a 
small proportion were FUS positive (9.08%). Interestingly, a slight increase in FUS 
positivity was observed after recovery in fresh media (31.05%) (Figure 4.6 B). 
4.6 Co-localisation with EWS 
Acute arsenite stress produced TRN1 stress granule foci that were also strongly 
immunoreactive for EWS (Figure 4.7 A). The degree of this co-localisation was 94.93%, 
therefore there was only a small minority of TRN1 foci not positive for EWS. The same 
was true of those TRN1 stress granule foci produced by prolonged arsenite stress 
(88.27%), and those foci that were present even after recovery (92.98%) (Figure 4.7 B).  
Acute tBH stress produced numerous punctate TRN1 stress granule foci as seen 
previously with this treatment (Figure. 4.8 A). Despite a difference in morphology 
between those TRN1 foci produced by arsenite and tBH the degree of co-positivity 
between TRN1 and EWS was equally almost complete (93.81%) (Figure 4.8 B). 
Prolonged stress with tBH showed similar findings with no substantial difference 
between TRN1 and EWS foci (95.86%), and after recovery TRN1 and EWS foci still co-
localised (95.38%) (Figure 4.8 A and B). 
In contrast to the oxidative stressors, acute osmotic stress produced numerous punctate 
TRN1 stress granule foci but a substantial number were EWS negative (39.19% negative 
60.81% positive) (Figure 4.9 B). After prolonged sorbitol stress drastically fewer TRN1 
foci co-localised with EWS (2.62%) whilst after the recovery period no co-localising 
cytoplasmic foci were observed (Figure 4.9 B).  
4.7 Co-localisation with TAF15 
Acute stress induced by all three stressors produced TRN1 stress granules that were 
only minimally positive for TAF15 (arsenite 5.93%, tBH 10.46%, sorbitol 1.48%) (Figure 
4.10 B 4.11 B and 4.12 B). However, prolonged stress induced robust TAF15 re-
110 
 
localisation to TRN1 stress granules and recovery in fresh media maintained the same 
staining pattern across all stressors (asenite 24hrs 98.39% after recovery 96.03%, tBH 
24hrs 100% after recovery 100%, sorbitol 24hrs 98.93% after recovery 100%)(Figure 
4.10 4.11 and 4.12). 
4.8 Co-localisation with Ubiquitin  
Given that the aggregates of FTLD-FUS are post-transcriptionally modified with ubiqitin, 
we investigated the TRN1 foci seen here with an ubiquitin antibody. Acute or prolonged 
oxidative stress (arsenite or tBuOOH) did not produce ubiquitin co-localisation with 
TRN1 foci (2hrs arsenite 0.56% 24hrs 10.12%, 2hrs tBH 0.86% 24hrs 8.24%). However, 
after a recovery period this changed, revealing good co-localisation between TRN1 and 
ubiquitin in these TRN1 foci (recovery after arsenite 97.22%, recovery after tBH 
91.34%) (Figure 4.13 and 4.14).   
Osmotic stress produced a slightly different staining pattern, with acute sorbitol stress 
producing TRN1 stress granule foci that are not positive for ubiquitin (only 0.21% 
positive), but after prolonged stress and prolonged stress followed by a recovery period, 
good co-localisation between TRN1 and ubiquitin could be seen within TRN1 foci (24hrs 
sorbitol 75.86%, and after recovery 97.82%) (Figure 4.15 A and B).  
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Figure 4.4. Arsenite stress induces translocation of nuclear FUS to the cytoplasmic 
compartment showing minimal co-positivity with TRN1 stress granules. Recovery in 
fresh media leaves TRN1 positive, FUS negative foci. TRN1 positive foci (A arrows). Co-
localisation quantification of foci counts shows 7.07% co-localisation in TRN1 foci at 
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2hrs and 3.48% at 24hrs, and 4.70% co-localisation after 6hrs recovery (B). Counts 
graphed as percentage of TRN1 foci also positive for FUS for ease of interpretation. Error 
bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm 
and 2.5µm within insets. N=3 
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Figure 4.5. tBH stress induces translocation of nuclear FUS to the cytoplasmic 
compartment showing minimal co-positivity with TRN1 stress granules. Recovery in 
fresh media leaves TRN1 positive, FUS negative foci. TRN1 positive foci (A arrows). Co-
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localisation quantification of foci counts shows 29.19% co-localisation in TRN1 foci at 
2hrs and 15.27% at 24hrs, but a 38.26% co-localisation after 6hrs recovery (B). Counts 
graphed as percentage of TRN1 foci also positive for FUS for ease of interpretation. Error 
bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm 
and 2.5µm within insets. N=3 
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Figure 4.6. . Sorbitol stress induces translocation of nuclear FUS to the cytoplasmic 
compartment showing partial co-positivity with TRN1 stress granules. Recovery in fresh 
media leaves TRN1 positive, FUS negative foci. TRN1 positive foci (A arrows). Co-
localisation quantification of foci counts shows 65.64% co-localisation in TRN1 foci at 
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2hrs and 9.08% at 24hrs, but a 31.05% co-localisation after 6hrs recovery (B). Counts 
graphed as percentage of TRN1 foci also positive for FUS for ease of interpretation. Error 
bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm 
and 2.5µm within insets. N=3 
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Figure 4.7. Arsenite stress induces translocation of nuclear EWS to the cytoplasmic 
compartment showing co-positivity with TRN1 stress granules. Recovery in fresh media 
leaves TRN1 and EWS positive foci. TRN1 positive foci (A arrows). Co-localisation 
quantification of foci counts shows 94.93% co-localisation in TRN1 foci at 2hrs and 
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88.27% at 24hrs, and 92.98% co-localisation after 6hrs recovery (B). Counts graphed as 
percentage of TRN1 foci also positive for EWS for ease of interpretation. Error bars SEM. 
Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm 
within insets. N=3 
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Figure 4.8. tBH stress induces translocation of nuclear EWS to the cytoplasmic 
compartment showing co-positivity with TRN1 stress granules. Recovery in fresh media 
leaves TRN1 and EWS positive foci. TRN1 positive foci (A arrows). Co-localisation 
quantification of foci counts shows 93.81% co-localisation in TRN1 foci at 2hrs and 
95.86% at 24hrs, and 95.38% co-localisation after 6hrs recovery (B). Counts graphed as 
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percentage of TRN1 foci also positive for EWS for ease of interpretation. Error bars SEM. 
Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm 
within insets. N=3 
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Figure 4.9. Sorbitol stress induces translocation of nuclear EWS to the cytoplasmic 
compartment showing partial co-positivity with TRN1 stress granules. Recovery in fresh 
media leaves TRN1 positive, EWS negative foci. TRN1 positive foci (A arrows). Co-
localisation quantification of foci counts shows 60.81% co-localisation in TRN1 foci at 
2hrs but 2.62% at 24hrs, and no co-localisation after 6hrs recovery (B). Counts graphed 
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as percentage of TRN1 foci also positive for EWS for ease of interpretation. Error bars 
SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 5µm and 
2.5µm within insets. N=3 
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Figure 4.10. Arsenite stress induces translocation of nuclear TAF15 to cytoplasmic pools 
showing co-positivity with TRN1 stress granules after prolonged stress. Recovery in 
fresh media leaves TRN1 and TAF15 positive foci. TRN1 positive foci (A arrows). Co-
localisation quantification of foci counts shows 5.93% co-localisation in TRN1 foci at 
2hrs but 98.39% at 24hrs, and 96.03% co-localisation after 6hrs recovery (B). Counts 
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graphed as percentage of TRN1 foci also positive for TAF15 for ease of interpretation. 
Error bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 
5µm and 2.5µm within insets. N=3 
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Figure 4.11. tBH stress induces translocation of nuclear TAF15 to the cytoplasmic 
compartment s showing co-positivity with TRN1 stress granules after prolonged stress. 
Recovery in fresh media leaves TRN1 and TAF15 positive foci. TRN1 positive foci (A 
arrows). Co-localisation quantification of foci counts shows 10.46% co-localisation in 
TRN1 foci at 2hrs but 100% at 24hrs, and 100% co-localisation after 6hrs recovery (B). 
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Counts graphed as percentage of TRN1 foci also positive for TAF15 for ease of 
interpretation. Error bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar 
in A represents 5µm and 2.5µm within insets. N=3 
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Figure 4.12. Sorbitol stress induces translocation of nuclear TAF15 to cytoplasmic pools 
showing co-positivity with TRN1 stress granules after prolonged stress. Recovery in 
fresh media leaves TRN1 and TAF15 positive foci. TRN1 positive foci (A arrows). Co-
localisation quantification of foci counts shows 1.48% co-localisation in TRN1 foci at 
2hrs but 98.93% at 24hrs, and 100% co-localisation after 6hrs recovery (B). Counts 
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graphed as percentage of TRN1 foci also positive for TAF15 for ease of interpretation. 
Error bars SEM. Overlay panels include blue nuclear DAPI stain. Scale bar in A represents 
5µm and 2.5µm within insets. N=3 
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Figure 4.13. Ubiquitin is found within TRN1 foci only after recovery in fresh media from 
arsenite stress. TRN1 positive foci (A arrows). Co-localisation quantification of foci 
counts shows 0.56% co-localisation in TRN1 foci at 2hrs and 10.12% at 24hrs, but 
97.22% co-localisation after 6hrs recovery (B). Counts graphed as percentage of TRN1 
foci also positive for ubiquitin for ease of interpretation. Error bars SEM. Overlay panels 
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include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm within insets. 
N=3 
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Figure 4.14. Ubiquitin is found within TRN1 foci only after recovery in fresh media from 
tBH stress. TRN1 positive foci (A arrows). Co-localisation quantification of foci counts 
shows 0.86% co-localisation in TRN1 foci at 2hrs and 8.34% at 24hrs, but 91.34% co-
localisation after 6hrs recovery (B). Counts graphed as percentage of TRN1 foci also 
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positive for ubiquitin for ease of interpretation. Error bars SEM. Overlay panels include 
blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm within insets. N=3 
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Figure 4.15. Ubiquitin is found within TRN1 foci after prolonged sorbitol stress and 
recovery in fresh media. TRN1 positive foci (A arrows). Co-localisation quantification of 
foci counts shows 0.21% co-localisation in TRN1 foci at 2hrs but 75.86% at 24hrs, and 
97.82% co-localisation after 6hrs recovery (B). Counts graphed as percentage of TRN1 
foci also positive for ubiquitin for ease of interpretation. Error bars SEM. Overlay panels 
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include blue nuclear DAPI stain. Scale bar in A represents 5µm and 2.5µm within insets. 
N=3  
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4.9 Statistical analysis of TRN1 foci reveals significant changes  
To illustrate the core findings of this immunocytochemical study, statistical analysis was 
undertaken by one-way ANOVA and Bonferroni post-test. To summarise the significant 
findings, the loss of G3BP in TRN1 foci after recovery from stress (arsenite, tBH or 
sorbitol) is significant. The gain of ubiquitin positivity in TRN1 foci after recovery is also 
significant. Maximal FUS positivity in TRN1 foci is achieved by acute sorbitol stress. 
Maximal EWS positivity in TRN1 foci is achieved by oxidative stress (arsenite or tBH). 
Maximal TAF15 positivity in TRN1 foci is achieved by prolonged stress (arsenite, tBH or 
sorbitol), and there is no significant difference between stressors. Maximal ubiquitin 
positivity in TRN1 foci is achieved after recovery from stress (arsenite, tBH, or sorbitol), 
and there is no significant difference between stressors. 
Statistical analysis of G3BP co-localisation with TRN1 foci shows the reduction seen after 
6 hours recovery in fresh media is significant for 24 hours 10µM arsenite (p<0.001), and 
24 hours 400mM sorbitol (p<0.001) (Figure 4.16 A). Unfortunately not enough data 
points were recorded for meaningful analysis of 24 hours 190µM tBH (i.e. too few foci 
were seen to allow the analysis to run).  
Additionally, the increase in ubiquitin positive TRN1 foci seen after recovery is also 
significant for arsenite (p<0.001), tBH (p<0.001), and sorbitol (p<0.05) (Figure 4.16 B).   
Comparing FUS co-localisation with TRN1 foci under acute (2 hours) arsenite 0.5mM, 
tBH 50mM and sorbitol 600mM treatment shows there is statistically more FUS positive 
TRN1 foci when cells are subjected to sorbitol stress compared to arsenite (p<0.001) or 
tBH (p<0.001).  Repeating this analysis for the EWS protein shows there are significantly 
fewer EWS positive TRN1 foci when the cells are subjected to sorbitol stress compared to 
arsenite (p<0.001), and tBH (p<0.001). No difference in TAF15 or ubiquitin positive 
TRN1 foci is seen across the three treatments in the acute stress condition (Figure 4.16 
C).  
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Comparing FUS co-localisation with TRN1 foci under prolonged (24 hours) arsenite 
10µM, tBH 190µM, and 400mM sorbitol treatment shows there was no significant 
differences in FUS positive TRN1 foci between arsenite and sorbitol or tBH and sorbitol 
treated cells. Repeating the analysis for EWS shows there is significantly fewer EWS 
positive TRN1 foci when the cells are subjected to sorbitol stress, compared with 
arsenite (p<0.001), or tBH (p<0.001).  There are no significant differences in the number 
of TAF15 positive TRN1 foci between arsenite, tBH or sorbitol treated cells in the 
prolonged stress condition. Additionally, the number of ubiquitin positive TRN1 foci 
after sorbitol treatment was significantly higher compared to arsenite (p<0.001), or tBH 
(p<0.001) (Figure 4.16 D). No significant difference between arsenite and tBH conditions 
was noted. 
Comparing FUS co-localisation with TRN1 foci after 6 hours of recovery from prolonged 
(24 hours) arsenite 10µM, tBH 190µM, and 400mM sorbitol treatment shows there are 
significantly more FUS positive TRN1 foci after recovery from tBH compared to arsenite 
(p<0.001) or sorbitol (p<0.001).  No significant differences in FUS positive TRN1 foci 
were apparent between arsenite and sorbitol treated cells. Repeating the analysis for 
EWS shows significantly fewer EWS positive TRN1 foci in cells recovering from sorbitol 
stress compared to arsenite (p<0.001), or tBH (p<0.001). No significant difference in 
EWS positive TRN1 foci was noted after recovery from arsenite compared to tBH stress. 
Finally, no significant differences were noted in TAF15 or ubiquitin positive TRN1 foci 
produced after recovery from arsenite, tBH or sorbitol stress (Figure 4.16 E). 
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Figure 4.16. Statistical analysis of TRN1 stress granule foci positivity for the FET proteins 
G3BP and ubiquitin. One-way ANOVA with bonferroni correction identifies significant 
difference under different conditions (* p<0.05 *** p<0.001). Changes in G3BP and 
ubiquitin positivity pre and post 6hrs recovery in fresh media (A & B). Differences in 
FUS, EWS, TAF15 and ubiquitin positivity of TRN1 stress granule foci at 2hrs (C). 
Differences in FUS, EWS, TAF15 and ubiquitin positivity of TRN1 stress granule foci at 
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24hrs (D). Differences in FUS, EWS, TAF15 and ubiquitin positivity of TRN1 foci after 
24hrs of stress and 6hrs of recovery in fresh media. Error bars SD.   
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4.10 Emetine pre-treatment prevented the formation of SGs and post-
stress foci.  
Emetine is a well-characterized pharmacological agent known to stabiles the polysome 
thereby preventing the formation of stress granules. To further confirm that the 
structures observed were indeed stress granules, and to investigate whether the TRN1 
foci seen after recovery were post-stress granule foci, SH-SY5Ycells were pre-treated 
with 6µg/ml emetine for two hours before repeating all the stress conditions. In all of the 
stress conditions investigated here, emetine pretreatment prevented the formation of 
stress granules. Moreover, the TRN1 positive ‘post-stress foci’ were absent from the 24 
hour stress followed by 6 hour recovery conditions (Figure 4.16). However, emetine 
pretreatment produced a much more pronounced TRN1 re-localisation to the cytoplasm 
when the cells were subjected to stress, compared to stress alone. Interestingly, even 
after 6 hours of recovery in fresh media, TRN1 had not returned to the nucleus.  
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Figure 4.17. Emetine pre-treatment prevents the formation of TRN1 positive stress 
granules but not the re-localisation to the cytoplasm.  In blank untreatred control and 
emetine treated, TRN1 is nuclear and G3BP is weak and diffuse (A). Arsenite, tBH, or 
sorbitol stress does not form G3BP positive stress granules but does result in TRN1 
cytoplasmic re-localisation (B, C and D).  Post-stress granule TRN1 foci are not present in 
emetine pre-treated stress-and-recovery cells. Scale bar in A represents 5µm. N=3 
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4.11 The TRN1 positive post-stress granule foci are P-bodies 
To further investigate the nature of the TRN1 positive G3BP negative foci found after 6 
hours of recovery in fresh media, these cells were stained for the P-body marker, mRNA 
decapping enzyme 1a (DCP1a). P-bodies are functionally related to stress granules 
because whilst stress granules collate the non-essential mRNA, the degradation of the 
mRNA takes place in P-bodies. Much like stress granules they are non-membranous 
aggregates that form and dissociate as required, and they are often found immediately 
adjacent to stress granules. However, unlike stress granules they are always present 
within the cell, even in the absence of stressors. Immunocytochemistry reveals that the 
TRN1 foci formed after arsenite, tBH or sorbitol stress followed by recovery in fresh 
media are strongly positive for DCP1a (Figure 4.17 B C and D arrows). Furthermore, 
whilst the TRN1 foci are P-bodies, not all P-bodies are TRN1 positive (Figure 4.17 A). 
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Figure 4.18. The TRN1 positive foci observed after recovery are P-bodies. Unstressed 
control cells shown normal nuclear TRN1 staining and numerous P-bodies (A). 10µM 
arsenite (B), 190µM tBH (C), or 400mM sorbitol (D) for 24 hours followed by 6 hours 
recovery in fresh media produces TRN1 positive foci that co-localise with the P-body 
marker DCP1a (arrow). Scale bar in A represents 5µm. N=3  
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4.12 Oxidative stress, not osmotic stress increases the TRN1 found in the 
urea fraction  
Given that highly insoluble TRN1 is associated with FTLD-FUS (Brelstaff et al., 2011), the 
solubility status of TRN1 was investigated with a similar technique to those 
investigations in brain tissue. Cells were lysed in RIPA buffer and untracentrifuged to 
reveal the RIPA insoluble pellet. This was then resuspended in urea buffer to give the 
highly insoluble fraction. Immunoblotting and densiometric quantification shows that, in 
a time dependent manner, the oxidative stressors arsenite and tBuOOH increase the 
amount of TRN1 found in the highly insoluble fraction (0.5mM arsenite for 2 hours 
p<0.01, 50mM tBH for 2 hours p<0.01) (Figure 4.18 A and B). This pattern was not seen 
with sorbitol stress (Figure 4.18 C). No change was seen in the TRN1 detected in the 
RIPA soluble fraction (Figure 4.18 A, B and C). No change was seen in either the RIPA or 
urea fractions of TRN1 when treated with any 24hr or 24hr plus recovery paradigm 
(Figure 4.18 D, E and F). To confirm that the method of solubility fractionation was 
robust and did not permit carry-over of proteins from the RIPA to the urea fractions 
blots were probed for the soluble enzyme glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).  None of the acute stress conditions revealed any detectable urea soluble 
GAPDH (Figure 4.18 G). This presence of GAPDH solely in the RIPA fraction has been 
reported elsewhere (Igaz et al., 2011). 
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Figure 4.19.  Acute oxidative stress increases the levels of insoluble TRN1. Densitometric 
quantification of immunoblots and analysis with one-way ANOVA followed by Dunnett’s 
post-test reveals 0.5mM arsenite increases detectable urea soluble TRN1 at 30 (*p<0.05), 
60 (*p<0.05) and 120 minutes (**p<0.01), and 50mM tBH over 30 (*p<0.05) 60 
(**p<0.01) and 120 (*p<0.01) hours increases the detectable urea soluble TRN1, but 
does not decrease the RIPA soluble TRN1 (A and B). No significant change in urea or 
RIPA soluble TRN1 levels is noted after 600mM sorbitol stress for 2 hours (C). Exposure 
to lower concentrations off stress over 24 hours does not affect urea or RIPA soluble 
TRN1 levels (D, E and F). No carry-over of proteins from the RIPA to urea fraction is seen 
with this technique (G).  Representative immunoblots of three independent experiments. 
TRN1 molecular weight approximately 102kDa. 5µg of protein was loaded in each lane. 
Normalisation to loading control was not possible due to extraction method. N=3 
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4.13 The prevention of stress granule formation does not affect oxidative 
stress induced increase of TRN1 found in the urea fraction  
TRN1 undergoes a dramatic compartmental re-localisation to stress granules which is 
accompanied by an increase in urea soluble TRN1 upon oxidative stress. To investigate 
whether these two phenomena are related SH-SY5Y cells were pre-treated with 16.3µM 
emetine dihydrochloride. The resulting stabilisation of polysomes and suspension of 
protein elongation prevents the formation of stress granules in response to 2 hours 
0.5mM arsenite stress. The cells were then lysed and fractionated as previously 
described. Comparison of urea soluble TRN1 levels from emetine pre-treated, non-pre-
treated, and unstressed control cells reveals the formation of stress granules is not the 
cause of increased urea soluble TRN1 levels (Figure 4.19). 
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Figure 4.20. Emetine pre-treatment does not prevent arsenite induced increase of 
insoluble TRN1. Immunoblotting of the urea soluble fraction shows a dramatic increase 
of insoluble TRN1 levels under 0.5mM arsenite for 2 hours compared with control cells. 
This is not prevented by blocking stress granule formation via 16.3µM emetine pre-
treatment. No loss of RIPA soluble TRN1 is seen under any treatment condition. 
Representative immunoblot of three independent experiments. Molecular weight of 
TRN1 approximately 102kDa. 5µg of protein was loaded in each lane. 
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4.14 Oxidative nor osmotic stress change the levels of RIPA or urea soluble 
FUS 
Given that oxidative stress dramatically increases the levels of urea soluble TRN1 in a 
manner akin to the biochemistry of FTLD-FUS, the solubility of FUS was investigated to 
see if this pattern repeated. Neither oxidative (0.5mM arsenite or 50mM tBH) nor 
osmotic (600mM sorbitol) induced a shift in insolubility similar to that seen in FTLD-FUS 
(Figure 4.20).  This suggests that the cellular mechanisms that drive FUS insolubility may 
be distinct to those of TRN1. For instance FUS may have a divergent set of interacting 
partners that drive its increasing insolubility under specific conditions that are not 
replicated in vitro by oxidative or osmotic stressors. 
4.15 Oxidative or osmotic stress shift TDP43 to the insoluble  fraction 
TDP43 is an important protein in the cause and pathology of FTLD-TDP. It also shares a 
good deal of similarity with FUS both in terms of structure and function. To investigate 
whether an RNA DNA binding protein similar to FUS is unaffected by cellular stressors, 
membranes were stripped and re-probed for TDP43. In contrast to FUS biochemistry, 
qualitative assessment shows both oxidative and osmotic stress shift TDP43 towards the 
insoluble fraction by reducing the RIPA soluble and increasing the urea soluble levels 
(Figure 4.22). This appeared to occur in a time-dependant fashion with the most 
pronounced loss of RIPA soluble TDP43 at 2 hours.  However, this is only a qualitative 
assessment since the urea fraction contained several higher molecular weight bands that 
did not resolve sufficiently to allow clear delineation of the correct band for 
quantification. These may be higher molecular weight species formed by ubiquitination, 
or other modifications such as phosphorylation.  
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Figure 4.21.  Oxidative (0.5mM arsenite or 50mM tBH) nor osmotic stress (sorbitol 
600mM) affects the solubility of FUS. No change is evident in RIPA or urea soluble levels 
of FUS upon arsenite (A), tBH (B) or sorbitol (C) exposure. Representative immunoblot of 
three independent experiments. Molecular weight of FUS in SDS PAGE approximately 
73kDa. 5µg of protein was loaded in each lane. 
 
 
 
 
Figure 4.22. Oxidative (0.5mM arsenite or 50mM tBH) and osmotic (600mM sorbitol) 
stress shifts TDP43 to the insoluble fraction. Arsenite (A), tBH (B) and sorbitol (C) 
reduce the levels of RIPA soluble TDP43 whilst increasing the urea soluble levels. 
Representative immunoblot of three independent experiments. Molecular weight of 
TDP43 approximately 43kDa. 5µg of protein was loaded in each lane. 
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4.16 TRN2b can bind TRN1 cargos and may act as a redundant nuclear 
importer 
In spite of a pronounced nuclear clearance of TRN1 in FTLD-FUS neurons (Figure 3.4) 
and a dramatic cytoplasmic re-localisation in stressed cells, there is often discernible 
nuclear FET protein (Figure 4.1-4.15). If their nuclear localisation was entirely 
dependent on the function of TRN1 any loss through aggregate sequestration or re-
localisation should result in profound FET protein re-localisation. TRN2 has two 
isoforms TRN2a and TRN2b, it has been suggested that due to high homology between 
TRN2b and TRN1 it may act as a redundant importer of some TRN1 cargos (Rebane et al., 
2004). To investigate this possibility SH-SY5Y TRN2b was immunoprecipitated using an 
antibody specifically targeted to TRN2b. Co-immunoprecpitation reveals detectable FUS, 
EWS, TAF15 and hnRNP A1 (Figure 4.22). This suggests that TRN2b could bind and 
possibly import these cargos which may have consequences in FTLD-FUS.   
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Figure 4.23. The TRN2b isoform can bind the FET proteins and the classical TRN1 cargo 
hnRNP A1. Co-immunoprecipitation demonstrates the TRN2b isoform of TRN2 can bind 
TRN1 cargos and may act as a redundant importer. Upper panel demonstrates equal 
input and loading by beta-actin. Lower panel beads only control lanes shows proteins 
only minimally bind to beads in the absence of the TRN2b antibody. I.P and Co-I.P. lanes 
show successful precipitation of TRN2b interacting proteins. Representative 
immunoblots of three independent experiments. Molecular weight of TRN2b in SDS 
PAGE approximately 95kD, FUS 73kD, EWS 90kD, TAF15 62kD, hnRNP A1 41kD.  
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4.17 TNPO1 and TNPO2 siRNA knockdown re-localises TRN1 targets to the 
cytoplasm 
To demonstrate that the FET proteins and hnRNP A1 are targets of TRN1 import in SH-
SY5Y cells TRN1 and TRN2 protein levels were knocked down by siRNA targeting of their 
respective mRNA. TRN2 was included in the knockdown siRNA pool because the isoform 
TRN2b may act as a redundant importer for these cargoes (Figure 4.23).  Maximum 
knockdown of TRN1 and TRN2 was achieved with 100nM siRNA over 6 days (knock 
down transfection repeated on days 3)(Figure 4.24 A quantified in B) before toxicity 
induced large scale apoptosis. Immunocytochemistry reveals non-targeting scramble 
siRNA does not affect the normal nuclear staining of the FET proteins, hnRNP A1 or 
TDP43 (Figure 4.24 C). However, the FET proteins and hnRNP A1 lose their nuclear 
definition and re-localise to a diffuse distribution throughout the cell upon TNPO1 and 
TNPO2 knockdown (Figure 4.24 C). Since TDP43 is known to be imported through a 
separate import pathway it is unsurprising that it is unaffected by TNPO1 and TNPO2 
knockdown. 
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Figure 4.24.  siRNA mediated knockdown of TRN1 and TRN2 results in approximately 
70% reduction in protein levels which re-localises the FET proteins, and hnRNP A1 but 
not TDP43 to the cytoplasm. Maximal reduction of TRN1 and TRN2 is achieved with 
100nM siRNA (A), which reaches 72.4% and 74% respectively (B). Scrambled siRNA 
does not affect normal nuclear staining of the FET proteins, hnRNP A1 or TDP43. 
Knockdown of TNPO1 and TNPO2 re-localises the FET proteins and hnRNP A1 to the 
cytoplasm but TDP43 remains nuclear. Representative immunoblot (A) of three 
independent experiments analysed for densiometric quantification (B). Molecular weight 
TRN1 approximately 102kD, TRN2 95kD. Scale bar 5µm.  
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4.18 Knockdown of TNPO1 and TNPO2 significantly increases the 
recruitment of FET proteins to stress granules 
To further investigate the role of TRN1 in the recruitment of its cargos to stress granules, 
knockdown cells were subsequently subjected to 0.5mM arsenite for 2 hours. 
Knockdown of TNPO1 and TNPO2 resulted in a significant increase of FUS and TAF15 
positive stress granules (p<0.001) compared with scrambled control siRNA (Figure 4.24 
A quantified in B). Unlike FUS and TAF15, EWS strongly localised to stress granules even 
in untransfected control cells (Figure 4.7 4.8 and 4.9), this pattern holds true in scramble 
and TNPO1 TNPO2 siRNA transfected cells (Figure 4.24 B). No change in ubiquitin 
staining was observed. This suggests that cytoplasmicaly re-localised FET proteins are 
sequestered into stress granules to a greater degree under conditions of TRN1 and TRN2 
knockdown. Perhaps most importantly, these results suggest that TRN1 and TRN2 are 
not required for stress granule incorporation of the FET proteins, despite being 
functional binding partners of those importins. 
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Figure 4.25. siRNA knockdown of TNPO1 and TNPO2 significantly increase FUS and 
TAF15 recruitment to stress granules. SH-SY5Y cells were transfected with either 
scramble or TNPO1 and TNPO2 siRNA before 0.5mM arsenite stress for 2 hours. Non-
targetting siRNA does not perturb the formation of stress granules (A arrow) or disturb 
the normal nuclear localisation of the FET proteins nor affect ubiquitin staining. 
Knockdown of TNPO1 and TNPO2 re-localises the FET proteins to the cytoplasm and into 
stress granules (A arrows) upon 0.5mM arsenite stress for 2 hours.  Quantification of 
G3BP stress granule counts also positive for FUS, EWS, TAF15 or ubiquitin in scramble or 
knockdown conditions via Mann-Whitney U test reveals a significant (***p<0.001) 
increase in FUS and TAF15 positive stress granules upon TNPO1 and TNPO2 knockdown 
(B). Scale bar in A represents 5µm and 2.5µm within insets. N=3 
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4.19 Over expression of TRN1 produces cytoplasmic staining that does not 
co-localise with FET proteins or stress granules  and may be artifactual 
The inclusions of FTLD-FUS have a unique immunohistochemical profile that includes 
TRN1 and many of its cargo proteins alongside generalised markers of aggregation like 
ubiquitin and p62. Stress granule based hypotheses of cytoplasmic inclusion formation 
appear muddied by the action of TRN1. In untransfected cell lines endogenous TRN1 
strongly re-localises to stress granules, which is accompanied by incomplete FET protein 
incorporation. Depletion of TRN1 via siRNA increases the sequestration of FUS and 
TAF15 in these foci, but they now lack the key TRN1 pathology. A more accurate 
situation would include TRN1 and all three FET proteins cytoplasmically mis-localised 
and aggregating. Several models of neurodegeneration employ over expression of a key 
protein to accentuate a phenotype that leads to aggregate formation and or 
degeneration. To this end, wild-type TRN1 plasmids were transiently transfected into 
SH-SY5Y cells. Western blotting demonstrates that TRN1 can be successfully expressed 
in SHSY5Y by transient transfection and anti-myc tag antibodies can detect the TRN1-
myc tagged protein. (Figure 4.25 A and B). Immunocytochemistry was performed using 
the myc antibody to stain for transiently expressed myc-tagged TRN1. Control 
untransfected cells showed minimal background staining (Figure 4.26 A). Transfection 
with wild type TRN1-myc produces unrefined cytoplasmic staining additional to the 
expected nuclear stain (Figure 4.26 C double arrows).  Cytoplasmic TRN1-mycstaining 
does not co-localise with any of the FET proteins (Figure 4.26 C). Oxidative stress with 
0.5mM arsenite for 2 hours induced stress granules (Figure 4.26 D arrows) but these did 
not co-localise with the TRN1-myc staining (double arrows).  Cytoplasmic myc staining 
weakly co-localised with ubiquitin in both unstressed (Figure 4.26 C) and stressed cells 
(Figure 4.26 D).  Despite a passing resemblance to the cytoplasmic aggregates of FTLD-
FUS, the cytoplasmic staining observed here is likely an artefact of overexpression.   
 
158 
 
 
Figure 4.26. Immunoblotting of TRN1-myc transfected SH-SY5Y cells shows –myc tag 
antibody detects TRN1-myc at 103kD, and probing for total TRN1shows increase in 
TRN1 from transfected cells. Transfection with 5µg of TRN1-myc plasmid DNA produces 
detectable levels of protein via –myc antibody (A). Probing with anti-TRN1 antibody 
reveals vast increase over endogenous levels of TRN1 when quantified with 
densitometry and analysed with Mann-Whitney U test (** P<0.01) (B). Representative 
immunoblots of three independent experiments. Protein load was 2µg in all lanes, and 
equal loading confirmed by β actin probe. Molecular weight of TRN1 102kD, TRN1-myc 
103kD.  
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Figure 4.27. Transfection with TRN1-myc plasmid DNA produces additional cytoplasmic 
staining that is unrelated to stress granules. Anti-myc antibody shows minimal 
background staining in unstressed (A) or stressed cells (B arrows). Unstressed 
transfected cells show cytoplasmic –myc staining negative for the FET proteins and 
weakly ubiquitin positive(C double arrows). 0.5mM arsenite for 2 hours produces stress 
granules (D arrows) separate from the –myc staining (D double arrows). Scale bar in A 
represents 5µm. N=3 
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4.20 Thioflavin S staining of TRN1-myc transfected cells is inconclusive  
One of the characteristic hallmarks of many neurodegenerative diseases is the formation 
of β-sheet enriched protein aggregates. These can be detected with Thioflavin S thanks to 
its ability to incorporate into this secondary structure and undergo a red shift in 
florescence. Unusually, FTLD-FUS inclusions are not thioflavin S positive and are 
therefore unlikely to contain proteins enriched for β-sheet structures. To investigate the 
nature of the additional cytoplasmic –myc staining SH-SY5Y cells were transfected as 
before and stained with thioflavin S. Unfortunately, lipofectamine produced false 
positives which preclude any meaningful interpretation of the transfected cells (Figure 
4.27).  
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Figure 4.28. Lipofectamine 2000 produces false positive thioflavin S staining. Control SH-
SY5Y cells are thioflavin negative, but lipofectamine2000 appears to produce false 
positive thioflavin S foci (arrows). Scale bar represents 5µm. N=3 
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4.21 Discussion 
These data demonstrate the nuclear importer TRN1 is radically re-localised to 
cytoplasmic stress granules in response to various stressors and incubation periods. The 
FET proteins are less amenable to stress granule re-localisation, but this can be 
increased by prolonging the incubation with stressors at lower concentrations. Recovery 
in fresh media produces TRN1 positive, G3BP negative foci. These are variably positive 
for the FET proteins and strongly positive for ubiquitin. These foci showed some co-
localisation with DCP1a, suggesting a link to P-bodies and mRNA degradation factors. 
Oxidative stress over 2 hours will increase the levels of urea soluble (RIPA insoluble) 
TRN1. This result does not hold true for FUS which remains resolutely unaffected in 
terms of solubility. The change in TRN1 insolubility is not due to incorporation into 
stress granules because blocking  stress granule formation with emetine in arsenite 
stressed cells did not rescue the increase in urea soluble TRN1 levels. The incorporation 
of FET proteins into stress granules does not appear to be mediated by TRN1. 
Unfortunately, over expression of TRN1 did not provide viable data because 
immunocytochemistry was hampered by artefacts, which could not be resolved due to 
lack of the appropriate empty vector.   
One of the central findings of this investigation is that the nuclear importer TRN1 readily 
re-localises to stress granules in SH-SY5Y cells. Previously, it has been shown that 
members of the importin family, including TRN1 re-localise to eIF4A positive stress 
granules under arsenite treatment in HeLa and HEK293 cells (Chang and Tarn, 2009). In 
this study a cell line with a neuron-like background (SH-SY5Y) was exposed to various 
stressors and the properties of endogenous TRN1 and the FET proteins were followed by 
sequential solubility extraction and immunofluorescence. This investigation shows that 
TRN1 re-localises to G3BP positive stress granules, and that a fraction of FUS and TAF15 
also re-localises to these TRN1 positive foci. EWS re-localises very strongly under 
oxidative stress which agrees with previous reports (Andersson et al., 2008a). However, 
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other authors have struggled to detect EWS in stress granules (Blechingberg et al., 
2012b), though this may be due to the different antibodies used in these studies. The 
choice of antibodies for the cellular studies presented here was always rooted in their 
ability to detect pathology in FTLD-FUS tissue. It is possible that only certain epitopes are 
exposed for detection with antibodies depending on how the protein is folded. 
Additionally, this may change if the protein is post-translationally modified either as a 
result of different stressors (oxidative or osmotic) or incorporation into stress granules. 
Examples of which include the fragile X mental retardation protein which is methylated 
when found in stress granules (Xie and Denman, 2011). Interestingly, the 
aforementioned study struggled to detect a EWS-GFP fusion protein in stress granules 
despite being able to detect the endogenous form (Andersson et al., 2008a). This may 
suggest that incorporation of a tag at the N terminal may alter protein translocation in 
response under oxidative stress. 
In contrast to the effect of oxidative stress on EWS, more prominent re-localisation of 
FUS was observed under the osmotic stressor sorbitol. This has been replicated to a 
greater extent in other cell lines (Sama et al., 2013). Whilst some re-localisation was seen 
after arsenite exposure, the majority of FUS remained nuclear, which agrees with 
previous reports that have not detected FUS in stress granules (Gal et al., 2011, Bosco et 
al., 2010).  Most authors report TAF15 is easily detectable in stress granules induced by 
arsenite or heat shock but those reports are from HeLa or HT22 cell lines (Andersson et 
al., 2008a, Marko et al., 2012). Since neuronal cells have a different mRNA profile, and 
TAF15 is a RNA binding protein, different linages might explain why detection at the 2 
hour time point in SH-SY5Y was muted. It is interesting to note that the number of TRN1 
positive stress granules also positive for TAF15 increased when cells were exposed to a 
lower concentration of stressor over a 24 hour period. It may be that in this particular 
cell line the recruitment of TAF15 to stress granules is slower than other proteins, or that 
a particular set of conditions or modifications that occur after prolonged stress are 
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required. For instance, a reduction in methylation status is associated with TAF15 
positive stress granules (Jobert et al., 2009a). Given that one of the hallmarks of FTLD-
FUS inclusions is the incorporation of ubiquitin and the proteasomal marker p62, the 
ubiquitin status of TRN1 positive stress granules and post-stress granule foci was 
investigated. The incorporation of ubiquitin after recovery in fresh media would seem to 
support a stress granule-inclusion precursor hypothesis but ubiquitin and ubiquitin 
associated proteins in stress granules is not unheard of (Athanasopoulos et al., 2010). 
Additionally, double staining of these TRN1 positive foci after 6 hours recovery with 
DCP1a suggests they are P-bodies and linked to mRNA processes like de-capping and 
degradation. P-bodies, unlike stress granules are constitutive, but they do respond to 
stimuli that effect mRNA translation and decay. However, they are highly related to 
stress granules and are often found adjacent to one another. They can pass mRNA 
between one another for processing and they also share a number of protein 
components such as RNA-associated protein 55 (Rap55), tristetraprolin (TTP), and TRN1 
(Buchan and Parker, 2009, Chang and Tarn, 2009).  Since P-body markers are not found 
within the inclusions of FTLD-FUS it would seem unlikely that the TRN1 positive P-
bodies seen here represent early inclusions.  
To further substantiate the nature of the stress granules and foci observed after acute 
and prolonged stresses together with recovery in fresh media, we pre-treated the cells 
with emetine. Emetine is a well-characterized pharmacological compound known to bind 
to the 40S subunit of the ribosome, stabilize the polysome, and promote disassembly of 
stress granules. The observation that emetine pre-treatment prevents the detection of 
cytoplasmic foci under all of the treatment conditions investigated here suggests that the 
foci observed are indeed bona fide stress granules, but additionally it suggests that the 
formation of these foci is also dependent on ribosomal disassembly induced by 
translation interruption in response to stress, and assembly of mRNA factors linked to 
stress granules.  The absence of stress granules or other foci after emetine pre-treatment 
168 
 
was accompanied by a pronounced cytoplasmic redistribution of TRN1 to the cytoplasm. 
One possible explanation is that TRN1 may require stress granules or a component of 
stress granules for re-nucleation in the context of cellular stress. It has been previously 
shown by FRET analysis of TRN1 in early stress granules that it is not statically 
sequestered away, but instead can shuttle in and out of stress granules (Chang and Tarn, 
2009). The same has been shown for the highly related protein importin , once again 
through FRET photobleaching of an arsenite induced stress granule (Fujimura et al., 
2010). It is possible that one of TRN1’s roles in the integrated stress response is to 
interact with an unidentified protein present in the stress granules which targets it back 
to the nucleus. One possibility is the Ran protein, which has been shown to be present in 
stress granules (Fujimura et al., 2010), and is an important co-factor for nuclear 
shuttling. 
Aside from cytoplasmic re-localisation, the production of insoluble protein species is a 
distinctive biochemical marker for FTLD (Neumann et al., 2006, Neumann et al., 2009a, 
Brelstaff et al., 2011). The results show that acute exposure to oxidative stress increased 
the insolubility of TRN1, but the osmotic stressor sorbitol did not produce a significant 
change in the insolubility of TRN1. This difference suggests there is a biochemical or 
cellular consequence of oxidative stress on TRN1 that reduces protein solubility. Given 
that urea soluble (highly insoluble) TRN1 is a characteristic of FTLD-FUS (Brelstaff et al., 
2011), these data support the hypothesis that the FTLD-FUS brain is subject to oxidative 
stress. To compare and contrast the response of FUS with another mRNA binding protein 
the blots were stripped and re-probed for TDP43. TDP43 is deeply involved in FTLD as 
the sole primary marker of pathology in FTLD-TDP, and only is occasionally reported in 
stress granules much like FUS (Liu-Yesucevitz et al., 2010, Colombrita et al., 2009).  In 
contrast to FUS, not only was the urea fraction of TDP43 increased over time, but this 
also corresponded to a concomitant decrease in the RIPA fraction. This finding has been 
subsequently recapitulated in published data using Cos7 cells and a reduced incubation 
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time and concentration of arsenite (Cohen et al., 2012). Those authors speculated that 
this shift in solubility is due to disulphide cysteine cross linking at C173-C175 induced by 
oxidative stress. Furthermore, osmotic stress appeared to produce the same pattern 
whereas previously this stressor had no effect on TRN1 or FUS. At the time of writing this 
effect of sorbitol stress on TDP 43 solubility is a novel finding and may suggest a 
convergent pathway of multiple stress types on TDP 43. Densitometric quantification 
and analysis is preferable to qualitative assessment but the presence of multiple higher 
molecular weight bands merging with the 43kDa signal precluded this. It is possible that 
these bands represent pathologically relavent post-transcriptional modifications such as 
phosphorylation, which is a known alteration of TDP 43 (Neumann et al., 2006). 
However, to clearify this issue would require phosphotase treatment to investigate 
whether the bands disappear.  
Given the dual observation of strong re-localisation to stress granules and increasing 
levels of insoluble protein a causal relationship between the two was investigated. 
Emetine blockade of stress granule formation does not prevent the rise in insoluble 
TRN1 levels in response to 2 hours 0.5mM arsenite stress despite TRN1 strongly re-
localising to stress granules and previous authors stating these foci represent insoluble 
aggregates (Kedersha and Anderson, 2007, Wolozin, 2012). The inference of this is that 
the biochemical consequence of oxidative stress on TRN1 occurs in the absence of stress 
granules.  
Despite the fact that TRN1 is a functional binding partner of the FET proteins and readily 
re-localises to stress granules, it is not responsible for the re-localisation of FET proteins 
to said foci. Knockdown of TRN1 and TRN2 by siRNA re-localises the FET proteins to the 
cytoplasm and subsequent 0.5mM arsenite stress for 2 hours significantly increases 
stress granule FET positivity. This would seem to argue that the importin protein TRN1 
(or TRN2) is not required for stress granule incorporation. Other studies into the 
recruitment of FUS and the other FET proteins into stress granules have strongly 
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implicated their zinc finger, glycine-rich domain and RRM which would seem to 
underscore the importance of RNA binding rather than TRN1 binding in stress granule 
recruitment (Bentmann et al., 2012, Marko et al., 2012).  Over expression of wild type 
TRN1 produced morphologically heterogeneous cytoplasmic staining additional to the 
normal nuclear localisation. This cytoplasmic staining was likely artifactual despite a 
passing similarity to the inclusions of FTLD-FUS. Neither the FET proteins nor stress 
granule markers co-localise with this staining suggesting it may be an artefact of over 
expression rather than unique inclusion formation. These data also contrasts with 
previously published reports describing co-localisation of over expressed GFP-TRN1 
with stress granules (Chang and Tarn, 2009).  Whether or not the additional cytoplasmic 
TRN1 staining represents an artefact or genuine inclusion formation, further 
characterisation is warranted. To elicudate the presence of this additional, often 
aggregation like, myc-TRN1 staining an empty vector should have been used as an 
overexpression control. This would allow the clarification of whether what is observed is 
just an artifact of overexpressing any protein or something specific to TRN1. However 
this was not possible here due to finantial and time constraints. Unfortunately, thioflavin 
S staining proved inconclusive because cells treated with only lipofectamine2000 gave a 
false positive result.  
In summary TRN1 positive stress granules are variably positive for the FET proteins, and 
G3BP negative TRN1 foci seen after recovery periods are likely to be P-bodies. The 
insolubility of TRN1 increases under oxidative stress but this does not require stress 
granule formation. Furthermore, TRN1 (and TRN2) is not responsible for FET protein 
incorporation into stress granules. Finally, over expression of TRN1 in SH-SY5Y cells 
produces unusual cytoplasmic staining. One final caveat to this work it that this SH-SY5Y 
line was not differentiated with retinoic acid into a more quiescent neuron like 
phenotype. The main reason for this is that retinoic acid treatment has been shown to 
alter the expression levels of the FET proteins (Andersson et al., 2008a) and it was 
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therefore decided that this variable should be avoided. Further investigations into a 
separate cell model are explored in the next chapter. 
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Chapter Five: Validation of stress 
granule findings in rat 
hippocampal primary neurons 
(Results III) 
5.1 Introduction 
It is widely accepted that oxidative stress has a major role in the neurodegeneration 
behind the myriad of dementias and movement disorders afflicting millions. Neurons are 
particularly susceptible to stress and oxidative damage by virtue of their high oxygen 
consumption, lower anti-oxidant enzyme activity in the aged brain, and elevated 
concentrations of poly unsaturated fatty acids in their cell membranes (Raichle and 
Gusnard, 2002, Marcus et al., 1998).  Given these unique properties, models of oxidative 
stress driven neurodegeneration constructed in transformed cells must be ported to 
more relevant ex vivo models before meaningful inferences are made regarding 
pathogenesis. 
Confirmation of data derived from transformed cell lines in primary cultures is a 
common feature of published research into neurodegeneration. For instance, the 
cytoplasmic re-localisation and subsequent aggregation into stress granules of ALS-
associated mutant FUS was confirmed in e19 cortical and hippocampal neurons 
(Dormann et al., 2010). Furthermore, because the movement and dynamics of stress 
granules are dependent on cytoskeletal elements, primary neurons have been utilised to 
study this in highly polarised cytoskeletal dependant morphology (Tsai et al., 2009).   
Hippocampal pyramidal cells are the most widely used thanks to their distinctive and 
defined morphology. A single axon sprouting from the soma, dendritic arborisation 
including apical and basilar dendrites all highly branch and peppered with dendritic 
spines form a distinctive silhouette. Hippocampal pyramidal neurons develop at 
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embryonic day 15, meaning when the tissue is typically harvested at embryonic day 18, 
the generation of pyramidal neurons is essentially complete. Harvesting at this stage has 
the added advantage of easily removable membranes, tissue amenable to dissociation, 
and minimal glial contamination. 
5.2 Hypothesis 
TRN1 and the FET proteins re-localise to stress granules in rat hippocampal primary 
neurons upon arsenite stress & the biochemistry of TRN1 will shift towards the insoluble 
fraction.  
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5.3 Mature hippocampal neurons are differentiated over five days  
To confirm that the dissection technique and culturing practices produced viable cells 
that differentiated into the morphologically characteristic profile of hippocampal 
neurons phase contrast microscopy was used to follow their in vitro differentiation. 
Three hours after plating cells had attached to the poly-D-lysine coated coverslips and 
lamellipodia were visible (Figure 5.1 A). Three days into differentiation the neurons had 
sprouted an axon and simple dendritic processes (Figure 5.1 B) corresponding to the 
‘Axonal outgrowth phase’ depicted in Figure 2. By day five, complex arborisation of the 
dendrites was obvious meaning the cell has fully matured and likely begun to form 
synapses with other cells (Figure 5.1 C). All subsequent experiments would take place on 
day five unless otherwise stated.  
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Figure 5.1. Cells differentiate into mature hippocampal neurons by day five in vitro. 
Phase contrast microscopy shows three hours after dissociation and plating the cells 
have adhered to the coverslip and minute lamellipodia are visible (A arrow). Three days 
into differentiation and a single axon has extended from the cell body (B double arrow). 
Five days into differentiation and the neuron has full differentiated showing a single 
axon (C double arrow), and extensive complex dendritic arborisation (C arrow heads).  
Scale bar in A represents 25µm.  N=3 
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5.4 Antibody characterisation on rat primary neuron lysate 
All previous experiments in this thesis have utilised antibodies raised against human 
peptides to visualise human tissue and cells. To ensure they recognise the same 
conserved proteins in rat neurons western blotting of cell lysate was undertaken, and the 
bands compared to expected molecular weight listed at Ensembl database 
(http://www.ensembl.org/Rattus_norvegicus). All but two of the antibodies available 
recognised a band of the appropriate molecular weight (Figure 5.2 asterisks). Mouse 
anti-TRN1 (abcam ab10303) failed to recognise the appropriate band at approximately 
102kD, instead recognising a smaller band at approximately 80kD. Mouse anti-G3BP only 
recognised very weak bands at approximately 100 and 40kD, neither near the correct 
molecular weight.  
Both species of FUS antibody recognised the appropriate expected band at 
approximately 74kD. Despite the predicted molecular weight of murine FUS being 
approximately 52kD, higher than expected bands on immunoblots are commonly seen in 
human lysate (Figure 4.2). Both species of TAF15 antibody recognised the appropriate 
band at 58kD for murine TAF15. Whilst several extra bands were highlighted by the 
mouse anti-EWS antibody the most prominent band was at the correct molecular weight 
of 68kD. The stress granule markers rabbit anti-G3BP and mouse anti-TIA-1 recognised 
bands at the expected size of 52 and 41kD respectively.  
For the subsequent experiments rabbit anti-TRN1 (abcam ab67352) and the appropriate 
co-stain antibody raised in mouse were used.  
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Figure 5.2. Most antibodies detect bands of correct corresponding molecular weight in 
rat neuron lysate. Bands of correct molecular weight for the protein to which an antibody 
is raised are indicated with an asterisk (*).  Mouse anti-TRN1 (msTRN1) and mouse anti-
G3BP (msG3BP) fail to recognise the correct bands. Both species of ubiquitin antibody 
(msUb and rbUb) produce the expected ubiquitin-smear. Protein load was 5µg in all 
lanes.  
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5.5 TRN1 and the FET proteins re-localise to stress granules in primary 
neurons 
The re-localisation of normally nuclear proteins to cytoplasmic stress granules is 
described for SH-SY5Y cells in the preceding chapter. Since this re-localisation has been 
suggested to be crucial for the development of cytoplasmic aggregates central to the 
development of FTLD-FUS, primary neurons were investigated to see whether this re-
localisation under arsenite stress was an isolated phenomenon of transformed cell lines 
or whether it replicated in primary neurons. Confocal microscopy shows unstressed 
control primary hippocampal neurons have strongly nuclear TRN1, TIA-1 and FET 
proteins (Figure 5.3 A). Actin staining reveals well defined projecting axons and complex 
dendritic arborisation typical of healthy hippocampal neurons. However, after 2 hours of 
0.5mM arsenite stress immunocytochemistry shows TRN1 has partially re-localised to 
cytoplasmic foci that strongly co-localise with the stress granule marker TIA-1. The re-
localisation is not complete because there is retention of the original nuclear TRN1 stain. 
The same is true of FUS, EWS and TAF15 which appear to partially re-localise to 
cytoplasmic TRN1 stress granule foci (Figure 5.3 B). Actin staining reveals loss of 
morphological polarisation, axon retraction and loss of dendritic complexity. 
Quantificantion of co-localisation with TRN1 foci shows complete agreement between 
the number of TRN1 foci also positive for TIA-1 indicating they are all stress granules. 
Co-localisation of all the FET proteins with TRN1 stress granule foci is seen (≥90% in all 
instances) (Figure 5.3 C).  
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Figure 5.3 continued overleaf 
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Figure 5.3. The nuclear protein TRN1 and the FET proteins partially re-localise to 
cytoplasmic stress granules. TRN1, the FET proteins and the stress granule marker TIA-1 
are nuclear in unstressed primary rat neurons (A). After 2hrs of 0.5mM arsenite stress 
TRN1 is present in cytoplasmic stress granules (TIA-1 positive) whilst also retaining 
some nuclear staining. The FET proteins also partially re-localise to these TRN1 positive 
stress granules (B). Quantification of numbers of TRN1 foci also positive for co-stain 
shows strong co-localisation of TIA-1, FUS, EWS and TAF15 in the TRN1 foci (C). Scale 
bar in A represents 20µm and 10µm in insets. Overlay includes blue nuclear DAPI stain. 
N=3. 
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5.6 Arsenite stress shifts TRN1 to the insoluble fraction in rat primary 
neurons 
Given that oxidative stress produces a significant increase in urea soluble TRN1, primary 
rat neurons were stressed to investigate whether this recapitulated. Untreated control 
cells show strongly detectable TRN1 in the RIPA soluble fraction and only small amounts 
detectable in the insoluble urea fraction. However, after 2 hours of 0.5mM arsenite stress 
no RIPA soluble TRN1 is detectable whilst the urea soluble fraction has increased 
markedly (Figure 5.4 A). Densitometric quantification and analysis by Mann-Whitney U 
test reveals the loss of RIPA soluble TRN1 is highly significant (**p<0.01). Additionally, 
the increase in urea soluble TRN1 is also significant (*p<0.05) (Figure 5.4 B). Adjustment 
to loading control was possible only in the RIPA fraction, not the urea fraction because 
there is no reliable control. Protein assay of all samples ensured equal loading across all 
lanes, including the urea fraction. 
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Figure 5.4.  Arsenite exposure shifts the biochemistry of TRN1 towards the insoluble 
fraction. Unstressed control cells show strong RIPA soluble and weak urea soluble TRN1. 
However, after 2hrs 0.5mM arsenite stress TRN1 has left the soluble RIPA fraction 
accompanied by an increase in urea fraction of TRN1 (A). Quantification with 
densitometry and analysis with Mann-Whitney U test shows the loss of RIPA soluble 
TRN1 is highly significant (**p<0.01), and the increase in urea soluble TRN1 is also 
significant (*p<0.05) (B). Immunoblot representative of three independent experiments. 
Protein loading was 5 µg in all lanes. Loading control for RIPA fraction was β actin but no 
loading control is available for urea fractions (na). Error bars SEM.  
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5.7 Prolonged arsenite stress produced the same immunocytochemical 
pattern as acute stress, but recovery in fres h media produced TIA-1 
negative foci.  
Previous investigations in this thesis using SH-SY5Y cells have shown that prolonged 
stress followed by recovery in fresh media led to stress granule marker negative TRN1 
and FET protein positive foci. To investigate whether this held true in primary neurons, 
cells were incubated with 0.5mM arsenite for 24 hours and then either fixed for 
immunocytochemistry or allowed to recover in fresh media for 6 hours. Widefield 
microscopy shows TRN1, TIA-1 and the FET proteins are strongly nuclear with some 
background FITC staining (Figure 5.5 A). However, after 24 hours of 0.5mM arsenite 
TRN1 has re-localised to cytoplasmic stress granules (TIA-1 positive). This re-
localisation is variable; in some instances it appears complete whilst in other cases there 
is some retention of the original nuclear stain (Figure 5.5 B). The FET proteins, FUS, EWS 
and TAF15 all strongly co-localise with these cytoplasmic TRN1 stress granule foci but 
similarly to TRN1 there is occasional retention of the nuclear stain (Figure 5.5 B). 
Quantification of TRN1 foci shows that in almost all instances TRN1 foci are also positive 
for TIA-1, and the FET proteins (C). This good co-localisation is a continuation of the 
pattern observed at 2 hours, but after 6 hours of recovery in fresh media the pattern 
changes. The TRN1 foci no longer co-localise with TIA-1 which has instead returned to 
the nucleus (Figure 5.5 D). However, strong co-localisation was still evident between 
TRN1 foci and the FET proteins. Quantification of TRN1 foci shows that in almost all 
instances after recovery, TRN1 foci are not positive for TIA-1, but remain strongly 
positive for the FET proteins (D). Statistical analysis of all the count data via one-way 
ANOVA with bonferroni correction reveals this is the only significant change in co-
localisation with TRN1 foci (p<0.001). 
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Figure 5.5 continued overleaf
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Figure 5.5.  Prolonged 0.5mM arsenite stress over 24hrs re-localises TRN1 and the FET 
proteins to stress granules, but recovery in fresh media shows TIA-1 negative foci. 
Unstressed control cells show nuclear TRN1, TIA-1 and FET proteins (A). Prolonged 
0.5mM arsenite stress after 24hrs produces TRN1 cytoplasmic foci co-localising with the 
stress granule marker TIA-1. The FET proteins FUS, EWS, and TAF15 also co-localise 
with TRN1 in these foci (B arrows). Quantification of numbers of TRN1 foci also positive 
for co-stain shows strong co-localisation of TIA-1, FUS, EWS and TAF15 in the TRN1 foci 
(C). Recovery in fresh media produced a different staining pattern showing 
predominantly TIA-1 negative TRN1 foci which nevertheless remained positive for the 
FET proteins (D arrows). Quantification of numbers of TRN1 foci also positive for co-
stain shows negligible co-localisation with TIA-1 but good co-localisation with FUS, EWS 
and TAF15 (E). Scale bar in A represents 15µm. Overlay includes blue nuclear DAPI stain. 
N=3 
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5.8 Reduction of TIA-1 positivity is statistically significant  
Due to the statistically significant reduction in G3BP staining seen after recovery in SH-
SY5Y cells, the same investigation was mounted for primary neurons. Analysis by ANOVA 
and Bonferoni post-test indicates the reduction of TIA-1 positivity in TRN1 foci is 
significant (p<0.001). It would appear that a large proportion of TRN1 foci seen after 
6hrs of recovery in fresh media are not stress granule marker positive.  
 
Figure 5.6. Statistical analysis reveals loss of TIA-1 positivity in TRN1 foci after recovery 
is significant. The proportion of TRN1 foci also positive for TIA-1 is significantly lower 
(p<0.001) after recovery in fresh media. Analysis by ANOVA.  
189 
 
5.9 Pre-treatment with the stress granule blocker Emetine prevents the 
formation of stress granules and therefore the re-localisation of TRN1 and 
the FET proteins  
To confirm that the foci observed in rat primary neurons are indeed stress granules, 
primary neurons were pre-treated with 16.4µM emetine before being stressed with 
0.5mM arsenite for 2 or 24 hours. The resulting lack of stress granules (TIA-1 or TRN1 
positive cytoplasmic foci) at 2hours suggests that the previously observed foci were 
indeed stress granules, and that cytoplasmic foci formation might require stress granule 
formation (Figure 5.6 B). Interestingly, in contrast to SH-SY5Y cells TRN1 was not re-
localised to the cytoplasm. Nor were any of the FET proteins. Emetine treatment alone 
did not affect the immunocytochemical staining pattern of TRN1, TIA-1, or the FET 
proteins which remained predominantly nuclear (Figure 5.6 A). Incubation with 0.5mM 
arsenite for 24 hours after pre-treatment resulted in cell detachment from the coverslip. 
This detachment is likely due to cell death. 
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Figure 5.6 continued overleaf
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Figure 5.7. Pre-treatment with the stress granule blocker emetine prevents the formation 
of stress granules. Emetine pre-treatment alone does not affect the nuclear localisation of 
TRN1, TIA-1 or the FET proteins (A). Pre-treatment with emetine before 2hrs of 0.5mM 
arsenite stress prevents the formation of stress granules (TIA-1 or TRN1 positive 
cytoplasmic foci) (B). Scale bar in A represents 15µm. Overlay includes blue nuclear DAPI 
stain. N=3 
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5.10 Discussion 
These data indicate western blotting of primary cell lysates shows the polyclonal anti-
TRN1 antibody and monoclonal FUS, EWS, TAF15 and TIA-1 recognise bands at the 
correct predicted size for their corresponding protein. Immunocytochemistry of 
unstressed control neurons reveals nuclear TRN1, FET protein and TIA-1 consistent with 
previous results from SH-SY5Y data and published descriptions (Tsai et al., 2009, 
Dormann et al., 2010, Blechingberg et al., 2012a). For the first time this work follows the 
response of TRN1 and the FET proteins to 2 hours of 0.5mM arsenite, and shows partial 
re-localisation from the nucleus to cytoplasmic TRN1 positive stress granule foci. 
Biochemical analysis of TRN1 solubility reveals a clear shift towards the insoluble 
fraction in response to this oxidative insult. Prolonging the incubation with arsenite for 
24 hours recapitulates the immunocytochemical pattern seen at 2 hours, but when 
neurons are allowed to recover in fresh media TRN1 positive TIA-1 negative foci 
predominate. Unlike SH-SY5Y cells these foci are all strongly positive for the FET 
proteins. Finally, emetine pre-treatment prevents the formation of stress granules in 
primary neurons and therefore the re-localisation of TRN1, and the FET proteins.  
It is perhaps unsurprising that TRN1 and the FET proteins are detectable in rat 
hippocampal neurons given the high degree of conservation across species 
(Blechingberg et al., 2012a, Burd and Dreyfuss, 1994). These evolutionarily conserved 
proteins likely serve important functions and may also require a conserved TRN1 to 
maintain their localisation (http://www.ncbi.nlm.nih.gov/gene/309126). Small 
differences are noted between the molecular weight of human and murine proteins. For 
example human FUS is composed of 526 amino acids while rat FUS has 518 producing a 
protein that is nonetheless 97% identical (Altschul et al., 1997).  
Immunocytochemistry of rat hippocampal neurons shows the nuclear staining of TRN1 
and the FET proteins replicates from transformed SH-SY5Y cells. Little published data is 
currently available to contrast these data with, but what is known is that other importins 
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are predominately nuclear in rat neurons (Kortvely et al., 2005), and overexpressed wild 
type FUS is also nuclear (Dormann et al., 2010). Perhaps most importantly there is no 
published description of TRN1 and the FET proteins in neurons subjected to oxidative 
stress. Arsenite at 0.5mM is commonly used to elicit stress granules formation and as a 
model of oxidative stress in primary neurons (Tsai et al., 2009, Kunde et al., 2011). 
Despite their reduced robustness compared to immortalised cell lines these data show 
they are able to survive for at least 24 hours in 0.5mM arsenite. Immunocytochemistry 
reveals the formation of cytoplasmic stress granules demarcated by the presence of TIA-
1, a commonly used marker of stress granules in primary neurons (Tsai et al., 2009).  
These are strongly positive for TRN1 which agrees with data gathered from the SH-SY5Y 
line describing strong and robust co-localisation of TRN1 with stress granules. However, 
unlike neuroblastoma lines the re-localisation of TRN1 was less pronounced because a 
considerable proportion remained nuclear. The same was true of EWS which retained its 
nuclear character whilst also being found in TRN1 positive stress granules. Unlike SH-
SY5Y cells TAF15 and FUS were readily found within the TRN1 positive stress granules 
of rat primary neurons after 2 hours of 0.5mM arsenite. Once again this was in addition 
to their nuclear stain, indicating partial incomplete re-localisation.  
Sequential solubility fractionation after 2 hours 0.5mM arsenite stress showed a 
pronounced effect of oxidative stress on the solubility of TRN1. Immunoblotting of RIPA 
soluble and urea soluble fractions revealed unstressed control primary neurons have a 
predominantly soluble pool of TRN1. However, this is undetectable after 2 hours of 
arsenite stress. In parallel to this there was a significant increase in the urea soluble 
fraction of TRN1. This suggests a shift in solubility towards an insoluble likely aggregated 
form of TRN1. In comparison to data collected form SH-SY5Y cells, this shift is far more 
pronounced. A significant increase in urea soluble TRN1 is seen in both cell cultures but 
the RIPA soluble fraction does not diminish in SH-SY5Y cells. The presence of TRN1 in 
the urea fraction is an important characteristic of FTLD-FUS (Brelstaff et al., 2011), but 
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presumably the loss of soluble TRN1 would also have a similar affect to removal by 
siRNA (Figure 4.24). This may explain the higher proportion of FUS, EWS, and TAF15 
positive stress granules. 
Prolonged incubation with 0.5mM arsenite over 24 hours recapitulates the findings at 
two hours with an abundance of TRN1 positive stress granules also positive for the FET 
proteins. However, after a 6 hour recovery period the staining profile has changed in a 
similar fashion to that seen in SH-SY5Y cells. Only 7.46% of TRN1 positive cytoplasmic 
foci seen at this time point are also TIA-1 positive and therefore stress granules. 
Furthermore, these TRN1 foci are strongly positive for all the FET proteins. These foci 
co-localised with the P-body marker DCP1a in SH-SY5Y cells but it remains to be seen if 
the same phenomenon is occurring here.  At the time of writing there are no published 
descriptions of stress granules dissociation or P-body transformation in primary 
neurons but given the importance of cytoplasmic TRN1 and FET protein aggregation to 
FTLD-FUS this is likely to change.  
Finally, emetine pre-treatment successfully prevented the formation of stress granules as 
illustrated by the lack of TIA-1 positive foci. Moreover, the lack of stress granules 
corresponded to a lack of TRN1 and FET protein re-localisation. This contrasts at least in 
part with the data from SH-SY5Y cells in that TRN1 did not re-localise to a diffuse 
cytoplasmic pattern. This may mean the response of human and rat TRN1 in the face of 
oxidative stress and emetine pre-treatment is different. Then again the observed 
difference may be due the immortalised or primary nature of the cells. Other 
transportins and importins have been implicated in controlling the cell cycle (Roscioli et 
al., 2012) (Lau et al., 2009). No data is available for the effect of emetine at 24 hours 
because this resulted in complete cell death. This observation may indicate that the 
formation of stress granules, at least in the short term is anti-apoptotic. Previous 
publications regarding the role of stress granules as an adaptive survival response might 
support this (Takahashi et al., 2013). 
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Chapter Six: Discussion 
6.1 Introduction 
Epidemiological studies suggest that FTD is the second most common cause of dementia 
in individuals under 65, just behind Alzheimer’s disease (Onyike and Diehl-Schmid, 
2013). Despite the first descriptions of FTD patients and FTLD pathology dating back 
over a hundred years (Pick, 1892), it was not until recently that a full appreciation of the 
various subtypes and idiosyncrasies has developed. In 1994 two research groups based 
in Lund and Manchester proposed clinical and neuropathological criteria for the 
diagnosis of FTD (1994). The implication of the RNA binding proteins TDP43 and later 
FUS (Neumann et al., 2009a) has further diversified an already heterogeneous disease. 
More than anything the renaissance of FTLD research has asked more questions than it 
has delivered answers. All the while no cure or effective disease modifying treatment is 
available, leaving patients and their families with cold comfort.  
TRN1 and defects in nuclear import were first implicated by investigations focused on 
ALS-FUS, namely the unusual clustering of causative mutations in the NLS of FUS 
(Dormann et al., 2010). It was deduced that these would retard the binding to TRN1 and 
therefore affect nuclear localisation. Given the well documented and widely accepted link 
between FTLD and ALS the finger of suspicion pointed squarely at TRN1 in FTLD-FUS.  
The discovery of abundant TRN1 pathology co-localising with FUS in FTLD-FUS (Brelstaff 
et al., 2011), shortly followed by two more TRN1 cargos (Neumann et al., 2011) 
compounds the case for a TRN1 centric pathology.  
It was noted relatively early on that cytoplasmic diffuse FUS is toxic (Ju et al., 2011), but 
FTLD-FUS is characterised by inclusion bodies. Consequentially, an appropriate model 
must include a paradigm of aggregation and inclusion formation. The FET proteins are all 
heavily involved in RNA binding which when combined with the observation of stress 
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granule markers in the inclusions begins to suggest these temporary RNA/protein foci as 
accomplices to aggregation. The data presented herein aligns with mounting publications 
suggesting that aberrant stress granule persistence may seed aggregate formation, or at 
the very least sequester FET proteins away from basal functions such as chaperoning 
mRNA (Fujii and Takumi, 2005).  
The absence of causative mutations in the aggregating proteins distinguishes FTLD-FUS 
from ALS-FUS. Moreover, this is doubly important because many more proteins are 
aggregating compared with ALS-FUS, including TRN1, EWS and TAF15. This thesis 
investigated the pathology of banked FTLD-FUS brains in terms of 
immunohistochemistry, and biochemistry of TRN1. Additionally it details the response of 
TRN1 to oxidative stress and described for the first time the propensity of this protein to 
change localisation and solubility in a manner akin to FTLD-FUS. Whilst this work 
explores the role of TRN1 it remains to be seen whether stress granules are definitive 
aggregate precursors, or even whether aggregates themselves are toxic or protective. 
The loss of nuclear FET protein likely has a myriad of consequences, defining which if 
any represents a single disease causing event is not attempted here due to time 
constraints. However, such an investigation is crucial if disease modifying treatments are 
to be designed.  
6.2 Summary 
In summary, the immunohistochemical staining profile of TRN1 in healthy control brain 
and spinal cord is nuclear. However, in FTLD-FUS it re-localises to neuronal cytoplasmic 
and intranuclear inclusions to co-localise with FUS, EWS and TAF15. TRN1 pathology is 
unique to FTLD-FUS with the one exception of NIIBD, but because only one case of this 
extremely rare disease was available little can be concluded. Importantly, whilst FUS was 
strongly detected in the poly glutamine inclusions of Huntington’s disease and 
spinocerebellar ataxia, TRN1 was absent. Biochemical solubility fractionation of healthy 
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control and FTLD-FUS frontal cortex reveals highly insoluble likely highly aggregated 
TRN1 in diseased brain. The inclusion of TRN1 appears to be specific in that no other 
importins are incorporated into the inclusions of FTLD-FUS. Variable positivity of NUP98 
and hnRNP A1 suggest the disease does not encompass FET proteins exclusively. Cellular 
studies in SH-SY5Y cells have shown TRN1 strongly re-localises to stress granules under 
oxidative and osmotic stress, but only increases in insolubility under the former. Low 
levels of FET protein positivity in said stress granules can be increased by prolonging the 
exposure to stress at lower concentrations. FUS does not change its solubility profile like 
TRN1. Recovery in stressor free fresh media changes the biology of TRN1 cytoplasmic 
foci by incorporating ubiquitin and DCP1a and defining them as P-bodies. Importantly, 
stress granules are not responsible for the increase in TRN1 insolubility suggesting an 
unidentified event outside of stress granules. Moreover, TRN1 is not culpable for FET 
protein inclusion in stress granules but it remains to be seen if FET proteins are 
responsible for TRN1 inclusion. Many of these findings hold true in primary neurons. 
Strong TRN1 stress granule incorporation is accompanied by near complete positivity for 
all the FET proteins. Additionally, TRN1 increases in terms of insolubility in response to 
arsenite stress. Recovery in fresh media recapitulates the loss of stress granule markers 
seen in SH-SY5Y cells but it remains to be seen if the foci have developed the 
characteristics of P-bodies. 
6.3 Suggested model 
From these data the following model of FTLD-FUS pathogenesis is suggested (Figure 6.1). 
Healthy neurons maintain a predominantly nuclear TRN1 and FET protein allowing them 
to splice appropriate mRNA whilst low levels in the cytoplasm still allow chaperoning of 
mRNA to dendrites for translation. As the neuron ages oxidative insult becomes more 
problematic, or an as yet unidentified change hampers TRN1 driven import. The result is 
the formation of cytoplasmic stress granules, and a shift towards insolubility of TRN1. 
The chronic nature of the stress means more and more FET protein is incorporated into 
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these foci. A change in protein characteristics, perhaps due to their prionoid properties, 
prevents the dissociation of these TRN1-FET foci after stress granule dissolution. Over 
time and continued oxidative stress these stress granule foci coalesce into a permanent 
inclusion body. Either this inclusion creates a toxic weight on the cell, or sequestration of 
proteins into this inclusion creates a loss of function in a vital cellular process such as 
splicing of tau and cytoskeleton maintenance (Orozco and Edbauer, 2013).  The result is 
an overwhelming cellular challenge that leads to loss of neuronal function and eventual 
cell death. The evidence for which is the spongiosis and massive inclusion burden seen in 
FTLD-FUS.  
6.4 Limitations 
Whilst this work contributes to the sum knowledge of the field it does not presume to 
hold all the answers to pathogenesis. Many questions still remain, some could be 
answered easily, others would require a great deal more time and resources. For 
example, the insolubility status of EWS and TAF15 in FTLD-FUS and cells exposed to 
oxidative stress remains unknown. Whilst other authors have reported a shift in 
insolubility, this is yet to be confirmed in the QSBB collection (Neumann et al., 2011).  
This thesis focused on FTLD-FUS but it would be interesting to see if EWS and TAF15 
also appear in the poly-glutamine inclusions of Huntington’s disease alongside FUS. 
Given their high degree of homology this might be expected but if not the sole inclusion 
of FUS would highlight a unique property in the FET family. The seeding of stress 
granules occurs via the prionoid domains of TIA-1 and other proteins, the incorporation 
of FET proteins is likely via their RNA binding domains, but little is known about the 
incorporation of TRN1. It would be informative to investigate whether it is recruited via 
its binding to FET proteins or some other method. A tripartite knockdown of FUS, EWS 
and TAF15 followed by arsenite stress may shed some light on TRN1 recruitment. 
However there are other proteins imported by TRN1 that also re-localise to stress 
granules, such as hnRNP A1. To avoid these confounding proteins the use of a global NLS-
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competitor peptide like M9 (Nakielny et al., 1996), would prevent or reduce TRN1 
binding. Subsequent treatment with arsenite might reveal a reduced TRN1 presence in 
stress granules. Now that is it clear that FUS, EWS and TAF15 are recruited to stress 
granules in neurons, investigations should now focus on what if any folding, 
dimerization, or post-transcriptional changes occur in these foci. This may yield clues as 
to why these foci appear to be resilient to stress granule dissolution. In this vein it is still 
uncertain whether inclusion bodies represent protective or toxic phenomena. There is 
evidence that loss of FUS increases the inclusion of exon 10 in tau mRNA leading to an 
increase in 4R tau (Orozco and Edbauer, 2013). In such a morphologically complex cell 
type loss of cytoskeletal control could have profound consequences. On the other hand, 
virtually all neurodegenerative diseases have some form of aggregate pathology despite 
a multitude of different mutations with different actions, suggesting that 
neurodegeneration is inexorably linked to aggregates. Finally, broader questions still 
remain to be answered. The QSBB collection of FTLD-FUS includes a mother and son pair 
who both developed the disease, with such a strong familial link why has a causative 
mutation yet to be found? Perhaps broader and more complex defects in an individual’s 
response to a lifetime’s exposure to oxidative stress are to blame.   
The discovery of TRN1 aggregating alongside a whole family of cargos has dramatically 
changed the landscape of FTLD-FUS research. Whilst a definitive pathogenic pathway has 
yet to be proven it has opened many new avenues of research. Undoubtedly one of these 
will spawn new drug targets and the promise of disease modifying treatments in the near 
future.  
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Figure 6.1. Possible progression of disease pathology in FTLD-FUS. In healthy normal 
neurons the importer TRN1 activity translocates the FET proteins FUS, EWS and TAF15 
back into the nucleus (top left). In response to reactive oxygen species (ROS) a 
proportion of TRN1, FUS, EWS and TAF15 re-localise to stress granules and TRN1 
becomes more insoluble (top right). These cytoplasmic foci do not dissociate after stress 
granule dissolution and incorporate ubiquitin (bottom left). Over time and chronic 
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oxidative stress, stress granules coalesce and take on inclusion morphology as 
permanent features (bottom right).  
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Appendix 1.1 
ALS-associate mutations in FUS 
DNA mutation Protein 
change 
Protein 
Domain 
Cognitive 
involvement 
Reported Paper 
c.52 C>T P18S SYGQ 
rich 
None (Belzil et al., 
2011a) 
c.170-172delCTT S57del SYGQ 
rich 
None (Belzil et al., 
2009) 
c.287-291 
delCCTACinsAT 
S96del SYGQ 
rich 
Mental 
retardation 
(Yan et al., 
2010) 
c.344 G>A S115N SYGQ 
rich 
None (van Blitterswijk 
et al., 2012) 
c.430-
447delGGAAAGCTAT 
G144Y149del G rich None (Belzil et al., 
2011b) 
c.467 G>A G156E G rich Dementia (Ticozzi et al., 
2009) 
c.518-
523delGAGGTG 
G174-
G175del 
G rich schizophrenia
, FTD 
(Kwiatkowski et 
al., 2009b) 
c.559 G>A G187S G rich None (Rademakers et 
al., 2010) 
c.571 G>A G191S G rich None (Corrado et al., 
2010) 
c.616 G>A G206S G rich FTD (Yan et al., 
2010) 
c.646 C>T R216C G rich None (Corrado et al., 
2010) 
c.674 G>T G225V G rich None (Corrado et al., 
2010) 
c.681-684delGGC G230delG G rich None (Kwon et al., 
2012) 
c.688 G>T G230C G rich None (Corrado et al., 
2010) 
c.700 C>T R234C G rich None (Corrado et al., 
2010) 
c.701 G>T R234L G rich None (Ticozzi et al., 
2009) 
c.730 C>T R244C G rich None (Kwiatkowski et 
al., 2009b) 
c.1196 G>T G399V ZnF None (Kwon et al., 
2012) 
c.1204-1232 
delinsGGAGGTGGAG
G 
S402-
P411delinsG
GGG 
ZnF None (DeJesus-
Hernandez et 
al., 2010) 
c.1385 C>T S462F ZnF None (Groen et al., 
2010) 
c.1392G>T M464I ZnF None (Nagayama et 
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al., 2012) 
c.1394-
1541delCTACCGGGG
CCGCGGCGGGGACC
GTGGGGCTTCCGAG
GG 
G466VfsX14 RGG 
rich 
None (DeJesus-
Hernandez et 
al., 2010) 
c.1420-1421insGT G472VfsX57 RGG 
rich 
None (Hara et al., 
2012) 
c.1449-1488del Y485AfsX514 RGG 
rich 
n.a. (Yan et al., 
2010) 
c.1459 C>T R487C RGG 
rich 
None (van Blitterswijk 
et al., 2012) 
c.1475delG G492EfsX527 NLS Mental 
retardation 
(Yamashita et 
al., 2012) 
c.1483delC R495EfsX527 NLS None (Yan et al., 
2010) 
c.1483 C>T R495X NLS None (Bosco et al., 
2010) 
c.1484delG R495QfsX52
7 
NLS None (Belzil et al., 
2012) 
c.1485delA G497AfsX52
7 
NLS Learning 
disabilities 
(Yan et al., 
2010) 
c.1506 dupA R502fsX15 NLS None (Belzil et al., 
2011b) 
c.1507-1508delAG G503WfsX12 NLS None (Kwon et al., 
2012) 
c.1509-1510delAG G504WfsX12 NLS Learning 
disabilities 
(Zou et al., 
2013) 
c.1520 G>A G507D NLS None (Hewitt et al., 
2010) 
c.1527-1528insTGCC K510WfsX51
7 
NLS None (Yan et al., 
2010) 
c.1528 A>G K510E NLS None (Suzuki et al., 
2010) 
c.1529 A>G K510R NLS None (Waibel et al., 
2010) 
c.1537 T>C S513P NLS None (Suzuki et al., 
2010) 
c.1540 A>G R514G NLS None (Vance et al., 
2009a) 
c.1542 G>C R514Sa NLS None (Chio et al., 
2009) 
c.1543 G>T G515C NLS None (Kwiatkowski et 
al., 2009b) 
c.1547 A>T E516Va NLS None (Robertson et 
al., 2011) 
c.1549 C>G H517D NLS None (Tsai et al., 
2011) 
c.1550 A>C H517P NLS None (Suzuki et al., 
2010) 
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c.1551 C>G H517Q NLS None (Kwiatkowski et 
al., 2009b) 
c.1552 A>G R518G NLS None (Lai et al., 2011) 
c.1553 G>A R518K NLS None (Kwiatkowski et 
al., 2009b) 
c.1554-
1557delACAG 
R518del NLS None (Baumer et al., 
2010) 
c.1555 C>T Q519X NLS None (Belzil et al., 
2011b) 
c.1561 C>T R521C NLS Parkinsonism 
and dementia  
(Belzil et al., 
2009) 
c.1561 C>G R521G NLS None (Ticozzi et al., 
2009) 
c.1561 C>A R521S NLS None (Millecamps et 
al., 2010) 
c.1562 G>A R521H NLS FTD (Blair et al., 
2010) 
c.1562 G>T R521L NLS None (Conte et al., 
2012) 
c.1564 A>G R522G NLS None (Kwiatkowski et 
al., 2009b) 
c.1570 A>T R524W NLS None (Hewitt et al., 
2010) 
c.1571 G>C R524T NLS None (Kwiatkowski et 
al., 2009b) 
c.1572 G>C R524S NLS None (Kwiatkowski et 
al., 2009b) 
c.1574 C>T P525L NLS None (Baumer et al., 
2010) 
c.1581delA X527YextX NLS None (Kwon et al., 
2012) 
     
Nucleotide numbering=cDNA numbering . Reference sequence is NM_004960.3. 
 del=deletion ins=insertion fs=frameshift ext=extention dup=duplication n.a.=not 
applicable 
Appendix 1.1. Table of ALS-associated FUS mutations  
  
230 
 
Appendix 1.2 
TRN1 cargos Associated disease Reference 
FUS FTLD-FUS / ALS-FUS (Neumann et al., 2009a, 
Neumann et al., 2009c, 
Vance et al., 2009a) 
EWS FTLD-FUS (Neumann et al., 2011) 
TAF15 FTLD-FUS (Neumann et al., 2011) 
 
hnRNP A1 
Inclusion body myopathy associated with 
Paget disease of bone / FTLD-TDP / ALS-
TDP43 / Cancer 
(Kim et al., 2013, Zhou et 
al., 2013) 
hnRNP A0 none  
 
hnRNP 
A2/B1 
inclusion body myopathy associated with 
Paget disease of bone / FTLD-TDP / ALS-
TDP43 
(Kim et al., 2013) 
hnRNP 
M3/M4 
Cancer (Laguinge et al., 2005) 
hnRNP D Viral infection (Lee et al., 2012) 
hnRNP H1 none  
PQBP-1 PolyQ expansion  (Kurosaki et al., 2012) 
SAM68 Cancer (Liao et al., 2013) 
SLM-2 none  
HEX1M1 none  
RBM39 Cancer (Sillars-Hardebol et al., 
2012) 
HuR Cancer (Wang et al., 2013) 
PABPN1 Muscular dystrophy                                                   (Anvar et al., 2013) 
YB1 Cancer (Maciejczyk et al., 2012) 
DDX3 Cancer / viral infection                                      (Bol et al., 2013, Lai et al., 2013) 
NXF1 Viral infection (York and Fodor, 2013) 
 
 
